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Abstract 
 
This Doctor of Philosophy thesis describes cystic fibrosis (CF), sleep parameters and 
novel measurement techniques to determine the effect of lung disease on sleep using 
non-invasive techniques.  
 
Cystic Fibrosis (CF) is characterised by lungs that are normal at birth, but as lung 
disease progresses with age, adults with CF can develop sleep abnormalities including 
alteration in sleep architecture and sleep disordered breathing. This thesis seeks to 
investigate simple non-invasive measures which can detect abnormalities of sleep and 
breathing in CF adults. The identification of respiratory sounds (normal lung sounds, 
coughs, crackles, wheezes and snores) will be examined using the non-invasive sleep 
and breathing measurement device, the Sonomat. The characterisation of these 
respiratory sounds will be based on spectrographic and audio analysis of the Sonomat. 
Cross-sectional and longitudinal analysis of adults with CF using polysomnography 
and the Sonomat will further assess objective sleep and breathing abnormalities.  
 
Additional to the examination of objective measurements of sleep, subjective 
evaluation using CF-specific and sleep-specific questionnaires will assess subjective 
sleep quality and QoL in adults with CF.  
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CHAPTER 1: LITERATURE REVIEW 
 
Cystic fibrosis (CF) is the most common lethal inherited disease in Australia with the 
carrier rate 1 in 25 and the incidence of CF in Australia was about 1 in 2800 live births 
(Massie et al., 2000). There have been recent advancements in the treatment, using CF 
transmembrane regulator (CFTR) modulator drug therapy, of the complications of CF 
but it still remains a progressive lung disease. Overnight oximetry and 
polysomnography (PSG) can be used to detect nocturnal respiration, sleep and other 
events. However, further, preferably non-invasive testing is required to assess other 
aspects of respiration including the presence of adventitial sounds.  
 
This PhD thesis describes cystic fibrosis (CF), sleep parameters and novel measurement 
techniques to determine the effect of lung disease on sleep using non-invasive 
techniques. The review below discusses the appraisal of literature of respiratory sounds 
and sleep disturbances that can be found in people with CF and the reasons why this is 
an important area of research for these adults. 
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SECTION A - NORMAL VENTILATION AND BREATHING 
 
Breathing can be defined as the process of respiration, during which air is actively 
inhaled into the lungs through the nose or mouth and then during normal quiet breathing 
expiration is due to passive muscle relaxation.  
Ventilation is the process by which there is an exchange of oxygen and carbon dioxide 
between the lungs and the atmosphere so that oxygen can be exchanged for carbon 
dioxide in the alveoli.  
 
1.1 ANATOMY OF THE AIRWAYS – TRACHEA TO ALVEOLAR SACS 
 
After passing through the upper airways including the nose or mouth, pharynx and 
larynx, air enters the tracheobronchial tree. The conducting zone, the first 16 
generations of the airways, comprises the airways beginning with the trachea down to 
the terminal bronchioles. This conducting zone, known also as the anatomic dead space, 
contains no alveoli and thus is incapable of gas exchange with venous blood. From the 
17th to 19th generations, in the respiratory bronchioles, alveoli start to appear and this 
zone is referred to as the transitional zone. The 20th to 22nd generations are lined with 
alveoli. These alveolar ducts and alveolar sacs (23rd generation), which terminate the 
tracheobronchial tree, are referred to as the respiratory zone, where gas exchange of 
oxygen and carbon dioxide takes place. 
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1.2 AIRWAY CELLS 
 
The respiratory tract from the upper airway to the terminal bronchioles is lined with 
pseudostratified columnar epithelium, with the predominant cells the ciliated epithelial 
cell, interspersed with mucus-secreting goblet cells and other secretory cells. In the 
larger airways, the ciliated cells are pseudostratified columnar cells whilst they become 
cuboidal in the bronchioles. In the bronchioles, the goblet cells become less frequent 
and are replaced by Clara cells. These Clara cells secrete proteins (including surfactant 
apoproteins SpA, SpB and SpD), lipids, glycoproteins and modulators of inflammation. 
The ciliated epithelium, along with mucus secreted by glands along the airways, goblet 
and Clara cells, constitutes an important defence mechanism for the lungs termed the 
“mucociliary escalator”. Recently, in a study published in Nature, a novel, rare cell type 
termed the “pulmonary ionocyte” which co-expresses FOXI1 and CFTR was reported 
(Plasschaert et al., 2018). The authors showed that Notch signalling is necessary and 
FOXI1 expression is sufficient to drive the production of the pulmonary ionocyte and 
they also demonstrated that the pulmonary ionocyte is a major source of CFTR protein 
activity in the conducting airway epithelium (Plasschaert et al., 2018). This discovery 
could be very important for CF physiology and how the cell states vary between 
homeostasis, injury-repair and disease.  
 
The alveolar surface is mainly composed of a thin layer of epithelial cell, the type I 
alveolar cells. Type II alveolar cells are found interspersed among the epithelial cells 
and are thought to produce the fluid layer that lines the alveoli. The type I cells allow 
most of the gas exchange between the alveolar air and the pulmonary capillary blood. 
Along the extra-cellular lining of the alveolar surface are found phagocytic alveolar 
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macrophages. These mononucleated cells phagocytose inspired particles such as 
bacteria.  
 
Mast cells are also found in the airways. The cells contain membrane-bound secretory 
granules that consist of many inflammatory mediators, including histamine, 
proteoglycans, lysosomal enzymes, and metabolites of arachidonic acid that can induce 
bronchoconstriction, stimulate mucus secretion, and induce mucosal oedema by 
increasing permeability of bronchial vessels.  
 
The alveolar-capillary unit is the site of gas exchange in the lung. The alveoli are almost 
completely enveloped in pulmonary capillaries. There may be as many as 170 alveoli 
per cubic millimetre of lung parenchyma resulting in about 50 to 100 m2 of surface area 
available for gas exchange by diffusion (Ochs et al., 2004).  
 
1.3 MUCOCILIARY CLEARANCE 
 
Mucus lining the airways comprises of two layers, an outer gel layer with trapped 
inspired particles and a sol layer that directly covers the ciliated epithelium. The cilia 
beat at frequencies between 10 and 15 Hz, and the mucus moves progressively faster 
as it travels from the periphery (Chilvers and O'Callaghan, 2000).  
 
In the non-diseased state, the airways cilia beat sequentially forming metachronous 
waves in such a way that the mucus covering the airways is moved up the airways, 
away from the alveoli and toward the pharynx. The “mucociliary escalator” is an 
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important mechanism of defence for the lungs by assisting in the removal of particles 
that are found in the airways.  
 
The airway surface liquid (ASL) is regulated by oppositely directed chloride ion and 
sodium ion flux (caused by osmotic gradients established by active ion transport) across 
the airway epithelium (Tarran et al., 2001). In CF airways this regulation is lost due to 
the absence of the CFTR-mediated chloride ion secretion and concomitant hyper-
absorption of sodium ions via the epithelial sodium channel (ENaC) (Boucher et al., 
1986, Stutts et al., 1995). Increased ENaC absorption contributes to dehydration of the 
ASL layer, the depletion of which is proposed to impair mucociliary clearance and 
hence reduced ability of the airways to clear bacteria and other foreign particles from 
the lower airways (Boucher, 2007, Goss and Ratjen, 2013b). Pezzulo et al., 
demonstrated that due to defects in the CFTR protein reduced bicarbonate secretion is 
seen in the airways of a pig CF model which in turn lowers the pH and subsequently 
reduces the respiratory epithelium’s ability to eradicate bacteria from the airway surface 
epithelium (Pezzulo et al., 2012). In a study by Abou Alaiwa et al., acidic pH was found 
to reduce the activity of individual ASL antimicrobials, impair synergism between 
them, and thus disrupt an important airway host defence mechanism (Abou Alaiwa et 
al., 2014). Interestingly, airway surface liquid pH in children in vivo has not been found 
to be altered in CF (Schultz et al., 2017), so more studies are needed to further 
investigate these varied results.  
 
In an article by Abdullah et al., following chronic exposure in primary human bronchial 
epithelial cultures to supernatant from mucopurulent material, there was the absence of 
the fluid secretory response in CF thereby producing a more dehydrated (concentrated) 
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mucus that was predicted to exacerbate mucus adhesion and accumulation, rather than 
exhibit the normal hydrating/flushing response as an adaptive host response (Abdullah 
et al., 2018). 
 
1.4 NORMAL RESPIRATORY SOUNDS 
 
Since Rene Laennec invented the first true stethoscope using a hollow wooden tube in 
Paris in 1816 (Laënnec, 1819, Roguin, 2006), the first seminal work on pulmonary 
sounds was detailed by him 3 years later, entitled “De l’auscultation mediate ou Traite 
du Diagnostic des Maladies des Poumon et du Coeur” (Laënnec, 1819).  
 
Interestingly, Laennec had the idea of using a hollow tube after observing children 
playing in a park communicating with each other using a hollow tube and a pin 
scratching on one end. It was only in 1945-1946 that the ideal properties of the modern 
stethoscope were described by Rappaport, Sprague and Groom (Roguin, 2006). These 
properties included the use of a binaural stethoscope with a combination chest piece, 
short tubing with low internal volume and well-fitting earpieces. Over time, pulmonary 
sounds have been described by many authors but it is only over the past 60 to 70 years 
that attempts have been made to universally define these sounds based on specified 
criteria including time (duration and timing within the respiratory cycle), frequency or 
pitch and intensity or loudness (Hadjileontiadis, 2008). Normal lung sounds are 
particular sounds heard over specific locations of the chest during respiration of healthy 
subjects. It is a noise that peaks with a frequency below 100 Hz (Gavriely et al., 1981). 
The characteristics of normal lung sounds heard over the chest wall are the result of the 
nature of the sound generator and the distortion of the sound upon transmission to the 
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location of detection. The inspiratory component of the normal lung sound is generated 
primarily within the lobar and segmental airways, whereas the expiratory component 
comes from more proximal locations (Pasterkamp et al., 1997). Air turbulence is 
presumed to generate the normal lung sounds. Lung sound amplitude differs between 
subjects and different locations on the chest surface, but primarily varies with the square 
of the air flow (Pasterkamp et al., 1997). 
 
The encasement of the pulmonary parenchyma within the rigid chest wall is an 
important factor that affects the way sound is propagated to the chest surface. The 
composition of the chest wall including ribs, muscle and skin make it a complex surface 
upon which to make acoustic measurements (Pasterkamp et al., 1997).  
 
The difference in measured acceleration of approximately 20 dB between the trachea 
and chest wall at lower frequencies has been reported together with relative dampening 
of the higher frequencies during transmission to the chest wall (Wodicka et al., 1990). 
Recent improvements in sound analysis, measurement and processing have extended 
the bandwidth to more than 1500 Hz to encompass the lung sound frequency range (Lu 
et al., 1995). Lu at al., found that sound at higher frequencies reaches the chest wall 
faster than at lower frequencies. This finding indicates that respiratory sound 
transmission is highly dispersive, most probably owing to frequency-dependent airway 
and parenchymal wave speeds (Lu et al., 1995). Ultimately, this tends to dampen or 
muffle the higher frequency sounds more than lower frequency sounds. 
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1.5 ADVENTITIAL RESPIRATORY SOUNDS 
 
Respiratory sounds, such as crackles, wheeze and squawks, have been recorded by 
physicians since the use of the first stethoscope developed by Laennec (Laënnec, 1819). 
However, the nomenclature of the sounds documented have had varying degrees of 
consensus among physicians. With the advent of new technology, it is now possible to 
record these respiratory sounds and obtain consensus regarding the characteristics of 
these sounds. An Ad Hoc Committee on Pulmonary Nomenclature was formed in the 
US and their report published in 1977 (Cugell et al., 1977) in an attempt to provide 
consensus statements on respiratory sound nomenclature. The Ad Hoc Committee on 
Pulmonary Nomenclature recommended using the term crackles to describe 
discontinuous lung sounds instead of the previous term, “rales” or “crepitations”. For 
high-pitched continuous sounds, the term wheeze was recommended. For low-pitched 
continuous sounds, the term “rhonchi” was suggested (Cugell et al., 1977). Further to 
this, expert respiratory physicians, engineers and physiologists held the 10th 
International Lung Sounds Association meeting in Tokyo in 1985 to review the current 
pulmonary sound nomenclature and provide recommendations for terminology in 
various languages including: English, French, German, Japanese, Portuguese and 
Spanish (Mikami et al., 1987). Again following the suggestions first made by Robertson 
and Coope in 1957 in the Lancet (Robertson and Coope, 1957), the symposium in 
Tokyo divided adventitious sounds into 2 major categories: continuous sounds or 
discontinuous sounds. The sounds can be further defined based on their physical 
properties (frequency, durations, initial deflection width) (Mikami et al., 1987).  
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Pulmonary pathology can clearly affect the amplitude and timing of sound transmission 
from the airways to the chest surface. In patients with emphysema, a decrease 
(Ploysongsang et al., 1982) and larger variability of transmitted amplitude at low 
frequencies was observed, which is qualitatively consistent with the common 
auscultatory finding of decreased lung sound intensity. In bronchial obstruction, such 
as seen in patients with asthma, an increase of higher frequency components of the 
sound spectrum can be seen without the appearance of wheeze; then during 
bronchodilation, the sound energy moves back to lower frequencies (Malmberg et al., 
1994). Increased non-musical breath sounds heard on both phases of the respiratory 
cycle can be suggestive of focal consolidation (Bohadana et al., 2014). 
 
Another method of sound classification uses sensors for lung sound recording. Two 
main types of sensors commonly used include: small microphones and accelerometers. 
Small microphones can come in different sizes and shapes which can affect the overall 
frequency response of the coupling chamber used in the microphone.  
 
Those microphones which are smaller and conically shaped have been found to be more 
sensitive to higher lung sound frequencies as described by Kraman et al. (Kraman et 
al., 1995). The optimal electret microphone couple chamber was found to be conical in 
shape, between 10 and 15 mm in diameter at the skin, and either not vented or vented 
with a tube no wider than 23 g or shorter than 20 mm (Kraman et al., 1995).  
 
Contact accelerometers are also able to be used to record lung sounds. They can be 
calibrated on a vibration table so their output is quantified. However, usually they are 
more expensive than microphones, are often fragile, and may exhibit internal 
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resonances near the lung sound frequencies of interest (Pasterkamp et al., 1997). 
Pasterkamp et al. examined the differences between contact and air-couple sensors and 
found that there was a high susceptibility to artefacts by noise from cable movements 
with the contact sensors (Pasterkamp et al., 1993) 
 
The development and widespread application of the Fast Fourier Transform (FFT) has 
made frequency analysis of sounds simpler, faster, more accurate, and less expensive 
than previously used methods such as phonopneumography (Loudon and Murphy, 
1984).  
Time domain analysis has been more widely applied to the study of discontinuous 
sounds, whereas frequency domain has been used to study continuous sounds (Loudon 
and Murphy, 1984).  
 
These findings were supported by the review of Pasterkamp et al., which supports the 
hypothesis that transmission of sound at low frequencies occurs at slower speeds 
primarily through parenchyma, whereas higher frequency sound travels through a 
faster, presumably more airway predominant route, as is the case in isolated lung 
preparations where the parenchyma and trachea are not in contact (Pasterkamp et al., 
1997, Patel et al., 1995, Rice and Rice, 1987). Patel et al. found that the phase delay of 
sound propagation to the posterior chest surface is frequency-dependent, with shorter 
delays of approximately 1ms at frequencies near 1500 Hz compared with roughly 2.5 
ms or more at frequencies below a few hundred Hz (Patel et al., 1995). There is also 
asymmetry in phase delays between the left and right posterior chest surface, and the 
phase delay to lower lung sites is greater than to upper sites at frequencies below 300 
Hz (Patel et al., 1995). There are relatively decreased delays to the left posterior chest 
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surface (ie sound propagation to the left is faster), as compared with the right (Patel et 
al., 1995). Thus, the heterogeneous anatomy of the thorax affects both the amplitude 
and phase delay of sound transmission in a manner that is frequency-dependent.  
 
Conventional Stethoscope 
 
Analysis of pulmonary sounds can be achieved firstly by listening to sounds at the body 
surface. The binaural stethoscope with a combination chest piece, tubing with low 
internal volume and well-fitting earpieces was developed based on the ideal properties 
required for auscultation as detailed in the 1940s by Rappaport, Sprague and Groom 
(Roguin, 2006). The classic stethoscope conducts sound through hollow tubes from a 
pliable diaphragm in contact with the skin of the chest of the patient and the ears of the 
physician. The stethoscope does not provide a frequency-independent transmission of 
sounds. Rather it selectively amplifies or attenuates sounds within the spectrum of 
clinical interest (Pasterkamp et al., 1997).  
 
Electronic Stethoscope 
 
The latest tool in auscultating pulmonary sounds is the use of computer technology to 
perform analysis of lung sounds using an electronic stethoscope with digital recording 
capabilities to create computer visualisation of sounds converting them to time, 
frequency and intensity variables for further analysis and the option to record 
respiratory sounds for later comparison.    
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Electronic stethoscopes have been available for more than 30 years, but with the 
introduction of digital techniques, they can now allow visual display of sounds in both 
standard waveform and spectral formats using computer based software programs. 
Prior to this, electronic stethoscopes could only amplify the acoustic signals including 
background noise (Bank et al., 2016). As more research has been conducted using 
digital sound analyses, widely accepted concepts based on the classic stethoscope have 
been challenged. In a paper by Pasterkamp et al., analyses of wheezes were so 
subjective that the inter-observer and intra-observer variability was described as 
somewhere “between chance and total agreement”, whereas the computer analysis they 
used allowed reproducible and objective characterisation of wheezing in patients with 
asthma (Pasterkamp et al., 1987). Inspiratory sounds measured simultaneously over the 
extra-thoracic trachea and at the chest surface contain highly unique regional 
information that can be reproducibly extracted with a knowledge of the breathing flow 
rate (Pasterkamp et al., 1997).  
 
As an added advantage, the electronic stethoscope allows the physician to record heart 
or lung sounds of their patient directly onto their computer for further visualisation and 
analysis. These sounds can also be used to calibrate and characterise the sounds 
allowing multiple users to listen to the same sound. Leng et al. examined a number of 
stethoscopes including the Thinklabs Rhythm 32 stethoscope which uses an 
electromagnetic diaphragm with a conductive inner surface to form a capacitive sensor. 
This diaphragm responds to sound waves identically to a conventional acoustic 
stethoscope, with changes in an electric field replacing changes in air pressure. This 
preserves the sound of an acoustic stethoscope with the benefits of amplification (Leng 
et al., 2015).  
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Sonomat 
 
The non-invasive recording device, the Sonomat, by use of product specific software, 
has the potential to record and characterise respiratory sounds such as crackles, cough 
and wheeze. Using an inbuilt microphone, the Sonomat can record cough. The 
microphone can then be used to manually score respiratory sounds, including cough, 
crackles and wheeze. At this time, the sounds need to be manually scored, however, 
new validation studies performed at the David Read Laboratory are investigating 
automated methods (Norman et al., 2009b, Norman et al., 2014).  
 
1.6 COUGH 
 
Definition of Cough  
 
A clear definition of cough is lacking in many scientific papers, and if there is a 
definition, none is consistent. In a consensus statement by the European Respiratory 
Society (ERS), the authors have recommended that all basic scientific articles should 
refer to cough as a three-phase motor act (Morice et al., 2007). This three phase 
expulsive motor act is characterised by: 1. An inspiratory effort (inspiratory phase); 2. 
Followed by a forced expiratory effort against a closed glottis (compressive phase); 3. 
Then opening of the glottis and rapid expiratory airflow (expulsive phase) (Morice et 
al., 2007). In particular, the ERS has recommended that for the purposes of acoustic 
recordings in clinical studies, cough should be described as a forced expulsive 
manoeuvre or manoeuvres against a closed glottis that are associated with a 
characteristic sound or sounds (Morice et al., 2007).  
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Pathophysiology of cough 
 
During sleep, mucociliary clearance from the lungs decreases in both normal subjects 
(Bateman et al., 1978), and those with airways disease (Hasani et al., 1993). There have 
been relatively few studies investigating cough during sleep due to difficulties in 
measuring cough. Smith et al. looked at 19 adult patients with a pulmonary 
exacerbation and performed daytime and overnight sound recordings with 13 of the 
patients having repeat recordings prior to discharge (Smith et al., 2006). They found 
that cough rates fell with treatment of the pulmonary exacerbation and coughing 
virtually stopped overnight by discharge (Smith et al., 2006). These findings are in 
contrast to Hamutcu et al., who found that in children with CF, treatment of a 
pulmonary exacerbation did not improve either subjective (using cough score and 
visual analogue scores) or objective (using an ambulatory cough recording device) 
measures (Hamutcu et al., 2002).   
 
Frequency of nocturnal coughing in children with CF has been shown to be higher than 
described for normal children (van der Giessen et al., 2009). As expected, nocturnal 
cough was more severe in children with more advanced lung disease (van der Giessen 
et al., 2009). Nocturnal cough has been studied in 10 patients with severe chronic 
bronchitis and emphysema and it was reported that coughs during true sleep were rare 
and hence cough was found to be normally suppressed during sleep and only rarely 
wakened patients (Power et al., 1984) 
 
Similarly, cough has been shown to substantially reduce during sleep even during acute 
cough due to an upper respiratory chest infection with objective cough frequency rates 
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at 19 cough per hour during the day and 1.7 cough per hour during the night (Sunger et 
al., 2013).  
 
Whilst in the normal healthy lung these changes are of relatively little consequence, 
they may impact on sleep during an upper respiratory tract infection, when sleep is 
fragmented by the recurrent arousals induced by the need to cough (Dobbin et al., 
2005). These above studies have showed varied results investigating cough during sleep 
and although in text books it is written, few papers have actually measured it. This 
thesis seeks to further investigate the presence or absence of coughs particularly during 
sleep in adults with CF.   
 
Measurement of Cough 
 
Currently, no standardised method of cough monitoring exists. No single cough 
monitor is thought to be the “gold standard”. There are a number of available methods 
of recording: automation of the cough recognition system, the Hull Automatic Cough 
Counter (HACC) (Barry et al., 2006); Leicester Cough Monitor (LCM) (Birring et al., 
2008); and ambulatory cardiorespiratory monitoring system using the LifeshirtTM 
(Coyle et al., 2005, Goodrich and Orr, 2009). 
 
The HACC uses digital signal processing to calculate characteristic spectral 
coefficients of sound events, which are then classified into cough and non-cough events 
by the use of a probabilistic neural network (Barry et al., 2006). Then the determination 
of the number of coughs inside each cough event was carried out by a human listener. 
The HACC followed by using a graphical user interface showed that for an one hour 
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recording, analysis took only one minute and thirty five seconds, with a sensitivity of 
80 % and specificity of 96 % compared with manual audio recording (Barry et al., 
2006).  
 
The Leicester Cough Monitor developed by Birring et al., detects cough using an 
automated cough recorder capable of recording for 24 hours (Birring et al., 2008). The 
LCM was shown to have a sensitivity of 91 % and a specificity of 99 % for detecting 
cough in comparison with manual cough counts (Birring et al., 2008).  
 
Coyle et al., demonstrated that the LifeshirtTM showed a high level of accuracy and 
agreement (kappa = 0.807) with overall sensitivity of 78 % and specificity of 99 % 
compared with video surveillance for the measurement of day-time and night-time 
cough in COPD patients (Coyle et al., 2005). The LifeshirtTM used a specialised 
software algorithm to identify cough (Coyle et al., 2005).  
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SECTION B - SLEEP 
	
1.7 INTRODUCTION TO SLEEP 
 
Sleep is a necessary behavioural state that occurs in every individual. However, sleep 
is different in every individual. In addition, disease states can alter sleep architecture 
and result in sleep fragmentation and arousals.  
 
Within sleep, two separate states have been defined on the basis of a constellation of 
physiologic parameters. These two states, rapid eye movement (REM) and non-REM 
(NREM) are distinct from one another as each are from wakefulness (Kryger et al., 
2016). NREM sleep is divided into 3 stages: N1 sleep, N2 sleep and N3 sleep (slow 
wave sleep) and R is used to name REM sleep as per the AASM terminology (Iber et 
al., 2007). The electroencephalogram (EEG) pattern in NREM sleep is commonly 
described as synchronous, with characteristic waveforms such as sleep spindles, K-
complexes and high-voltage slow waves. The NREM stages closely parallels a depth 
of sleep continuum, with arousal thresholds generally lowest in N1 sleep and highest in 
N3 sleep (Kryger et al., 2016). In contrast, REM sleep is defined by EEG activation, 
muscle atonia, and episodic bursts of rapid eye movements (Kryger et al., 2016).  
 
In normal healthy adults, sleep is entered through NREM sleep and REM does not occur 
until after approximately 80 minutes, and NREM and RM sleep alternate through the 
night, with an approximately 90-minute cycle. N3 sleep predominates in the first third 
of the night and is linked to the initiation of sleep and the length of time awake. REM 
sleep predominates in the last third of the night and is linked to the circadian rhythm of 
the body temperature (Kryger et al., 2016). Wakefulness in sleep usually accounts for 
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less than 5 % of the night, with NREM sleep constituting 75 - 80 % of sleep and REM 
sleep accounting for 20 – 35 % of sleep, occurring in 4 to 6 discrete episodes (Kryger 
et al., 2016) 
 
Sleep disturbances are commonly reported by patients with chronic respiratory disease. 
Sleep disruption can contribute to impaired daytime functioning and overall quality of 
life (Bouka et al., 2012, Dancey et al., 2002, Fauroux et al., 2012, Milross et al., 2002). 
 
1.8 RESPIRATORY EVENTS DURING SLEEP 
 
An apnoea is a period during sleep where there is no breathing. In the updated revision 
of the 2007 AASM Manual for the Scoring of Sleep and Associated Events, an apnoea 
in adults was defined as a drop in the peak airflow measurement by ≥ 90 % of pre-event 
baseline using an oro-nasal thermal sensor or an alternative apnoea sensor for ≥ 10 
seconds (Berry et al., 2012). Hypopnoea in adults is scored when the peak airflow signal 
excursions drop by ≥ 30 % of pre-event baseline using nasal pressure or an alternative 
sensor for ≥ 10 seconds in association with either ≥ 3 % arterial oxygen desaturation or 
an arousal (Berry et al., 2012). However, it should be noted that in Australian 
laboratories, guidelines proposed by ASTA/ASA are used (Thornton et al., 2011). The 
apnoea definition remains used by the ASTA/ASA (Thornton et al., 2011), which is a 
period of ≥ 10 seconds where there is cessation of breathing. For an hypopnoea, the 
definition is a 50 % reduction in airflow accompanied by an arousal or a fall in oxygen 
saturation of 3 % or more (Thornton et al., 2011).  
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There have been multiple attempts of scoring snoring during sleep but none is widely 
used. Even in the position statement by ASTA/ASA, definitions of snoring were absent. 
Details have been suggested regarding the recording of snoring sound by microphones, 
piezo sensors or ambient sound pressure level – decibel meters but no definitions are 
made to assist the sleep technician in scoring snoring sounds (Thornton et al., 2011). In 
the Westmead laboratory, recorded sound signals from the room microphone were 
analysed. Previous studies from our laboratory have defined snore sounds but did not 
describe other sounds, such as a cough (Lee et al., 2008). A snore sound was defined 
as an obvious deflection from background sound level (with no minimum decibel 
threshold), which was in-phase with inspiration and occurred during sleep (Lee et al., 
2008). Each individual snore was manually scored, and a score index (snores per hour 
of sleep) was calculated. Each 30 second sleep epoch that contained 3 or more snore 
sounds was classified as a “snoring epoch”. The total number of “snoring epochs” was 
then expressed as a percentage of the total number of sleep epochs (snoring sleep time) 
(Lee et al., 2008).  
 
1.9 SLEEP DISORDERED BREATHING (SDB) 
 
Using the International Classification of Sleep Disorders (ICSD), sleep-related 
breathing disorders span a spectrum including disorders resulting in upper airway 
obstruction during sleep, disorders that alter breathing patterns, and disorders that 
produce hypoventilation or hypoxaemia (Sateia and Hauri, 2005).  
The severity of sleep related obstructive breathing events has been described as follows: 
• Mild: 5-15 events per hour 
• Moderate: 15 to 30 events per hour 
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• Severe: greater than 30 events per hour (Flemons et al., 1999) 
 
Lower airway dysfunction is not considered in these guidelines. Interestingly, the 
American Academy of Sleep Medicine (AASM) recommendations for syndrome 
definition of sleep disordered breathing made no mention of arousal from sleep due to 
coughing, sneezing or grunting (Flemons et al., 1999).  It was likely that criteria can be 
developed to separately classify cough arousals, and that these could become routinely 
measured in patients with chronic lung disease who undergo sleep studies.  
 
1.10 SLEEP MEASUREMENT 
 
Introduction 
 
Sleep may be measured using subjective or objective methods. Sleep is most reliably 
objectively measured using in-laboratory polysomnography (PSG), which continuously 
measures a series of physiological variables, including the EEG and electro-oculogram 
(EOG) to assess sleep stages, nasal flow, oximetry and body posture to assist in 
assessment of arousals and oxygen saturation during the night. The “gold standard” of 
sleep measurement remains in-laboratory polysomnography. However, due to the 
increasing prevalence of sleep disorders, home-style sleep studies are emerging in the 
field of sleep measurement. In-laboratory sleep studies can create an artificial 
environment for subjects and recording sleep at home may allow the subject to sleep 
better in their own home environment.   Detailed descriptions of the methods used for 
polysomnography and the Sonomat are in Chapter 2 – Methods.  
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Diagnostic polysomnography 
 
In-laboratory polysomnography (PSG), measures a series of variables including the 
electro-encephalogram (EEG), electro-oculogram (EOG), electro-myogram (EMG), 
respiratory effort using inductive plethysmography, oxygen saturation in addition to a 
room microphone used to record sound events (Iber et al., 2007, Thornton et al., 2011) 
 
Particularly for this project, recording of respiratory sounds was important if we were 
to analyse these abnormalities in the CF population. In the AASM guidelines, 
microphones for snoring sound were recommended with a sampling frequency of 500 
Hz (Iber et al., 2007). Good sensitivity in the range of 20 Hz to 3 KHz was 
recommended (Iber et al., 2007). In Australian sleep laboratories (as in our sleep 
laboratory), decibel (sound level) meters are commonly used. These sound meters 
measure the ambient sound pressure level within the bedroom and provide a 
quantitative validated measure of the sound which can be compared with environmental 
noises.  
 
Sonomat 
 
A simple system to address limitations for in-laboratory PSG has been developed called 
the Sonomat (Norman et al., 2014, Norman et al., 2009a, Norman et al., 2009b).  The 
Sonomat is a new, non-invasive recording device which can document sleep and 
breathing parameters at home using a portable mat which sits on top of the patient’s 
mattress, underneath the sheets (Norman et al., 2009b). The mat contains two room 
microphones and four highly sensitive vibration sensors, strategically positioned to 
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detect breath sounds, breathing movement and body movement, giving both respiratory 
and arousal information, allowing calculation of numbers of breathing and movement 
arousals through the night. All variables are recorded and stored directly on a SD card 
within the Sonomat. This makes the Sonomat the ideal system to perform repeated 
overnight studies over a number of weeks at home and has been used in different patient 
groups (Johnson et al., 2011, Ngiam et al., 2011, Norman et al., 2009a, Norman et al., 
2009b). 
 
The Sonomat has been previously validated in subjects with a clinical history of OSA 
(Norman et al., 2014). There were positive correlations between the PSG and Sonomat 
for measures of sleep time, respiratory events and the AHI (all correlations > 0.89) 
(Norman et al., 2014).  
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SECTION C - CYSTIC FIBROSIS 
 
1.11 INTRODUCTION TO CYSTIC FIBROSIS 
 
Cystic Fibrosis (CF), the most common lethal inherited disorder in Australian, affects 
1 in 2,800 live births (Massie et al., 2000). CF is caused by defects in a single gene on 
the long arm of chromosome 7 encoding a protein, the cystic fibrosis transmembrane 
regulator (CFTR), which primarily functions as a cyclic adenosine monophosphate-
regulated chloride channel. The CF gene was successfully identified in 1989 in a 
collaborative effort by the groups of Lap-Chee Tsui and John O’Riordan at Toronto’s 
Hospital for Sick Children, together with Francis Collins at the Howard Hughes 
Medical Institute at the University of Michigan (Kerem et al., 1989, Riordan et al., 
1989, Rommens et al., 1989). It is thought that dysfunction of the CFTR protein alters 
the balance of chloride secretion and sodium absorption to an absorptive state that 
results in airway surface dehydration (Boucher, 2007). Airway surface liquid depletion 
has been proposed to impair mucociliary clearance and reduce ability of the airways to 
clear bacteria and other foreign particles from the lower airways (Goss and Ratjen, 
2013b).  
 
CF is characterised by lungs that are normal at birth, but with increased inflammation 
and infection within the first year (Ranganathan et al., 2017). The primary cause of 
morbidity and mortality in CF is chronic endobronchial infection associated with an 
intense host inflammatory response leading to progressive airway destruction (Ramsey 
and Boat, 1994, Rosenfeld et al., 2001). Although infection remains the major trigger 
of airway inflammation in CF, the response to any pro-inflammatory stimuli is altered 
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in CF, and neutrophil dominated inflammation persists in the majority of patients (Goss 
and Ratjen, 2013a). Sagel et al., have demonstrated that neutrophil elastase has 
predictive value for subsequent lung function decline in CF and longitudinal changes 
in sputum biomarkers are related to lung function changes (Sagel et al., 2012). That is, 
that higher baseline neutrophil elastase concentrations were associated with faster rates 
of decline in forced expiratory volume in one second (FEV1) % predicted (Sagel et al., 
2012). Being able to identify biomarkers which can predict and monitor disease 
progression could have a significant impact on clinical regimens in CF patients.  
 
Risk factors for decline in FEV1 in paediatric patients included female gender, 
pancreatic insufficiency, poor nutritional status, and infection with Pseudomonas 
aeruginosa (Konstan et al., 2007). In addition, crackles, daily sputum production, 
wheezing, sinusitis, number of pulmonary exacerbations treated with IV antibiotics and 
elevated liver function tests were found to be additional risk factors for FEV1 decline 
in children (Konstan et al., 2007). Further to this study in children, the risks factors in 
adults were explored by this group, however, daily cough was found to be associated 
with decline only in the younger adults (age 18 – 24 years) but not in the older adults 
(age ≥ 25 years) (Konstan et al., 2012). In final multivariate models, statistical 
significance of factors in the younger age group (age 18 – 24 years) included: female 
gender; baseline FEV1 % predicted; daily cough; sinusitis; pancreatic enzyme use; 
mucoid P. aeruginosa; multidrug-resistant P. aeruginosa; B. cepacia (Konstan et al., 
2012). In contrast, the only factors that were found to be statistically significant in the 
older age cohort (≥ 25 years) were: baseline FEV1 predicted, sinusitis and pancreatic 
enzyme use (Konstan et al., 2012). These authors discussed the reason that some factors 
were not found to be significant may be that in adult patients, the risk factor (eg 
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crackles) has been present for an extended period of time and the disease progression 
associated with its onset has already occurred (Konstan et al., 2012).  
 
1.12 DIAGNOSIS 
 
In NSW, new born screening was introduced in 1981, with the other states 
progressively undertaking newborn screening such that now 60 % of all new diagnoses 
of CF are made by newborn screening (NBS) (Ruseckaite et al., 2018). Meconium ileus 
was reported in 5.6 % of cases, gastrointestinal symptoms were reported in 11.1 %, and 
respiratory symptoms in 9.7 % (Ruseckaite et al., 2018). Early diagnosis is associated 
with improved health outcomes in these patients (Southern et al., 2009). As of 
December 2016, 49.3 % of all CF patients were homozygous for F508del and 42.9 % 
were compound heterozygous F508del (Ruseckaite et al., 2018). The genetic mutation 
F508del, G551D or G542X was present in nearly 95 % of CF patients (Ruseckaite et 
al., 2018) 
 
1.13 PREVALENCE 
 
In Australia, the incidence of CF is about 1 in 2,800 live births (Massie et al., 2000). 
Approximately 1 in 25 Australians are carriers of a genetic mutation responsible for CF 
(Massie et al., 2007). As of December 2016, the median age of patients with CF was 
19.3 years with the proportion of adults in the CF Registry in Australia at 53.2 % 
(Ruseckaite et al., 2018) 
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1.14 SYMPTOMS 
 
At birth, CF can manifest in a number of ways including presentation with meconium 
ileus, failure to thrive, reduced or stunted growth or recurrent chest infections, 
particularly if the child’s diagnosis is delayed. As the disease progresses, lung function, 
failure to thrive or abdominal issues may worsen and if not treated correctly result in 
irreversible disease. Various methods have been employed, such as CT-detected 
structural lung disease, in an attempt to intervene early to reduce the progression, 
severity and disease burden later in life (Newbegin et al., 2018a)  
 
Daytime cough 
 
Those people with CF who have established lung disease often will have a daily cough, 
particularly in the mornings. Even though airway clearance can reduce cough, it is often 
still present. One of the hallmark features of a pulmonary exacerbation is the presence 
of increased cough.  Cough is well known to occur on a regular basis in those with mild, 
moderate, and severe lung disease but quantitative studies (day or night) have only 
recently been started.  A recent cross-sectional study using an ambulatory recording 
device has documented frequent coughing in CF adults (Kerem et al., 2011). However, 
no long-term studies have examined the use of cough recorders to determine if 
increasing cough is the earliest abnormality in a CF adult developing a pulmonary 
exacerbation.   
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The subjective reporting of cough is less reliable than objective measures. Increased 
cough frequency and duration comprise some of the common symptoms associated 
with pulmonary exacerbations in people with CF (Dakin et al., 2001, Fuchs et al., 1994). 
 
Cough is commonly used as an objective measure in clinical studies of CF patients. A 
recent study using the Lifeshirt™, a portable cough monitoring device, has documented 
the circadian variability of cough in CF adults, showing a median of 41 coughs per hour 
while “awake”, compared with 2 coughs in the nocturnal part of the study (Kerem et 
al., 2011). But the definition of “sleep” in this study was based on body position and 
breathing pattern.  No measure of the resultant sleep fragmentation was made, nor any 
quantitative or even semi-quantitative measure of the forces involved in the coughs – it 
was just recorded as the presence of cough.  Finally, these ambulatory cough recorders 
will not record other features of sleep disordered breathing such as grunting, snoring, 
increased respiratory effort, nor hypoventilation. Something that is simple, non-
invasive and can be used on a nightly basis to measure sleep-cough and resultant 
arousals would be required to help predict pulmonary exacerbations. Hence, the 
portable Sonomat device may be useful to measure these sleep disturbances in CF 
people.   
 
As noted above, increased cough frequency is a common symptom of an impending 
pulmonary exacerbation. In an attempt to objectively monitor cough in children with 
CF, Hamutcu et al examined 14 children with CF using an ambulatory cough recorder 
(LR100 cough recorder) and a conventional tape recorder (Hamutcu et al., 2002). These 
authors found no significant correlation between admission, discharge cough objective 
scores, day or night-time cough scores, nor day or night time visual analogue scores 
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(VAS) (Hamutcu et al., 2002). In addition, they did note that there was no improvement 
between admission and discharge scores despite increases in spirometry (Hamutcu et 
al., 2002). These results may be affected by the small number of subjects studied and 
the fact that the authors measured the numbers of cough epochs and not the duration of 
the individual epoch which may correlate better with patient perception of cough as the 
patients may notice long coughing bouts rather than the number of cough epochs more.  
 
In 19 adult CF subjects (median age of 23 years), cough sound recordings were obtained 
using a digital recording device whilst patients were admitted with a pulmonary 
exacerbation (Smith et al., 2006). Manually scored coughs fell significantly by 51 % (p 
< 0.001) during daytime and 72 % (p = 0.049) during night time over the course of the 
admission (Smith et al., 2006). Only the change in night VAS correlated with change 
in objective cough rates (p = 0.001). The change in VAS during the day did not correlate 
with change in objective day cough rate (p = 0.070). However, the length of cough 
epochs during  the day and night significantly reduced with treatment (p = 0.009) 
(Smith et al., 2006). However, this was arduous task as each recording took 
approximately 2.5 to 3 hours to process and the subject had to put on a bulky vest device 
to measure the coughing. This suggests that there is a need for an automated system 
that is compatible with day to day living to measure such parameters such as night time 
and daytime cough. 
 
Nocturnal cough 
 
Anecdotally, it is often noted by the patient’s partner or parent that the patient’s 
breathing during sleep worsened a few days before the patient was first aware of a 
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developing exacerbation. An increase in arousals in the nights before an exacerbation 
(according to Fuch’s criteria) may well be the key to early recognition of an impending 
exacerbation (Fuchs et al., 1994).  The current research will examine cough and other 
respiratory disturbances and their resultant sleep fragmentation in CF patients; as part 
of the longitudinal study, nocturnal sleep disordered breathing before and after 
exacerbations will be investigated. The changes in sleep in CF adults may be able to 
determine an earlier abnormality seen during the evolution of a pulmonary 
exacerbation. 
 
1.15 PULMONARY EXACERBATIONS 
 
A person with CF will develop periods when they have more cough, more sputum, feel 
unwell and may lose lung function capacity, as an exaggerated response to chest 
infections. These are clinically termed “exacerbations” and treated with antibiotics, but 
the exact definition of a pulmonary exacerbation varies widely. The most commonly 
used definition in people with CF is the definition used initially by Fuchs et al. during 
their treatment trial of aerosolised recombinant human DNase and proposed that a 
pulmonary exacerbation was reported to have occurred in patients with any 4 of the 
following 12 signs or symptoms and in whom patients subsequently required 
intravenous antibiotics (Fuchs et al., 1994). The 12 parameters included: change in 
sputum; new or increased haemoptysis; increased cough; increased dyspnoea; malaise, 
fatigue or lethargy; temperature above 38 degrees Celsius; anorexia or weight loss; 
sinus pain or tenderness; change in sinus discharge; change in physical examination of 
the chest; decrease in pulmonary function by 10 percent or more from a previously 
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recorded value; or radiographic changes indicative of pulmonary infection (Fuchs et 
al., 1994).  
Clinical treatment regimens for CF have outlined the need for early intervention to 
lessen the number and severity of pulmonary exacerbations, which in turn, lessen the 
loss of pulmonary function and delay the onset of respiratory failure and death (Doring 
et al., 2012). It has been shown that one quarter of CF patients treated with antibiotics 
for acute exacerbations did not recover to baseline function (Sanders et al., 2011). 
Therefore, the early recognition and treatment of pulmonary exacerbations is critical to 
further improvements in CF survival (Newbegin et al., 2018b, Ranganathan et al., 
2017). However, despite improvements in therapy for CF, death from respiratory failure 
still occurs in > 90 % of patients (Bell et al., 2011).  
  
For shorter duration or milder pulmonary exacerbations, many will spontaneously 
resolve leading to the difficulties in the definition of an exacerbation as outlined above 
(Abbott et al., 2009). For those exacerbations that are slightly more severe or lasting 
longer, then oral and / or nebulised antibiotics may be sufficient treatment, but for 
longer duration and more severe exacerbations, intravenous antibiotics in hospital are 
often necessary (Flume et al., 2009b, Goss and Ratjen, 2013b). 
 
Whilst the onset of a CF exacerbation is usually thought to occur over 1-2 days, this is 
generally based on the patient’s recognition of their symptoms (Ferkol	et	al.,	2006,	Goss	
and	Burns,	2007,	Goss	et	al.,	2009). Many authors are proposing a clinical paradigm to 
detect an earlier abnormality in the onset of a pulmonary exacerbation in CF (Bilton et 
al., 2011, Dakin et al., 2001). Simple peak flow measurements, like those used in 
asthma, are unlikely to be useful for CF as mild and moderate exacerbations can occur 
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with relatively little change in peak flow or spirometry. Previous authors have found 
that the value of symptoms in identifying pulmonary exacerbations is high but 
performing daily symptom cards may be hard for the subject and not necessarily a 
sensible option for long-term use (Dakin et al., 2001).  
 
An alternative method of evaluating pulmonary exacerbations may be identification of 
respiratory sounds, such as coughs or crackles, which indicate sputum retention. These 
respiratory sounds can be measured day and night to identify changes in impairment of 
airway functioning signifying a possible pulmonary exacerbation due to difficulty 
clearing mucus. Optimising non-invasive measurements of markers to predict the onset 
of an exacerbation would be useful to the long-term management of people with CF.  
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SECTION D - SLEEP AND CYSTIC FIBROSIS  
 
1.16 INTRODUCTION TO SLEEP AND CYSTIC FIBROSIS 
 
Disease states can alter sleep architecture and result in sleep fragmentation and 
arousals. As lung disease worsens with age, adults with CF develop worsening sleep 
disordered breathing (SDB) (de Castro-Silva et al., 2009, Fauroux et al., 2012, Katz, 
2014, Milross et al., 2004, Veronezi et al., 2015). 
 
Advances in sleep medicine have enabled in-depth parameters of sleep to be analysed 
in a wide variety of medical conditions. Patients with CF may be predisposed to poor 
sleep quality due to a variety of factors including upper and lower airway abnormalities 
and impaired ventilation and perfusion. Furthermore, other contributors to CF sleep 
abnormalities may include medications, constipation, gastro-oesophageal reflux, 
chronic anxiety or depression.  
 
As noted above, patients with CF produce increased sputum volume each day, even 
when they have relatively mild lung disease.  As mucociliary clearance is reduced 
during sleep (Bateman et al., 1978), the secretions produced through the night will 
gradually accumulate in the airways until they provide such a strong stimulus to cough 
that an arousal from sleep is induced. As part of this arousal, the cough threshold is 
reduced sufficiently to allow the subject to cough. In patients with suppurative lung 
disease, such as CF, the increase in nocturnal cough is such that they cannot wait until 
morning, and must awaken through the night to cough and clear retained secretions.  
This may impact on sleep long term, even during periods of clinical stability. There 
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have been a number of studies investigating sleep abnormalities in subjects with CF 
(Dobbin et al., 2005, Milross et al., 2004, Milross et al., 2001b), but none have 
investigated using non-invasive methods such as the novel Sonomat, which is a portable 
device used to record sound and movement parameters in a mat that sits on top of the 
patient’s mattress with no attachments to the patient.  
  
As part of this research, sleep parameters will be examined, in particular the presence 
of sleep fragmentation due to cough, in adults with CF with normal lungs and those 
with mild, moderate and severe disease during periods of clinical stability.   
 
Faroux et al. researched 25 children and 55 young adults with CF and showed that 
people with CF exhibited poor sleep quality with impaired sleep efficiency but this did 
not predict nocturnal gas exchange (Fauroux et al., 2012). However, nocturnal 
hypoxaemia was shown to occur in 20% of subjects and nocturnal hypercapnia in 47% 
of subjects (Fauroux et al., 2012).  
 
Nocturnal hypoxaemia often occurs prior to daytime abnormalities of gas exchange 
(Perin et al., 2012). Furthermore, worsening hypercapnic respiratory failure, as a 
marker of pulmonary deterioration, has been strongly linked with reduced survival 
(Kerem et al., 1992). 
 
In a home based study of CF subjects, recruited from a Chicago CF Clinic, using wrist 
actigraphy for 14 days and questionnaires, it was demonstrated that stable CF patients 
have disrupted sleep and higher PSQI scores than control subjects (Jankelowitz et al., 
2005). These authors also found a significant correlation of fragmentation index 
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(measure of restlessness calculated by summing the percentage of minutes spent 
moving with the percentage time spent immobile per minute) with FEV1 and PSQI 
scores (Jankelowitz et al., 2005). 
 
Dobbin et al. demonstrated that during hospitalisation for an exacerbation, adults with 
CF had worse sleep: sleep quality, sleep efficiency, time in REM and time in slow wave 
sleep were all significantly reduced (Dobbin et al., 2005).  Restudying this group 10 to 
14 days after the initial study, demonstrated that virtually all these abnormalities had 
improved after a course of intravenous antibiotics (Dobbin et al., 2005).    Whilst this 
study clearly demonstrates improvement in PSG following 2 weeks of intensive 
therapy, the time course of deterioration before the start of an exacerbation is currently 
not known. Given anecdotal data that partners / parents notice night-time cough a few 
days before an adult with CF notes their own exacerbation, it is likely that changes in 
night-time parameters occur at least a few days before clinical recognition. Parallel to 
the earlier intervention in asthma exacerbations, analysing reliever use rather than 
clinical symptoms, and earlier recognition of deterioration may offer therapeutic 
options before clinical status worsens significantly (Busse et al., 2008). 
 
A cross-sectional study performed in adults with CF when clinically stable was 
undertaken by Perin et al., 2012 to investigate what are the best predictors of sleep 
desaturation in CF patients (Perin et al., 2012). These authors studied 51 clinically 
stable CF subjects (FEV1 ranged from 115 % to 19.5 % of predicted, mean 57.7 % ± 
24.7 % of predicted) and 25 age-matched healthy control subjects and found CF patients 
had impaired subjective sleep quality with a higher Epworth Sleepiness Scale (ESS) 
and Pittsburgh Sleep Quality Index (PSQI) scores than controls (p = 0.002 and p < 
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0.001, respectively) (Perin et al., 2012). They demonstrated a significant difference 
between CF subjects and controls in ESS with 26 % of the CF subjects reporting an 
ESS of more than 10 versus 8 % of control subjects (p < 0.001) (Perin et al., 2012). 
Overnight polysomnography demonstrated a higher arousal index in the adults with CF 
compared with healthy age-matched controls (12.1 ± 6.1 events per hour vs 8.9 ± 4.7 
events per hour, p = 0.02) (Perin et al., 2012). Interestingly, sleep efficiency was similar 
in the groups (81.1 ± 11.9 vs 82.0 ± 7.8 %, p = NS) and AHI was normal in both groups 
(0.3 events per hour in CF group vs 0.5 events per hour in control group, NS) (Perin et 
al., 2012). 
 
There were statistically significant differences in oxygenation: mean sleep peripheral 
capillary oxygen saturation (SpO2), nadir sleep SpO2 (85.8 ± 6.3 % vs 92.6 ± 2.5 %, p 
< 0.001), sleep desaturation where SpO2 during sleep of less than 90% for  ≥ 5 minutes 
with a nadir of  < 85 % (15 versus 0 %, p < 0.001) and difference between awake SpO2 
and nadir SpO2 (9.2 ± 4.6 vs 5.2+ 1.9 %, p < 0.001) (Perin et al., 2012). The above 
study by Perin et al. highlights that sleep efficiency and AHI may be normal in subjects 
with CF but the more subtle measures of abnormalities during sleep require further 
development. Milross et al. studied 32 adults with CF using PSG, lung function, 
respiratory muscle strength and arterial blood gas reports to examine the predictors of 
sleep disordered breathing (Milross et al., 2001b). These authors concluded that 
evening PaO2 significantly contributed to the ability to predict both sleep-related 
desaturation (p < 0.001) and the rise in transcutaneous carbon dioxide from NREM 
sleep to REM sleep (Milross et al., 2001b).   
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The vast majority of studies in CF subjects have only included subjects with moderate 
or severe pulmonary disease from CF (Dobbin et al., 2005), often those patients 
awaiting lung transplantation, with the studies designed to answer whether non-
invasive ventilation offers benefits by reversing respiratory abnormalities during sleep 
(Dobbin et al., 2004, Katz, 2014, Piper et al., 1992). The subtler changes may suggest 
the development of an exacerbation rather than frank deterioration in lung function. 
Hence, the proposed area of research will investigate the relationship between cough, 
arousals and sleep fragmentation in subjects with CF with a range of lung function.    
 
Overall, there has been a lack of standardisation in defining nocturnal arousals 
(particularly those due to cough or other respiratory events), making comparisons 
between studies difficult. Therefore, this research will evaluate the prevalence of sleep 
disordered breathing in addition to investigating the range of abnormal sleep parameters 
seen in patients with CF, in particular the presence of cough and other respiratory 
noises, such as crackles, and the relationship to nocturnal arousals. 
 
1.17 PREVALENCE 
 
The magnitude of the issue of nocturnal desaturation in CF adults was demonstrated in 
recent studies by Young et al., who showed that more than 25 % of clinically stable CF 
adults (mean age: 31 years, mean FEV1 42 % predicted)  exhibit nocturnal oxygen 
desaturation, which was associated with reduced quality of life (Young et al., 2011).  A 
Canadian study of 19 adult CF subjects with severe lung disease (average FEV1 28 % 
predicted) found significantly increased arousals from sleep, significantly reduced 
sleep efficiency, reduced mean arterial oxygen desaturation and worse neurocognitive 
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function compared with 10 healthy control subjects (Dancey et al., 2002).  However, 
cough and cough related arousals were not reported.  Although in their discussion, these 
authors documented that the sleep technicians reported coughing interfered with sleep 
in four patients no further analysis was described (Dancey et al., 2002). Cough was 
proposed as one of the factors that may result in sleep disruption and sleep loss (Dancey 
et al., 2002). 
 
1.18 PATHOPHYSIOLOGY 
 
Nocturnal cough has the potential to contribute to impaired sleep quality and abnormal 
sleep architecture by causing arousals. Previous studies have investigated these issues 
including Stokes et al.; and Francis et al. (Francis et al., 1980, Stokes et al., 1980). In 
the small study of 9 patients with CF, Stokes et al. demonstrated that in a third of these 
patients (range FEV1 17 – 81 % predicted), cough during sleep was associated with 
sleep disruption (Stokes et al., 1980). In this particular study, episodes of cough 
(manually observed) during stages 1 and 2 sleep delayed progression to deeper stages 
of sleep, while protracted cough occasionally halted progression to REM sleep (Stokes 
et al., 1980). In the study performed by Francis et al., 20 CF patients with severe lung 
disease (mean age of 18.2 years, mean FEV1 35.7 % predicted), showed a mean 7.4 % 
fall in SaO2 (detailed in their paper as SaO2,  measured by ear oximetry) during REM 
sleep compared with a 2.0 % fall in the control group (Francis et al., 1980). 
 
Studies have demonstrated that CF patients with severe respiratory disease exhibit 
marked nocturnal oxygen desaturation and nocturnal carbon dioxide retention when 
asleep (Milross et al., 2004).  Desaturation worsens during sleep due to a combination 
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of hypoventilation, impaired lung mechanics and ventilation-perfusion mismatching 
(Milross et al., 2001a).   
 
Intermittent and recurrent nocturnal hypoxia has been a proposed mechanism for the 
stimulus for the development of pulmonary hypertension in patients with OSA, this 
may also be seen in CF patients as documented by Fraser et al.(Fraser et al., 1999). 
Further confirmed by Perin et al., 2012, these authors found that adult CF patients who 
had sleep hypoxaemia were more predisposed to desaturate at submaximal exercise and 
to present echocardiographic findings suggesting pulmonary hypertension (Perin et al., 
2012, Fraser et al., 1999). However, little research has been performed in adults with 
CF with mild lung function abnormality.  
 
1.19 OBJECTIVE SLEEP MEASUREMENTS 
 
Polysomnography 
 
Most studies of sleep in CF subjects have measured in-laboratory PSGs over 1 or 2 
nights, examining patients with moderate to severe lung disease secondary to CF. In 19 
CF subjects, significantly reduced total sleep time (TST) (p = 0.048) and sleep 
efficiency (p=0.004) was seen along with CF subjects demonstrating significant 
hypoxaemia during sleep (mean oxygen saturation of haemoglobin in arterial blood  
(SaO2) 84.4 %), which was associated with reduced sleep efficiency (Dancey et al., 
2002). The AHI of CF subjects in the Perin study was normal at 0.3 events per hour, 
which was not significantly different compared to controls (0.5 events per hour) (Perin 
et al., 2012). However, in this study there was a small but statistically significant 
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difference (p = 0.02) between the CF group and normal group for the arousal index 
(Perin et al., 2012). 14 CF subjects and 8 control subjects underwent exercise testing 
and overnight sleep studies (Bradley et al., 1999). Interestingly, in comparison to other 
studies, these authors found no significant differences in sleep efficiency, arousal 
frequency, or sleep architecture between the CF and control groups (Bradley et al., 
1999). However, as expected, oxygen levels during sleep were significantly lower in 
the CF group (mean FEV1 of 1.55 Litres) compared with the control group (mean FEV1 
4.01 Litres) (Bradley et al., 1999).  
 
Sonomat 
 
At the time of writing this review, no studies using the Sonomat have been reported in 
the literature using CF subjects. Hence, this research project will be the first using the 
Sonomat in CF subjects. We propose a simple non-invasive machine that simply 
requires the person with CF to sleep on the mat to record a number of variables 
including sound and movement. This thesis aims to further validate the Sonomat for 
the characterisation of respiratory sounds which may be important for managing people 
with CF-related lung disease. 
 
1.20 SUBJECTIVE MEASUREMENTS 
 
Epworth Sleepiness Scale (ESS) 
 
The ESS is a commonly used measurement of daytime sleepiness (Johns, 1991). 
Subjects are asked to rate on a scale of 0-3 how likely they would be to doze off or fall 
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asleep in eight different situations (Johns, 1991). The raw numbers are summed 
together to give a score between 0 and 24. It has been well validated in the OSA 
population but has also been used in studies of CF subjects. In the study by Jankelowitz 
et al., the mean ESS scores for the CF subjects were higher but not statistically 
significant than in the control subjects (6.75 ± 3.32 vs 5.72 ± 3.63, p = 0.39), however, 
the value was still considered normal (ESS < 10) (Jankelowitz et al., 2005). In another 
study by Dancey et al., again ESS was within normal limits (ESS 7.3 ± 4.4) (Dancey et 
al., 2002). 
 
Pittsburgh Sleep Quality Index (PSQI) 
 
The PSQI is a self-reported questionnaire that measures the subjects’ recollection of 
sleep quality over the previous four weeks. The PSQI consists of 19 questions. A global 
PSQI score of greater than 5 indicates that a subject is a “poor sleeper” (Buysse et al., 
1989). The PSQI has been used previously in studies of CF subjects including a study 
by Jankelowitz et al., investigating sleep quality and sleep disruptions in CF patients 
(Jankelowitz et al., 2005). These authors found that the PSQI score was significantly 
higher in CF subjects (6.45 ± 3.31, p = 0.04) than in controls (Jankelowitz et al., 2005). 
In a study of 51 clinically stable adult CF patients and 25 age-matched controls, CF 
patients had significantly higher ESS,  PSQI scores as well as a higher arousal index 
than the controls (p < 0.05) (Perin et al., 2012).  
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CF Quality of Life (QoL) 
 
QoL in adults with CF has been previously studied by a number of authors. More 
recently due to the emerging therapies targeting certain CF gene mutations, there has 
been interest in assessing changes in quality of life following commencement of these 
novel drugs. Hence, QoL questionnaires are being utilised to assess important 
secondary endpoints of clinical trials that are not always demonstrated by change in 
spirometric parameters or exercise capacity. 
 
There are currently a number of questionnaires that have been validated to assess 
quality of life including depression and anxiety in chronic respiratory diseases. The 
most utilised questionnaires for chronic respiratory patients include: the St George 
Respiratory Questionnaire (SGRQ) (Jones et al., 1991) and the Hospital Anxiety and 
Depression Scale (HADS) (Zigmond and Snaith, 1983). In particular for CF patients, 
two main questionnaires were developed: the Cystic Fibrosis Questionnaire (CFQ) 
English version (Quittner et al., 2000), then the CFQ-Revised (Quittner et al., 2005) 
and the CF QoL questionnaire (Gee et al., 2000). The CFQ-R has been the primary 
questionnaire utilised as a measure of secondary endpoints in therapeutic drug trials. 
The CFQ-R and CF QoL are further discussed below. 
 
The St George Respiratory Questionnaire (SGRQ) was initially designed to measure 
the impact of overall well-being in patients with obstructive airways disease including 
those patients with COPD (Jones et al., 1992, Harper et al., 1997), asthma (Jones et al., 
1991, Quirk et al., 1991) and bronchiectasis (Wilson et al., 1997). In the SGRQ, there 
are 50 items with 76 weighted responses divided into 2 parts with 3 components 
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including symptoms, activity and impacts components. The weights provide an 
estimate of the distress associated with the symptom or state described in each item. 
Scores ranging from 0 to 100 are calculated for each component, as well as a total score 
which summarises the response to all items (Jones et al., 1991). A score of zero 
indicates no impairment of quality of life (Jones et al., 1991). A previous multi-centre 
study showed significant correlations between total score and presence of cough, 
sputum and wheeze in 141 subjects with long-standing airflow limitation (r2 = 0.11, 
0.06 and 0.25, respectively; p < 0.0001, p = 0.002 and p < 0.0001, respectively) (Jones 
et al., 1992). In particular, the SGRQ symptom score was significantly higher indicating 
worse health in patients with daily cough and sputum production (Jones et al., 1992). 
Correlations found between SGRQ scores and a range of measures appeared to be 
appropriate to the section of the SGRQ under study. However, the major limitation of 
this questionnaire is that it has not been validated in the CF population. Therefore, a 
need was identified to establish a QoL questionnaire that captured different aspects of 
QoL in CF patients, hence the CFQ was created.  
 
Other scales have measured different items, for example, the Medical Research Council 
(MRC) respiratory symptoms questionnaire and MRC dyspnoea scale. The MRC 
dyspnoea scale and 6 minute walking distance were closely related to SGRQ Activity 
score (p = 0.0001, p = 0.0052, respectively) but not to the SGRQ Symptom score (p = 
0.16, p = 0.53, respectively) in the above study of patients with long-standing airflow 
limitation (Jones et al., 1992). Anxiety and depression scores correlated best with the 
SGRQ Impact section (r2 = 0.38, r2 = 0.39, respectively) (Jones et al., 1992). The 
dominant factors influencing the total SGRQ score were found to be wheeze, dyspnoea 
and anxiety (Jones et al., 1992). The SGRQ was subsequently translated from British 
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English to American English (SGRQ-A) and was modified by altering the time of 
symptom reporting from 1 year to 1 month. The total scores based on the 1-year and 1-
month symptom reports correlated with FEV1, MRC dyspnoea scale and 6MWT 
distance (p ≤ 0.01) but not the FEV1 % predicted (Barr et al., 2000).  
 
Zigmond and Snaith, 1983, developed a self-assessment scale used to detect states of 
depression and anxiety in the setting of a hospital medical outpatient clinic called the 
Hospital Anxiety and Depression Scale (HADS) (Zigmond and Snaith, 1983). The 
HADS contains 7 items in the two areas of anxiety and depression with each item scored 
between 0 and 3. The assessment for each patient takes about 20 minutes. The total 
score for anxiety and depression is calculated separately with a score of 0 - 7 indicating 
normal emotions, 8-10 indicating a borderline abnormal emotional disorder and a score 
of 11 - 21 demonstrating an abnormal emotional disorder (Zigmond and Snaith, 1983). 
The HADS has not been widely used in the CF population and has not been validated 
in this population so was not used during the current study.  
 
Cystic Fibrosis Quality of Life (CF QoL) Questionnaire  
 
Gee et al., 2000 developed a disease specific health related QoL measurement, the 
Cystic Fibrosis Quality of Life (CF QoL) (Gee et al., 2000). They identified a need to 
measure the impact of CF on daily functioning and interviewed patients, specialist 
medical and allied health staff as well as reviewed the literature and examined other 
QoL measures to identify specific areas of concern to adults and adolescents with CF. 
The developed validated questionnaire can be used:  as an outcome measure in clinical 
trials; to assess the impact of disease progression on patient’s well-being; and, for 
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monitoring individual patients. The CF QoL questionnaire is a fully validated disease 
specific measurement consisting of 52 items in total which covers the 8 domains of: 
physical functioning; social functioning; treatment issues and chest symptoms; 
emotional functioning, concerns for the future, interpersonal relationships; body image; 
and career concerns (Gee et al., 2000). All items are scored from 1 to 6 and then scaled 
to produce a score of between 0 and 100 for each section above. A transformed score 
indicates the value that has been achieved out of a maximum of 100 with 100 indicating 
the most positive QoL levels possible. As this is a validated disease specific 
questionnaire it was thought its use in the current study would complement the results 
of the CFQ-R measurement currently under widespread use in clinical trials. The CF 
QoL measure can also be used to assess patient’s well-being longitudinally and Gee et 
al., 2005 described data from routine clinical use that would suggest a change of 5 
points on the CF QoL scales can indicate a small, meaningful change as perceived by 
the patient (Gee et al., 2005).  
 
Cystic Fibrosis Questionnaire (CFQ) and Cystic Fibrosis Questionnaire-Revised 
(CFQ-R) 
 
Originally, the CFQ was designed by the French group starting in 1995 led by 
Bernadette Henry and Peirre Aussage and was then translated into the English version 
by Quittner et al. (Henry et al., 2003, Quittner et al., 2000). Later it was revised by 
Quittner et al. and the results were published in 2005 as the CFQ-revised version 
(Quittner et al., 2005). To be discussed in Chapter 2 – Methods, the CFQ-R 
questionnaire was used in this study as it has been well validated in the CF population. 
Briefly, the CFQ-R is a disease-specific questionnaire that measures health related 
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quality of life for patients older than 14 years (Quittner et al., 2005). This questionnaire 
consists of 44 items on 12 generic and disease-specific scales. It encompasses general 
domains of quality of life: physical functioning, role functioning, vitality, health 
perceptions, emotional functioning and social functioning, as well as domains specific 
to CF: body image, eating disturbances, treatment burden, and respiratory and digestive 
symptoms (Quittner et al., 2005). 
 
Of note, the CFQ-R has only one question pertaining to sleep or night time symptoms: 
“Have you woken up during the night because you were coughing?” (Quittner et al., 
2005). CF patients may experience sleep disturbances due to a number of factors 
including awakening due to cough, pain, medications or sleep disordered breathing. In 
turn, these sleep disturbances can impact on the quality of life in CF patients.  
 
Although the generic and disease specific questionnaires are useful to investigate 
various quality of life domains, sleep is not highly featured in these questionnaires. For 
example, in both the SGRQ and CFQ-R, there is only one item that asks about sleep 
disturbance as a result of cough and breathlessness (Jones et al., 1991, Quittner et al., 
2005). 
 
Studies of sleep disturbance in CF patients have been performed but few studies have 
looked at the correlation of these sleep disturbances and QoL. Hence, upon review of 
the current literature, the Pittsburgh Sleep Quality Index (PSQI) was found to be the 
most robust and has been previously used to assess sleep quality in CF patients (Buysse 
et al., 1989). The details of the PSQI can be found in Chapter 2 - Methods. 
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In clinically stable adults with CF, impaired sleep quality measured by the PSQI was 
related to reduced disease-specific QoL in CF (Bouka et al., 2012). In this study, higher 
PSQI scores significantly correlated with lower CFQ-R scores for specific domains of 
vitality, emotional functioning, social, role, eating disturbance and digestive symptoms 
(p<0.05) (Bouka et al., 2012). These results are in keeping with the knowledge that 
poor sleep quality impacts on an individual’s quality of life. Although the PSQI was 
able to show correlations with CFQ-R, the Epworth Sleepiness Scale did not show these 
correlations except in the vitality domain (Bouka et al., 2012).  Higher scores on the 
PSQI correlated with lower scores on the domains looking at mental health (vitality, 
emotional functioning, social and role). Hence, anxiety and depression may be related 
to reduced quality of sleep in CF patients. Other factors including nocturnal 
hypoxaemia, disorders of breathing during sleep and gastrointestinal issues can all 
impact negatively on sleep and sleep quality. The PSQI is the only questionnaire that 
attempts to address some of these issues (Buysse et al., 1989). 
 
Of the questionnaires evaluated for review above, the most rigorously tested and the 
most applicable for our CF population, included the PSQI, CF QoL and the CFQ-R. 
These questionnaires were used in Chapter 6 – Sleep Quality and Quality of Life in 
Adults with CF to examine the relevant issues (QoL as well as sleep quality) for adults 
with CF with a range of lung function. 
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SUMMARY 
 
Cystic fibrosis (CF) is a genetic disease which is associated with lung disease secondary 
to recurrent respiratory infections caused by impairments of mucociliary clearance. 
These infections can result in progressive lung scarring, respiratory failure and 
ultimately death. Respiratory sounds including cough and crackles may indicate sputum 
retention in adults with CF. Use of non-invasive methods to measure respiratory sounds 
and events will be trialled during sleep to establish if there are changes which occur 
during sleep in adults with CF. Evaluation of the quality of life and sleep quality in 
patients with CF will also be studied in this thesis to add to the knowledge base of the 
issues that affect these patients.  
 
This PhD thesis will examine a number of areas related to the recording and 
characterisation of respiratory sounds and sleep disordered breathing that occurs in 
adults with CF. The following chapters will outline the results of each of the projects 
undertaken to examine the above areas of interest. Chapter 2 will outline the Methods 
undertaken for each of the projects. Respiratory sounds will be discussed using the 
results from analyses of the Sonomat in Chapter 3. The results of overnight sleep studies 
using both the in-laboratory PSG and Sonomat will be examined in Chapters 4 and 5. 
Quality of life in adults with CF will be reported in Chapter 6. In Chapter 7, conclusions 
from the thesis will be detailed.  
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CHAPTER 2: METHODS 
 
2.1 INTRODUCTION 
 
All data in this thesis were obtained from adults (aged 18 – 70 years) who gave consent 
for the acquisition and analyses of data. There were four main areas of measurements 
in this thesis, namely: 1. questionnaires measuring the quality of life in adults with 
cystic fibrosis (CF) as well as the quality of sleep; 2. abnormalities of sleep structure in 
adults with CF; 3. identification of respiratory sounds using alternative and novel 
techniques; 4. respiratory sounds recorded at night. The methods involved in these areas 
are discussed below. 
 
2.2 SUBJECTS 
 
Adults with CF were recruited from the CF Service at Westmead Hospital, Sydney. The 
diagnosis of CF had been confirmed on genetic testing and / or elevated sweat chloride 
levels (> 60 mEq/L). Patients attending the adult CF service at Westmead Hospital 
(aged >18 years) between 1st January 2013 until 30th November 2016 were approached 
and offered the opportunity to participate in any or all of the projects.  
 
The protocols were all approved by the Westmead Hospital Human Research Ethics 
Committee (HREC2012/12/4.9(3627) AU RED HREC/12/WMEAD/427. Written 
informed consent was obtained for all subjects.  
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2.3 ANTHROPOMETRIC DATA 
 
Data recorded included: a) CFTR genotype; b) age; c) gender; d) standard 
anthropometric data consisting of: weight, height and calculation of body mass index 
(BMI).  
 
2.4 LUNG FUNCTION 
 
Lung function was recorded using the Vitalograph® (Vitalograph, Lenexa, KS, United 
States). Spirometry was performed in accordance with American Thoracic 
Society/European Respiratory Society criteria (Miller et al., 2005). Forced expiratory 
volume in 1 second (FEV1) and forced vital capacity (FVC) were recorded. Predicted 
spirometric parameters were derived using reference values from Hankinson et al., 
1999 (Hankinson et al., 1999). Disease severity was classified using the equations for 
percentage predicted of FEV1 and divided into: mild (FEV1 ≥ 70 % predicted), 
moderate (FEV1 60-69 % predicted), moderately severe (FEV1 50-59 % predicted), 
severe (FEV1 35-49 % predicted) and very severe (FEV1 < 35 % predicted) categories 
(Pelligrino et al., 2005).  
 
2.5 QUESTIONNAIRES 
 
Participants completed four questionnaires: i). Cystic Fibrosis Questionnaire – Revised 
(CFQ-R) Appendix A (Quittner et al., 2005); ii). CF Quality of Life (CF QoL) 
questionnaire Appendix B (Gee et al., 2000); iii). Pittsburgh Sleep Quality Index 
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(PSQI), Appendix C (Buysse et al., 1989); iv). Epworth Sleepiness Scale (ESS), 
Appendix D (Johns, 1991).   
 
i). Cystic Fibrosis Questionnaire – Revised (CFQ-R) (Quittner et al., 2005). The CFQ-
R is a disease-specific questionnaire that measures health related quality of life over the 
preceding 2 weeks for people with CF older than 14 years (Quittner et al., 2005). This 
questionnaire consists of 44 items on 12 generic and disease-specific scales. It 
encompasses general domains of quality of life: physical functioning, role functioning, 
vitality, health perceptions, emotional functioning and social functioning; as well as 
domains specific to CF: body image, eating disturbances, treatment burden, and 
respiratory and digestive symptoms (Quittner et al., 2005). Each item included ratings 
of frequency or difficulty on a 4-point scale (where 1 = always, 2 = often, 3 = 
sometimes, 4 = never; or 1 = very true, 2 = somewhat true, 3 = somewhat false, 4 = 
very false; see Table 2.1). Scores are then standardised on a 0 to 100-point scale, with 
higher scores representing better quality of life for each particular domain. In the pre-
transplant group of participants who underwent two separate sleep studies 
longitudinally, assessment of the differences between the two-time points was based on 
previous work performed by Quittner et al. (Quittner et al., 2009). These authors 
reported the minimal clinically importance difference score was 4.0 (for stable subjects) 
whilst a change of 8.5 points (for subjects with a current exacerbation) was used to 
define improvement after a 28-day course of inhaled tobramycin (Quittner et al., 2009).  
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Table 2.1. Cystic Fibrosis Questionnaire – Revised (CFQ-R) Scoring 
Answer Score 
Very true Always 1 
Somewhat true Often 2 
Somewhat false Sometimes 3 
Very false Never 4 
4-point scale used for scoring in CFQ-R.  
CFQ-R: Cystic Fibrosis Questionnaire – Revised. 
 
ii). CF Quality of Life (CF QoL) questionnaire (Gee et al., 2000). This is a self-
administered questionnaire developed by Gee et al. (2000) (Gee et al., 2000), which 
measures the self-described quality of life over the previous 2 weeks in several 
domains. This questionnaire contains 52 items in total which covers the 8 domains of: 
physical functioning; social functioning; treatment issues and chest symptoms; 
emotional functioning; concerns for the future; interpersonal relationships; body image; 
and career concerns. All items are scored from 1 to 6 (see Table 2.2) and then scaled to 
produce a transformed score of between 0 and 100 for each section. A transformed 
score indicates the value that has been achieved out of a maximum of 100 with 100 
indicating the most positive QoL levels possible.  
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Table 2.2. Cystic Fibrosis – Quality of Life (CF QoL) Scoring 
For Sections 1 to 4 answers For Sections 5 to 8 answers Score 
All of the time Strongly agree 1 
Most of the time Agree 2 
Good bit of the time Slightly agree 3 
Sometimes Slightly disagree 4 
Occasionally Disagree 5 
Never Strongly disagree 6 
Scoring of CF-QOL, using a 6-point scale. CF-QOL: Cystic Fibrosis Quality of Life 
Questionnaire.  
 
iii.) Pittsburgh Sleep Quality Index (PSQI) (Buysse et al., 1989). The PSQI is a self-
completed questionnaire that records subjective sleep quality over the previous four 
weeks. The PSQI consists of 19 questions. Seven domains of sleep are covered: 
duration of sleep; sleep disturbance; sleep latency; daytime dysfunction due to 
sleepiness; sleep efficiency; overall subjective sleep quality; requirement of 
medications to sleep. The range of values for each scored domain is 0 to 3, see Table 
2.3. For questions 1 to 4, each question is scored according to the PSQI scoring system 
to calculate the transformed score between 0 and 4 (see Appendix A). In the event that 
a range is given for an answer (eg 30 to 60 minutes is written as the answer to question 
2, “minutes to fall asleep”), the average of the two values was calculated and then 
entered (eg 45 minutes in the above example). In all cases, a score of “0” indicates no 
difficulty, while a score of “3” indicates severe difficulty. The seven domain scores are 
then added to yield one “global” score, with a range of 0 to 21 points, “0” indicating no 
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difficulty and “21” indicating severe difficulties in all areas. A global PSQI score of 
greater than 5 indicates that a subject is a “poor sleeper” (Buysse et al., 1989). 
 
Table 2.3. Pittsburgh Sleep Quality Index (PSQI) Scoring 
Answer Score 
Not during the past month 0 
Less than once a week 1 
Once or twice a week 2 
Three of more times per week 3 
Scoring on a 4-point scale for PSQI.  
 
iv). Those subjects who underwent an overnight diagnostic sleep study also completed 
the Epworth Sleepiness Scale (ESS) on the night of their study Appendix D (Johns, 
1991). The ESS is a commonly used measurement of daytime sleepiness (Johns, 1991). 
It is a self-administered questionnaire and the subjects are asked to rate on a scale of 0 
to 3 how likely they would be to doze off or fall asleep in eight different situations 
(Johns, 1991), where 0 = would never doze, 1 = slight chance of dozing, 2 = moderate 
change of dozing, 3 = high chance of dozing (see Table 2.4). The situations included: 
sitting and reading; watching television; sitting, inactive in a public place; as a 
passenger in a car for an hour without a break; lying down to rest in the afternoon when 
circumstances permit; sitting and talking to someone; sitting quietly after a lunch 
without alcohol; in a car, while stopped for a few minutes in the traffic. A distinction 
was made between dozing off and simply feeling tired. The raw numbers were added 
to give a score between 0 and 24. A raw score of 10 or greater in the general population 
was considered to suggest increased daytime somnolence.  
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Table 2.4. Epworth Sleepiness Scale (ESS) Scoring 
Chance of dozing Score 
Would never doze 0 
Slight chance of dozing 1 
Moderate chance of dozing 2 
High chance of dozing 3 
For each situation, subjects were asked to score chance of dozing on a 4-point scale (0 
to 3). Total score out of 24. 
 
2.6 POLYSOMNOGRAPHY 
 
Standard overnight in-laboratory polysomnographic (PSG) recordings were performed 
using a computerised acquisition system (Compumedics E-series, Compumedics, 
Abbotsford, Victoria, Australia). The PSG recorded the following signals: electro-
encephalogram (EEG), electro-oculogram (EOG), submental electro-myogram (EMG), 
electro-cardiogram (ECG), thoraco-abdominal excursion (respiratory induction 
plethysmography), nasal flow (pressure transducer), oro-nasal flow (thermistor), 
snoring sounds (calibrated room sound level meter; Rion NL-20, NL-31; Rion Co. Ltd, 
Tokyo, Japan), pulse oximetry (SpO2; Biox 3700s; Ohmeda, Boulder, CO, USA), leg 
movements, and body position.  
 
Polysomnography Scoring Criteria 
 
All PSG studies were scored according to the American Academy of Sleep Medicine 
(AASM) 2007 guidelines for scoring sleep stages, arousals, and respiratory events with 
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the alternate (Type B) hypopnoea criteria used (Iber et al., 2007). The studies were all 
scored using the 2007 AASM guidelines in use prior to the adoption of the revised 
guidelines published by Berry et al. in 2012 (Berry et al., 2012).  
 
Sleep Stages 
 
Stage W (wake) was scored when more than 50 % of the epoch had alpha rhythm over 
the occipital region. Stage N1 non-REM sleep (NREM) sleep was scored when the 
alpha rhythm was attenuated and replaced by low amplitude, mixed frequency activity 
for more than 50 % of the epoch. In subjects who did not generate alpha rhythm, scoring 
stage N1 commenced with the earliest of any of the following phenomena: activity in 
the range of 4-7 Hz with slowing of background frequencies by ≥ 1 Hz from those of 
stage W; Vertex sharp waves; or Slow eye movements. Stage N2 NREM sleep occurred 
when one or both of the following occurred during the first half of that epoch or the last 
half of the previous epoch: one or more K complexes not associated with arousals; or 
one or more trains of sleep spindles. Stage N3 NREM sleep was scored when 20 % or 
more of an epoch consisted of slow wave activity. Stage R (Rapid eye movements 
(REM) sleep) was scored when all of the following occurred within that epoch: low 
amplitude, mixed frequency EEG, low chin EMG tone and REM (Iber et al., 2007). 
 
Scoring of events 
 
Total sleep time in the PSG included sleep during all stages of sleep. By convention, 
there had to be 10 seconds of sleep before an arousal, defined as an abrupt change in 
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EEG signal to higher frequencies lasting from 3 to 15 seconds, could be scored. If these 
changes persisted for more than 15 seconds, the epoch was then scored as awake.  
 
An apnoea was defined as a reduction in amplitude of airflow (both nasal pressure and 
flow thermistor) to less than 10 % of baseline for at least 10 seconds. A central apnoea 
was defined by the absence of respiratory effort on thoracic and abdominal inductive 
plethysmography signals. An obstructive apnoea was defined as an apnoea 
characterised by continuation or an increase of respiratory effort on thoracic or 
abdominal inductive plethysmography or diaphragmatic EMG. Hypopnoeas were 
scored when the following criteria were fulfilled: 1. A clear decrease (≥ 30 %) from 
baseline in the amplitude of a breathing signal (nasal pressure or inductive 
plethysmography) during sleep, with baseline defined as the mean amplitude of stable 
breathing and oxygenation in the two minutes preceding onset of the event (in 
individuals who have stable breathing pattern during sleep) or the mean amplitude of 
the three largest breaths in the two minutes preceding onset of the event (in individuals 
without a stable breathing pattern); 2. This decrease in breathing was associated with 
oxygen desaturation of ≥ 3 % or an EEG arousal; 3. The event lasted longer than 10 
seconds, and at least 90 % of the event’s duration must have met the amplitude 
reduction criteria.  
 
Apnoea-Hypopnoea Index (AHI) was defined as the number of apnoeas and 
hypopnoeas per hour of sleep. Respiratory disturbance index (RDI) was the total 
number of apnoeas, hypopnoeas and respiratory effort related arousals (RERAs) per 
hour of sleep. Periodic limb movements of sleep were scored when at least 4 
consecutive leg movements occurred, providing each individual leg movement had a 
	 	
	 57	
duration of between 0.5 and 10 seconds. Each leg movement was separated by an 
interval of between 4 and 90 seconds. Sleep efficiency was calculated by dividing the 
total sleep time by total time from sleep onset to awakening next morning. A 
spontaneous arousal was defined as an arousal with no detectable cause. A respiratory 
arousal was defined as an arousal caused by a hypopnoea or apnoea. A RERA was 
defined as flattening of the nasal pressure waveform last for 10 seconds or longer, and 
leading to an arousal, but not reaching criteria for hypopnoea. Arousal index was 
defined as the total of spontaneous, respiratory and leg movement arousals per hour of 
sleep. Oxygen desaturation index (ODI) was defined as the number of times per hour 
that the SpO2 reduced by at least 3% from baseline.  
 
2.7 SONOMAT 
 
The Sonomat device was developed by Sonomedical Pty Ltd (Balmain, NSW, 
Australia). The mattress was made from a thin piece of foam (Dunlop Foams, 
Dandenong, Victoria, Australia) with dimensions of 650 mm (width) x 1780 mm 
(length) x 40 mm (thickness) to sit on top of a regular single sized mattress. The foam 
was enclosed with StaphChek (Herculite, Emigsville, PA, USA), which is a protective 
thermoplastic fabric commonly used in healthcare environments that can be cleaned 
between subjects. The mattress can be folded for ease of transport with a total weight 
of 6 kilograms. Four identical sensors were embedded into the foam mattress and these 
contained a polyvinylidine fluoride (PVDF) foam that generated a voltage when 
deformed, by sounds and movements. Sounds were recorded using these 4 sensors as 
well an additional two room microphones embedded in the foam mattress. The Sonomat 
setup included an in-built microprocessor to analyse the outputs of the PVDF foam and 
	 	
	 58	
sound sensors recording them on a standard secure digital (SD) card. The 
microprocessor mattress was connected to an earthed power source. The mattress was 
placed directly on top of the subject’s bed mattress, covered with a standard sheet. The 
subject lay on the Sonomat with no physical attachments or wires impeding sleep.  
 
The Sonomat recording was started manually via a button pressed by a sleep technician 
in the Sleep Lab. At the time of awakening in the morning, the Sonomat was turned off 
using the same process as above by a sleep technician. Data were stored on a SD card 
(SanDisk, Milpitas, CA) within the Sonomat in a proprietary file format. At the end of 
the study, the SD card was removed and the files manually transferred to a computer 
for further analysis.  
 
Acoustic signals were recorded at a sampling frequency of 4000 Hz and movement 
signals were recorded at a sampling frequency of 250 Hz. The two room microphones 
were each capable of detecting audible room sounds in the range 20 Hz to 2000 Hz. 
Software developed to review the Sonomat recordings (Sonomat Replay) allowed 
visual interpretation of signals, audible replay of the recorded sounds and the manual 
scoring of specific physiological events.  
 
Sonomat Scoring Criteria 
Using the Sonomat, the definition of sleep onset could not include the EEG criteria 
listed above for the PSG. Sleep onset was defined at the last series of frequent body 
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movements which followed the subject lying down with the intention to sleep. 
Awakening was defined when frequent body movements persisted or sounds (such as 
talking) indicated the subject was awake. Body movements were considered to be 
indicative of wake similar to actigraphy, a well-accepted method of quantifying sleep 
from movement-based signals. The total duration of “wake time” (body movements) 
was removed from the total recording time (TRT) to calculate the “quiescent duration” 
(Qd). This Qd duration (minutes), containing all periods of postural immobility, was 
used as an estimate of total sleep time (TST).  
 
Respiratory sounds taken from audio sensors and room microphones in the Sonomat 
were analysed visually and if necessary, clarified using manual audio replay of sounds. 
Furthermore, the sound was analysed using WaveSurfer (WaveSurfer 1.8.8p4 -
1112300908. Copyright © 2000-2011 Jonas Beskow and Kare Sjolander), a software 
program that produces spectrograms allowing a visual representation of sound. 
Interactive sound analysis software was also used to analyse cough sounds (Mills et al., 
2018). 
 
Respiratory sounds were scored throughout the night.  These sounds included: snores, 
cough, crackles and wheezes. All respiratory sounds could be identified visually and 
classification could be confirmed with auditory replay.  
 
Snores were characterised by periodic components and harmonics in the breath sounds 
with fundamental frequency peaks from 20-30 Hz up to approximately 250-300 Hz 
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were scored as snores within Sonomat recordings. 
 
Cough sounds were differentiated from breath sounds as sounds that contained an initial 
wide distribution of sound frequencies between 50 and 2000 Hz of short duration and 
high sound intensity which then tapered off over the next few seconds. Cough sounds 
were further classified into a single cough or multiple coughs and were confirmed on 
audio replay. Total cough time was the total time of cough sounds analysed on the 
study. Cough time per hour was generated by dividing the total cough time by the Qd.  
 
Crackles were visually identified when rapid bursts of high amplitude “popping” 
sounds were present. When more than 1 second of a breath contained multiple popping 
sounds, across inspiration and/or expiration, the breath was scored as containing 
crackles. Again, crackle time per hour was generated by dividing the total time of 
crackle sounds by the Qd.  
 
Finally, wheezes were identified by visual analysis where there was a predominant 
“musical” frequency of ≥ 400 Hz at very high intensity and duration of more than 
500ms. Wheeze time was calculated based on the number of seconds the breath sounds 
contained wheeze sounds. Wheeze time per hour was generated by dividing total 
wheeze time by the Qd. 
 
Sonomat scoring criteria of respiratory events were developed to be similar to PSG 
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AASM scoring guidelines (Iber et al., 2007). However, the Sonomat used the breath 
sounds signal as a measure of airflow. To ensure scoring consistency, the minimum 
duration of a respiratory event was defined as at least 10 seconds. Respiratory events 
scored using the Sonomat included: hypopnoeas (reduction of breathing movements 
from baseline by ≥ 30 %) and apnoeas (complete cessation of breath sounds). An 
obstructive apnoea was scored when the absence of breath sounds was associated with 
continued breathing movements. A central apnoea was scored when the absence of 
breath sounds was associated with the absence of breathing movements. The Apnoea-
Hypopnoea Index from the Sonomat studies (AHI MAT) was generated by dividing the 
number of respiratory events by the Qd. It should be noted that the Sonomat is not able 
to score RERAs (which were based on flattening of the nasal flow data tracings and 
EEG arousals in PSG) and the PSG was not able to identify coughs, crackles or 
wheezes.  
 
2.8 STATISTICAL ANALYSES 
 
Statistical and graphical analyses were performed using SPPS v.22 (SPSS Inc., IL, 
USA) and GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA, USA). Normally 
distributed data were presented as mean ± standard deviation (SD), and non-normally 
distributed data were presented as median and interquartile range (IQR). Further details 
regarding specific statistical analyses relevant to each study will be discussed in each 
chapter. 
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CHAPTER 3: RESPIRATORY SOUNDS 
 
3.1 INTRODUCTION 
 
The identification of respiratory sounds has been an essential part of the physical 
examination performed by doctors for many years. Differences in the pulmonary 
sounds can lead the physician to diagnose a variety of pulmonary and cardiac 
conditions, but often the classification is very subjective, dependent on the physician 
involved.  
 
 
3.1.1 Classification of Respiratory Sounds 
 
The European Respiratory Society (ERS) Task Force on Respiratory Sounds 
established a project, entitled Computerized Respiratory Sound Analysis (CORSA), to 
provide consensus through standardisation of respiratory sounds nomenclature 
(Pasterkamp et al., 2016). They presented their findings in 2016 in the European 
Respiratory Journal (Pasterkamp et al., 2016). Using a standardised set up of a 
professional stethoscope attached to a small microphone and video camera, data were 
acquired and recorded. A reference collection of 20 recordings was used and described 
by expert members of the Task Force (Pasterkamp et al., 2016). Further to the 
classification used by CORSA, a modification was recommended by the ERS Task 
Force to use “normal (basic) sounds” instead of “breath sounds” (Pasterkamp et al., 
2016). Also, these authors recommended the term “vesicular sounds” should be 
replaced by “normal” or “basic” lung sounds (Pasterkamp et al., 2016).  
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3.1.2 Normal Lung Sounds  
 
The breathing sound heard on the chest of a healthy person is called a normal lung 
sound, previously known as a breath sound or vesicular sound. It is a noise that peaks 
in frequency below 100 Hz, where it is mixed with and difficult to distinguish from 
muscle and cardiovascular sounds (Gavriely et al., 1981). The characteristics of normal 
lung sounds heard over the chest wall are the result of the nature of the sound generator 
and the distortion of the sound upon transmission to the location of detection. For 
normal lung sounds, the power of the signal decreased exponentially as frequency 
increased as detailed in a study of 10 healthy subjects by Gavriely et al. (Gavriely et 
al., 1981). In the review by Pasterkamp et al., the normal lung sound spectrum is devoid 
of discrete peaks and is not musical (Pasterkamp et al., 1997).  
 
Body size also affects respiratory sounds. Pasterkamp et al. reported after studying 9 
infants compared with 20 older children and adults that the main difference of lung 
sounds in infants compared with older children and adults was in the reduction in power 
below 250 Hz, whereas sound attenuation above 300 Hz was similar (Pasterkamp et al., 
1996a). The different resonance behaviour of a small thorax and small airways or less 
contribution of low frequency muscle noise may explain the difference of normal lung 
sounds in young children (Pasterkamp et al., 1996a).  
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3.1.3 Normal Tracheal Sounds 
 
The tracheal sound signal is loud covering a wider range of frequencies than lung 
sounds at the chest wall, with distinct inspiratory and expiratory phases and a close 
relation to airflow (Gavriely and Cugell, 1996). Respiratory and Sleep Physicians are 
interested in tracheal sounds as indicators of upper airway flow obstruction and as the 
source for qualitative and potentially quantitative assessments of airflow. The 
generation of tracheal sounds is primarily related to turbulent air flow in upper airways, 
including in the pharynx, glottis, and subglottic regions. Flow turbulence and jet 
formation at the glottis cause pressure fluctuations within the airway lumen. Sound 
pressure waves within the airway gas, and airway wall motion are likely contributing 
to the vibrations that reach the neck surface and are recorded as tracheal sounds 
(Pasterkamp et al., 1997).  
 
Tracheal sounds have been characterised as broad spectrum sound, covering a 
frequency range from less than 100 Hz to more than 1500 Hz, with a sharp reduction 
in power above a cut off frequency of approximately 800 Hz (Gavriely et al., 1981). 
The spectra of tracheal sounds exhibit peaks and troughs that are related to airway 
dimensions and dependent on gas density, indicating their origin from resonance within 
the upper airways. In another study by Pasterkamp, Schafer et al., the spectral shape of 
tracheal sounds is highly variable between subjects but quite reproducible within the 
same person, reflecting the strong influence of individual airway anatomy (Pasterkamp 
et al., 1996b).  Soufflet et al., looked at different methods of evaluating instantaneous 
flow from tracheal sounds and found differences in reference curves observed among 
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subjects are likely explained by the different airway morphological features of subjects 
(Soufflet et al., 1990).  
 
3.1.4 Bronchial breathing 
 
Bronchial breathing has been characterised by soft, non-musical sounds, heard on both 
phases of the respiratory cycle (can mimic tracheal sounds). These sounds indicate 
patent airway surrounded by consolidation lung tissues or fibrosis (Bohadana et al., 
2014). 
 
3.1.5 Adventitial Sounds 
 
A variety of pulmonary sounds have been described including crackles (rales, 
crepitations, discontinuous adventitial sounds); wheezes (rhonchi, continuous 
adventitial sounds); coughs; squawks or squeaks. Note, that coughs are produced by 
the upper airway but will be discussed in this section.  
 
More than 40 years ago, Murphy et al. proposed a technique to characterise pulmonary 
sounds objectively using time-amplitude plots to provide reproducible visual displays 
of the different features of pulmonary sounds (Murphy et al., 1977). These authors 
proposed that time-expansion wave-form analysis of pulmonary sounds provides a 
scientific and objective method for differentiating the various lung sounds that could 
aid in the diagnosis of a variety of pulmonary and cardiac conditions (Murphy et al., 
1977). 
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Spectrograms give a visual representation of the spectral information of lung sounds 
showing frequency and amplitude against time. The x-axis corresponds to time and the 
y-axis corresponds to frequency. The spectrogram displays the timing in the breathing 
cycle at which a particular frequency / amplitude combination occurs. Coloured 
spectrograms highlight significant amplitude features (z-axis). Intensity of the sound at 
a particular instance is represented by the different colours of the spectrogram, as shown 
below in Figure 3.1, reproduced from Reichert et al. (Reichert et al., 2008).  
 
Figure 3.1 Example of a Spectrogram. Reproduced from Reichert et al. 2008 
(Reichert et al., 2008) 
Time expanded waveform analysis (TEWA) is a technique that assists in distinguishing 
between the different patterns of lung sounds by presenting the details of the acoustic 
signal with increased resolution. This is accomplished by zooming in on the time or x-
axis of the waveform. Sahgal demonstrated some examples of time domain plots of 
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(for example containing higher-frequency 
components), audible both during inspiratory and 
expiratory phase.
Known trackers
Crackles: these adventitious explosive and 
discontinuous sounds appear generally during 
inspiratory phase. They are characterised by their 
specifi c waveform, their duration, and their location 
in the respiratory cycle. A crackle can be characterized 
by its total duration, as fi ne (short duration) or coarse 
(long duration). Occurrences of crackles in lung 
sounds usually refl ect a pathological process in 
pulmonary tissue or airways.
Cough sound: transient sound induced by the 
cough refl ex with a frequency content between 
50 and 3000 Hz. The characteristics of cough 
sounds are different in several pulmonary dis-
eases. Cough sounds containing wheezes are 
typical in asthma.
Rhonchus: rhonchus is a low-pitched wheeze 
containing rapidly damping periodic waveforms 
with a duration of >100 ms and frequency of <300 
Hz. Rhonchus can be found, for example, in 
patients with secretions or narrowing in large air-
ways and with abnormal airway collapsibility.
Snoring sound: it is a respiratory low-frequency 
noisy sound with periodic components (fundamen-
tal frequency 30–250 Hz) detected usually during 
sleep induced by abnormal vibrations in the walls 
of the oropharynx. It is typical inspiratory sound 
but a small expiratory component can appear espe-
cially in patients with obstructive sleep apnea.
Squawk: with relatively short inspiratoy adven-
titious sound having a musical characteristic, 
occasionally found in patients with interstitial lung 
disorders. Acoustically, its waveform may resem-
ble that of short wheezes, but they are often pre-
ceded by a crackle. The duration of squawks may 
vary between 50 and 400 ms. The basic mecha-
nisms of their origin probably differ from those of 
wheezes in obstructive lung diseases.
Stridor: it is a very low-frequency wheeze 
originating in the larynx or trachea. It appears most 
frequently during inspiration. It can be audible at 
the mouth, at the trachea and over the chest wall. 
Stridor can appear, for example, in whooping 
cough, and in laryngeal or tracheal stenosis.
Wheeze: this adventitious and continuous sound 
presents a musical character. Acoustically, it is char-
acterized by periodic waveforms with a dominant 
frequency usually over 100 Hz and with duration of 
≥100 ms; hence, the sound must include at least 
10 successive vibrations. Wheezes are usually 
associated with airways obstruction due to various 
causes. If the wheeze contains essentially a single 
frequency, the wheeze is called monophonic. If it 
contains several frequencies, it is termed a poly-
phonic wheeze.
Visualisation methods
Phonopneumogram: it is a simultaneous and 
overlapped display of sound signal and airfl ow in 
time domain during breathing:
Spectrogram: it concerns representation in 
which time is represented in abscises, frequency 
in ordinate, and the intensity of the signal by a 
palette of colors (Fig. 1).
Analysis methods
Artifi cial neural network (ANN): it is a mathe-
matical model based on biological neural networks. 
It consists in an interconnected group of artifi cial 
neurons and processes information using a con-
nectionist approach to computation. Generally, it 
is an adaptive system that changes its structure 
based on external or internal information that fl ows 
through t e network during the le rning phase. A 
perceptron is a specifi c type of artifi cial neural 
network, that can be seen as the simplest kind of 
feedforward neural network: a linear classifi er.
k-nearest neighbor algorithm (kNN): it is a 
method for classifying objects based on closest 
Figure 1. Example of Spectrogram.
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lung sounds in both time unexpanded and time expanded modes (Sahgal, 2011). For 
example, normal tracheal lung sounds have an irregular shape without repetitive 
patterns on the time-domain plots. Wheeze and rhonchi have a periodic waveform, 
which is either sinusoidal or more complex. Crackles show a sudden short deflection 
followed by deflections with greater amplitude (Figure 3.2, reproduced from Sahgal 
(Sahgal, 2011). 
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Figure 3.2 Time (seconds) domain plots of the amplitudes of lung sounds. Seen in 
both the time unexpanded (top panels) and time expanded (bottom panels) modes. A) 
normal tracheal lung sounds; B) wheeze; C) rhonchi; D) crackle; (Sahgal, 2011). 
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Figure 13 Time domain plots of lung sounds seen in both the time unexpanded and 
time expanded modes (A) normal (tracheal), (B) wheeze, (C) rhonchi, (D) crackle.
Rhonchi is a low-pitched wheeze with a duration 
of 100 milliseconds and frequency of 300 Hz.4 Frequency 
spectrum of rhonchi sound is shown in Figure 9, where 
 frequency lies in the range of about 0 to 200 Hz.
Spectrograms give a visual of the spectral information 
of lung sound. It displays the instance at which a par-
ticular frequency occurs. Colored spectrogram highlights 
significant amplitude features. Intensity of the sound at a 
particular instance is represented by the different colors of the 
 spectrogram. The x-axis corresponds to time and the y-axis 
 corresponds to frequency.
The breathing-associated sound heard on the chest of a 
healthy person is called the normal lung sound. The spectro-
gram of these sounds usually exhibits continuous magnitude 
decay from lower to higher frequencies and higher spectral 
components lie in the region lower than 100 Hz.5 These 
characteristics are shown in Figure 10, which is a spectrogram 
of a normal vesicular sound.
Crackles are short discontinuous explosive sounds and 
when viewed in the short-time interval usually generate verti-
cal lines in the spectrogram with a duration 20 milliseconds. 
This characteristic is shown in Figure 11, which represents 
the spectrogram of a respiratory cycle containing fine crackles 
during the inspiration phase.
Wheezes have duration 100 milliseconds, with their 
fundamental frequency and harmonics 100 Hz. Since 
these characteristics are continuous, the resulting spectro-
gram consists of harmonics of higher pitch which indicate 
the existence of wheeze.5 This property can be seen in 
Figure 12.
Time expanded waveform analysis (TEWA) is a 
technique that assists in distinguishing between the dif-
ferent patterns of common lung sounds by presenting the 
details of the acoustic signal with increased resolution. 
This is done by zooming in on the time or x-axis of the 
waveform. Figure 13, shows the TEWA of some the lung 
sound samples studied. In the figure, normal lung sounds 
have an irregular shape without any repetitive pattern. 
Wheeze and rhonchi have a periodic waveform, which is 
either sinusoidal or more complex. Crackles show a sud-
den short deflection followed by deflections with greater 
amplitude.6
In the testing phase the tool developed using LabVIEW 
gave the desired results, thus providing a base for carrying 
out further study and including additional features to increase 
the feasibility of such a system being used by both medical 
practitioners and patients.
While working on the project, a great deal of stress was 
placed on making it as user-friendly as possible. The reason 
for this being that similar systems developed by researchers 
failed to make an impact due to the difficulty the users 
faced using them.
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Wheezes 
 
In respiratory medicine, wheeze is perhaps the most widely used acoustic term. 
Wheezes are thought to be musical in character and are continuous sounds characterised 
mainly by their pitch harmonics and duration.  They are typically last longer than 80 to 
100 milliseconds, with their fundamental frequency and harmonics greater than 100 
Hz. Their frequency range extends from less than 100 Hz to more than 1 kHz and higher 
frequencies may be measured inside the airways (Akasaka et al., 1975). In 1977, the 
ATS proposed that wheezes may not necessarily extend more than 250 ms, but will be 
typically longer than 80 to 100 ms (Cugell et al., 1977).   
 
Wheezes usually identify the presence of an obstructive pathology, for example, 
asthma. Sahgal demonstrated the frequency spectrum of wheeze contained a dominant 
frequency of 400 Hz (Sahgal, 2011). Rhonchi is a term to refer to a low-pitched wheeze 
with a duration of more than 100 milliseconds and frequency of less than 300 Hz. 
Furthermore, wheezes are mainly a sound production phenomenon, whereas breath 
sounds over a lobar pneumonia are mostly due to changes in the transmission function 
of the affected lung (Gavriely et al., 1981). 
 
Computer based analysis of wheeze is now possible with algorithms that relate the 
amplitude of sharp spectral peaks to the average lung sound amplitude (Baughman and 
Loudon, 1984, Shabtai-Musih et al., 1992). Beck et al. investigated histamine challenge 
in 12 children and analysed computerised lung sounds, including wheeze (Beck et al., 
1992). Prior to using computer analysis of lung sounds, the histamine challenge, as a 
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means of evaluation of asthma, was stopped at the point where wheezes were detected 
by a stethoscope or microphone placed over the trachea.  
 
Other authors have also previously investigated analysis of wheeze as a means of 
identifying respiratory abnormalities earlier than the awareness and reporting of these 
abnormalities from patient’s themselves (Sanchez et al., 1993). However, in 1993 
Sanchez et al. reported findings from their study of 23 CF patients and found that 
although wheeze is a specific indicator of bronchial hyper-responsiveness, wheeze was 
absent in 50 % of the CF patients who tested positive with methacholine (Sanchez et 
al., 1993). In addition, of the subjects who did not respond based on spirometric 
parameters to the methacholine test, none of them developed wheeze (n = 13), yielding 
a specificity of 100% (Sanchez et al., 1993). However, it should be noted that the results 
of the above studies were from studies with small subject numbers.  
 
Crackles 
 
Crackles are another acoustic term that is used in respiratory medicine. Detailed in an 
early Lancet article by Forgacs in 1967 (Forgacs, 1967), crackles were described as 
“miniature explosions, heard much more often during inspiration than during 
expiration. Their pattern is remarkably constant.”  Crackles are short discontinuous 
explosive sounds with a duration of less than 20 milliseconds (Pasterkamp et al., 1997). 
Fine crackles have been defined with a duration of 5 msec and typical frequency of 650 
Hz and coarse crackles with a duration of 15 msec and a typical frequency of 350 Hz 
(Bohadana et al., 2014).  
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Murphy et al. examined the waveform of fine and coarse crackles in subjects with 
fibrotic lung disease (Murphy et al., 1977). In the study by Murphy et al., time expanded 
wave form analysis provided reproducible visual displays that allowed documentation 
of the differentiating features of lung sounds and enhanced the diagnostic utility of the 
sounds (Murphy et al., 1977).  They found that in these patients, the fine crackles were 
shorter in duration and thus had higher frequency content than the coarse crackles found 
in subjects with pneumonia (Murphy et al., 1977). Murphy et al. reported that most 
crackles have a duration range from 1 to 10 milliseconds and show a great diversity of 
patterns with large variations in the period of the deflections, that is the length in time 
of the individual cycles, and in the total number of cycles (Murphy et al., 1977). 
Crackles have a distinctive appearance in time-expanded waveform analysis: a sudden 
short deflection followed by deflections with greater amplitude (Charbonneau et al., 
2000). It has been proposed that fast Fourier transformation is not as useful in analysing 
the crackles as they are short bursts of sound. A sampling rate of 5,512 Hz provides a 
sufficient frequency range for the analysis of crackles (ie. 0 - 2700 Hz). However, the 
study of several fine crackles may require a wider range of analysis and hence the use 
of a sampling rate of greater than or equal to 11,025 Hz is recommended (Charbonneau 
et al., 2000).  In more detail, the following measurements can be applied to characterise 
waveform of crackles: 1. The initial deflection width (IDW) – the duration of the first 
deflection of the crackles; 2. Two-cycle duration (2CD) – duration of the first 2 cycles 
of the crackles; and 3. The largest deflection width (LDW) - the width of the largest 
deflection of the crackles. The most commonly used indices for crackles are:  the time 
duration of the initial deflection and the duration of the first two cycles of the waveform 
(Fredberg and Holford, 1983, Pasterkamp et al., 1997).  
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Based on guidelines from the ATS in 1977, the mean durations of IDW and 2CD of 
fine crackles are 0.7 and 5 milliseconds, and those of coarse crackles are 1.5 to 10 
milliseconds (Cugell et al., 1977). The latest published guidelines from CORSA have 
proposed the 2CD of fine crackles is <10 milliseconds and that of coarse crackles >10 
milliseconds (Sovijarvi et al., 2000). The frequency range of the crackles sound is 60 
to 2000 Hz, with the major contribution being in the range of 60 to 1200 Hz (Abbas 
and Fahim, 2010). Hoevers and Loudon proposed a different set of parameters to 
characterise crackles, namely, largest deflection width (LDW1); which is the duration 
of the largest deflection of the crackle (Hoevers and Loudon, 1990). 
 
In interstitial lung disease, the number of crackles has been associated with the severity 
of the pulmonary disease (Epler et al., 1978).  By using the timing and waveform 
characteristics of crackles, a two-dimensional discriminant analysis can be applied as 
suggested by Sovijari et al. (Sovijärvi et al., 1996).  
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Figure 3.3 Waveform parameters of crackles in time-expanded waveform display. 
IDW: initial deflection width; 2CD: two-cycle duration; LDW: largest deflection width. 
Reproduced from Sovijärvi et al. Figure 1 p 172. (Sovijärvi et al., 1996).  
 
Sovijärvi et al. compared the timing and wave form variables of crackles using 
discriminant analysis. The paired Mahalanobis distances (measure of how many 
standard deviations away a point is from the mean of the distribution) between the data 
of different disease groups were used to describe the relative difference between two 
crackle variables simultaneously. The differences between the disease groups were 
visualised using a two-dimensional display of individual data and ellipses (Figure 3.4). 
The middle point of an ellipse represented the mean values of the variables of the 
groups, and the area of an ellipse is outlined by the standard deviations of the same 
variables (Figure 3.4).  
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Fig. 1. Waveform parameters of crackles in time-expanded waveform display. IDW=initial deflection width, 
ZCD=two-cycle duration, LDW=largest deflection width. 
of the underlying pulmonary disorder. In previous studies, crackles have been assessed 
by analysing their waveform or timing during respiratory cycles (Nath & Capel, 1974a, 
b; Kudoh et al., 1977;Murphy etal., 1977; Holford, 1982; Dalmasso et al., 1984; A1 Jarad 
et al., 1994). The waveform variables of crackles most commonly used are the initial 
deflection width (IDW), two-cycle duration (2CD; Holford, 1982) and the largest 
deflection width (LDW; Hoevers & Loudon, 1990). The variables are illustrated in Fig. 
1. The duration of a crackle has been shown to be dependent on the disease (Epler et 
al., 1978; Forgacs, 1978; Fredberg & Holford, 1983; Piirila et al., 1991; Piiril  1992a; A1 
Jarad er al., 1994). In a recent comparative study involving patients with cryptogenic 
fibrosing alveolitis (CFA), bronchiectasis (BE), chronic obstructive pulmonary disease 
(COPD) and acute heart failure (HF), the waveform variables were significantly differ- 
ent among most of the groups, and could separate CFA from HF with no overlapping, 
CFA showing the shortest duration of the waveform variables (Piirila et al., 1991). In 
pneumonia, the waveform of the crackles was shown to become shorter during recovery 
(Piirila, 1992a). Also, the characteristics of crackles in pulmonary asbestosis have shown 
to differ from those in heart failure (A1 Jarad et al., 1994). 
Studies on the occurrence and t ming of inspiratory and expiratory crackles have also 
demonstrated differences between pulmonary diseases (Nath & Capel, 1974a, b; Kudoh 
et al., 1977; Forgacs, 1978; Walshaw et al., 1990). In our recent comparative study, the 
end-point of crackling during inspiration occurred significantly later in CFA than in 
COPD, with no overlap, but the discrimination power of the timing variables between 
the other groups studied was not as good (Piirila et al., 1991). The previous study, 
however, suggested that the waveform and timing variables of crackles used separately 
0 1996 Blackwell Science Ltd, Clinical Physiology, 16, 171-181 
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Figure 3.4 Two-dimensional illustration of end-point crackling - as the timing 
variable and Initial deflection width (IDW) as the waveform variable in: crypogenic 
fibrosing alveolitis (CFA; n=10), bronchiectasis (BE; n=10), COPD (n=10), heart 
failure (HF; n=10), acute pneumonia (PnI; n=11) and pneumonia in the recovery stage 
(PnII; n=9). Sovijärvi et al.: Figure 2, page 175 (Sovijärvi et al., 1996). 
 
The two dimensional distances between the patient groups (cryptogenic fibrosing 
alveolitis, bronchiectasis, COPD, heart failure, acute pneumonia and recovery from 
pneumonia) were the largest by combining the IDW and the end-point of crackling 
(Sovijärvi et al., 1996). This end point of crackling (percentage of duration of 
inspiration) showed a very high discrimination power between the different disease 
groups (F-power 12.46, p < 0.0001) (Sovijärvi et al., 1996). IDW seemed to be the best 
waveform variable for separating the diseases (F-value 18.55, p < 0.0001) (Sovijärvi et 
Two-dimensional analysis of crackles in pulmonary diseases 175 
CFA 
Pnll 
+ 
I I I I 
1 .o 1.5 2.0 2.5 I . 0 
Initial deflection width (ms) 
Fig. 2. Two-dimensional illustration of end-point of crackling as the timing variable and IDW as the waveform 
variable in cryptogenic fibrosing alveolitis (CFA; n=10), bronchiectasis (BE; n=10), COPD (n=lO), heart 
failure (HF n=10), acute pneumonia (PnI; n = l l )  and pneumonia in the recovery stage (PnII; n=9). The 
mid-points of the ellipses indicate the mean value of the variables in the groups; the areas are outlined with a 
standard deviation of the variables. Individual mean values are indicated by small symbols of different types 
according to the diagnosis. 
x 100 no. of correct classifications with a test variable no. of patients in the diagnosis group 
The classification is defined to be correct if (1) an individual value of a variable belongs 
to the patient group with correct diagnosis based on the criteria indicated below; or (2) 
an individual value of a variable does not belong to a patient group with some other 
diagnosis. The mean value+-one standard deviation of a variable in a diagnosis group 
was used as the cut-off level for the classification. 
The correct classifications were counted for the following variable pairs: end-point of 
crackling in an inspiratory cycle (EC) and IDW, and beginning of crackling in an 
inspiratory cycle (BC) and 2CD. The correct classification obtained with the two-dimen- 
sional analysis (EC+IDW and BC+2CD) indicates that the values of the two variables 
with two different dimensions measured from the same sound sample classify the 
crackles correctly. 
0 1996 Blackwell Science Ltd, Clinical Physiology, 16, 171-181 
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al., 1996). The discriminating property of 2CD was slightly lower (F-value 15.14, p < 
0.0001) (Sovijärvi et al., 1996). As discussed by Sovijärvi et al. 1996, in previous 
studies, the waveform variables IDW, 2CD (Murphy et al., 1977) and LDW (Hoevers 
and Loudon, 1990) were used to classify crackles into either fine or coarse crackles, 
however, this kind of classification has been shown to have only a limited value in the 
separation of pulmonary diseases. Sovijärvi et al. concluded that two dimensional 
analysis was better able to separate the diseases than was found for single-dimensional 
analyses of the same crackle data (Piirila et al., 1991, Sovijärvi et al., 1996). Two-
dimensional analysis also offers a new opportunity regarding the visual presentation of 
both the timing and waveform characteristics of crackles. The present study 
investigating the capabilities of the Sonomat enabled further analysis of these 
waveforms and timing of adventitial sounds. However, it should be noted that the foam 
used in the Sonomat mattress may be different from other measurement devices. In 
addition, the sounds from the subject needed to pass through their clothes and bedding 
which may dampen the sounds recorded by the Sonomat. 
 
There have been a number of studies investigating devices to identify crackles 
automatically (Kaisla et al., 1991, Murphy et al., 1989, Pasika and Pengelly, 1994, 
Pasterkamp et al., 1997, Sarkar et al., 2015, Sovijarvi et al., 2000). However, to date, 
no one device has been utilised universally. 
 
Sahgal described a method of recording breath sounds and adventitial sounds with 
remote respiratory monitoring capability that integrates the various techniques used to 
detect abnormal lung sounds (Sahgal, 2011). A specifically designed software platform 
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employing LabVIEW software was used to design a system that monitored the 
respiratory sounds of the patient. The program calculated the respiratory rate, displayed 
the time expanded waveform of the lung sound, and computed the fast Fourier 
transform and short-time Fourier transform to present the power spectrum and 
spectrogram respectively. These parameters were then transmitted synchronously to the 
remote station using the Internet for online monitoring of the patient (Sahgal, 2011). 
The power spectrum is the frequency domain data representing the power distribution 
of a sound with respect to frequency. As discussed in their results, crackle sounds 
generally occur during inspiration and appear in the time domain at regular intervals 
with extremely low amplitude (Sahgal, 2011). Their frequency usually ranges from 100 
to 2000 Hz or even higher. In the power spectrum of crackle sounds, the main frequency 
ranged from 0 to 600 Hz (Sahgal, 2011).  
 
Cough 
 
Cough as a respiratory reflex is characterised by sudden expulsion of air at a high 
velocity accompanied by a transient sound of varying pitch and intensity. One single 
cough consists of an inspiratory phase followed by an expiratory effort with the glottis 
closed (compressive phase) and the sudden opening of the glottis with rapid expiratory 
airflows (expulsive phase) (Sovijarvi et al., 2000). 
 
The sound from a cough is transient with a frequency range between 50 and 3000 Hz. 
The characteristics of cough sounds are different in different pulmonary diseases 
(Sovijarvi et al., 2000). 
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In our CF population with bronchiectasis, we were interested in cough, crackles and 
wheeze as these adventitial sounds may reflect the presence of sputum retention. As CF 
respiratory disease progresses, the accumulation of sputum and mucus plugs leads to 
further inflammation and parenchymal destruction ultimately leading to respiratory 
failure. By identifying these adventitial sounds, there is scope to document the presence 
of sputum in the airways. Changes over time could then be measured, with acute 
changes likely to reflect the onset of an exacerbation. Earlier detection of the changes 
in crackles could be similar to daily auscultation. However, this could be burdensome 
in the long term. Having this auscultatory examination occur automatically may 
identify changes in adventitial sounds and hence allowing early treatment with the aim 
to prevent further lung destruction and respiratory failure. Therefore, adequate 
identification of lung sounds is important in the treatment of adults and children with 
CF.  
 
3.2 AIM	
 
The aim of this project included: identification of respiratory sounds at night (coughs, 
crackles and wheezes) based on spectrographic and audio analysis using the Sonomat.  
 
3.3 HYPOTHESIS 
 
We can define and identify respiratory sounds (coughs, crackles and wheezes) based 
on visual, spectrographic and audio analysis using the Sonomat. 
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3.4 METHODS OF IDENTIFYING RESPIRATORY SOUNDS 
3.4.1 Subjects 
 
Subjects were recruited from the adult CF Service at Westmead Hospital, Sydney. All 
subjects had a diagnosis of CF confirmed on genetic testing and / or elevated sweat 
chloride levels (> 60 mEq/L). Patients attending the adult CF service at Westmead 
Hospital (aged >18 years) between 1st January 2013 until 30th November 2016 were 
approached and offered the opportunity to participate in the project.  
 
The protocols were all approved by the Westmead Hospital Human Research Ethics 
Committee (HREC2012/12/4.9(3627) AU RED HREC/12/WMEAD/427. Written 
informed consent was obtained for all subjects.  
 
Examples of respiratory sounds were selected from 4 subjects who had undergone an 
overnight sleep study in the Sleep Lab at Westmead Hospital using the Sonomat. 
Demographics of the subjects are shown in Table 3.1. 
 
3.4.2 Sonomat 
 
As described in Chapter 2 – Methods, Section 2.7, the Sonomat device contained four 
identical sensors containing a polyvinylidine fluoride (PVDF) film that generated a 
voltage when deformed. Sounds were recorded using these 4 sensors as well as two 
additional room microphones embedded in a foam mattress. Acoustic signals (breath 
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sounds) were recorded at a sampling frequency of 4000 Hz and movement signals are 
recorded at a sampling frequency of 250 Hz. Propriety software, Replay, was developed 
for the exclusive use of the Sonomat data for analysis of signals.  
 
The scoring criteria used for the Sonomat is detailed in Chapter 2 – Methods, section 
2.7. Breath sounds that contained periodic components with fundamental frequency 
peaks from 20-30 Hz up to approximately 250-300 Hz were scored as snores within 
Sonomat recordings; these could be confirmed aurally using manual replay and manual 
scoring. 
 
Respiratory sounds were analysed visually and then clarified using the audio replay of 
sounds. If there was still uncertainty, the sound was analysed using WaveSurfer, a 
software program to analyse spectrograms (WaveSurfer 1.8.8p4 -1112300908. 
Copyright © 2000-2011 Jonas Beskow and Kare Sjolander). Interactive sound analysis 
software was also used to analyse cough sounds using the Raven Pro version 1.4 
computer software (Mills et al., 2018). 
 
In keeping with the current consensus of respiratory sounds nomenclature from The 
European Respiratory Society Task Force on Respiratory Sounds, all respiratory sounds 
were classified as per these recommendations (Pasterkamp et al., 2016). Cough sounds 
were identified aurally and visually from normal lung sounds that contained an initial 
wide distribution of sound frequencies between 50 and 2000 Hz of short duration and 
high sound intensity which then rapidly tapers off.  
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Crackles were identified by using visual identification of rapid bursts of sound that are 
low pitched, high amplitude with a long duration of more than 1 second across both 
inspiration and expiration.  
 
Finally, wheezes were identified by visual analysis where there was a predominant 
frequency of approximately 400 Hz at very high intensity with multiple harmonics and 
duration of more than 500ms.  
 
3.5 RESULTS 
 
Four subjects were selected as a representative group from those subjects who had 
undergone an overnight sleep study in the sleep laboratory. Demographic details are 
shown in Table 3.1. 
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Table 3.1. Demographic Details of Subjects Selected for Respiratory Sound 
Samples 
Respiratory 
Sound  
Identified 
Subject 
ID 
Age 
(years) 
BMI 
(kg/m2) 
Genotype FEV1 
(% pred) 
Colonisation 
Normal 33 21 19.2 F508del/ 
G551D 
89 MucPSA 
Cough 3 28 19.6 F508del/ 
F508del 
51 MucPSA 
Staph aureus 
Crackles 5 31 21.0 F508del/ 
G542X 
59 MucPSA 
Wheeze 9 47 27.7 UNK/ 
UNK 
46 MucPSA 
N = 4. BMI: body mass index; FEV1: forced expiratory volume in 1 second; MucPSA: 
Pseudomonas aeruginosa. 
 
Based on the recordings from the Sonomat, different respiratory sounds can be detected 
and classified as described below.  
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Normal Lung Sounds 
 
Figure 3.5 Normal Lung Sounds - over 3 breaths in 10 seconds. 
The above figure demonstrated 3 consecutive normal lung sounds over a 10 second 
period in an adult with CF with normal lung function. There was a biphasic signal for 
inspiration (upward deflection) and expiration (downward deflection) on the breathing 
movement signal. On the breath sound channel, the amplitude of the sound was shown. 
Spectral analysis (spectrogram) depicted the different sound frequencies (vertical axis) 
and intensities (colour of sounds: louder is red and yellow, softer blue and green) versus 
time. In normal lung sounds, there were no predominant frequencies as shown for the 
3 breaths in Figure 3.5.  All continuous frequencies (horizontal lines) visible in the 
background were generated from equipment in the laboratory. 
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Cough Sounds 
 
Figure 3.6 Cough Sounds - over 10 seconds 
 
Coughs were identified on the Sonomat data tracings in both the breathing movement 
and breath sound signals and confirmed using manual audio playback. This figure 
demonstrated multiple coughs with both single coughs and cough paroxysms (more 
than 1 cough). There were two short coughs at the beginning of the period followed by 
a cough paroxysm. Using spectral analysis, these coughs showed a wide distribution of 
sound frequencies and short duration. 
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Crackles 
 
Figure 3.7 Crackles - over 10 seconds 
 
Figure 3.7 showed 4 episodes of expiratory crackles over a 10 second period. The 
Sonomat was able to differentiate crackles from normal breath sounds due to the 
presence of short bursts of sound within each breath sound. Crackles were better able 
to be visualised on breath sound tracings rather than the spectrogram shown above.  
 
 
Short bursts 
of sounds  
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Wheezes 
 
Figure 3.8 Wheezes - over 10 seconds 
 
Using spectral analysis, the figure above showed 3 wheezes with a louder continuous 
sound at 400Hz.  
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Snores 
 
 Figure 3.9 Snores - over 10 seconds 
The above figure demonstrated 4 expiratory snores over 10 seconds. Distinct bands of 
colour (green) indicated the frequencies at which the upper airway is vibrating. The 
lowest band was the fundamental frequency with the higher frequency bands with 
multiple harmonics. 
 
 
 
	 	
	 87	
3.6 DISCUSSION 
 
This study aimed to use the Sonomat to characterise respiratory sounds. The principal 
characteristics of lung sounds include characterisation of frequency, intensity, duration 
and quality (Hadjileontiadis, 2008). The time and frequency domain characteristics of 
the sound signal likely reflect pathological changes that occur with pulmonary disease 
associated with CF. Using a signal analysis technique (spectrography), abnormal lung 
sounds can be visually detected as well as audibly confirmed. Our study was similar to 
a study performed by Saghal et al., who used lung sounds from Stethographics Inc 2007 
© (Stethographics) to demonstrate the ability to remotely monitor the respiratory 
activity of a patient (Sahgal, 2011). Our results are in keeping with those studies 
documented above including the published papers from Saghal et al. and Bohadana et 
al. (Bohadana et al., 2014, Sahgal, 2011). 
 
Our study showed the qualitative differences between respiratory sounds. The data 
analysed above are novel and can be used as a foundation to develop automated 
algorithms which would classify different respiratory sounds based on their unique 
frequency, intensity and duration characteristics. Future studies will be useful to 
analyse respiratory sounds in groups of subjects to categorise parameters which are 
similar and can be validated between subjects for different respiratory sounds. This 
particular area of interest has not been demonstrated previously in CF patients and 
hence, is highly novel. Whilst it was not possible in this thesis to demonstrate the 
differences of sounds that occur both within subjects and between subjects, further 
analysis grouping subjects’ respiratory sounds will be required to provide adequate 
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information for the development of algorithms. These grouped data have been collected 
and are the origin of current novel research investigating sound characteristics in 
respiratory disease, particularly in relation to cystic fibrosis.  
 
Changes of the presence or absence of respiratory sounds can be useful in the clinical 
assessment of subjects. For example, increasing presence of crackles may indicate that 
airway clearance is either suboptimal or not effective. Early identification of such 
changes in respiratory sounds may allow clinicians to intervene earlier and recommend 
increasing physiotherapy airway clearance techniques or even prescribe antibiotics 
(Doring et al., 2012). In addition, automated review of respiratory sounds could provide 
physicians another method of monitoring patients either in real-time or via 
telemedicine.  
 
3.7 CONCLUSION 
 
Using the Sonomat, respiratory sounds (normal lung sounds, coughs, crackles and 
wheezes) were characterised based on spectrographic and audio analysis. In the case of 
crackles, short bursts of higher amplitude and frequency sound can be identified within 
each breath. In contrast, wheezes have a loud musical sound at approximately 400 Hz. 
The Sonomat can be used at a single time point or longitudinally over a number of days 
or weeks to identify these respiratory sounds in subjects with cystic fibrosis.  
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CHAPTER 4: CROSS-SECTIONAL OBJECTIVE SLEEP 
MEASUREMENTS IN ADULTS WITH CYSTIC FIBROSIS 
 
4.1 INTRODUCTION 
 
CF impacts on sleep in a number of ways including sleep fragmentation, sleep 
disordered breathing, hypoventilation, rhinosinusitis or by coughing due to impaired 
mucus clearance from the lower airways (Dobbin et al., 2005, Milross et al., 2004, Perin 
et al., 2012, Spier et al., 1984, Stokes et al., 1980). More than 30 years ago, nocturnal 
hypoxaemia was identified in adults with severe lung disease due to CF (Francis et al., 
1980, Muller et al., 1980, Spier et al., 1984, Tepper et al., 1983). In particular, these 
authors demonstrated oxygen desaturation during sleep with more severe desaturation 
during  hypoventilation in REM sleep (Francis et al., 1980, Muller et al., 1980, Spier et 
al., 1984, Tepper et al., 1983). Repeated desaturation during sleep may contribute to 
the development and progression of cor pulmonale in patients with CF with sustained 
elevation of pulmonary arterial pressure. Ultimately, the development of cor pulmonale 
is a poor prognostic factor for survival (Stern et al., 1980). 
 
Whilst polysomnography is the gold standard to investigate sleep disordered breathing, 
as noted above, it may miss arousals due to cough or other lower airways dysfunction. 
(See details of polysomnography in Chapter 2 – Methods, Section 2.6).  
 
Non-invasive methods of detecting sleep disordered breathing are providing additional 
ways to supplement the conventional methods using overnight polysomnography. In 
1981, a novel non-invasive method of detecting heart rate and respiration was 
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investigated by Alihanka et al. (Alihanka et al., 1981).  Using a static charge-sensitive 
bed (SCSB), respiratory movements and the ballistocardiogram (reflecting the strength 
of the myocardial contraction) were recorded based on body movements inducing a 
static charge distribution in the “active” layers of the mattress, these “active” layers 
were two separate plastic layers. These charges induced potential differences between 
two large metal plates located under the mattress and isolated from each other by a stiff 
insulating plate. The potential difference between the metal plates was recorded by a 
conventional differential (AC or DC) amplifier (Alihanka et al., 1981). As more interest 
has developed into the respiratory regulation during sleep, many disorders including 
sleep apnoea, sleep disordered breathing and their cardiopulmonary consequences are 
now being studied. Kirjavainen et al. investigated a sensor mattress used in the 
detection of sleep apnoea (Kirjavainen et al., 1996). These authors found that in heavy 
snorers, episodes of high frequency spiking occurred on the static charge sensitive bed 
(SCSB). Further to night time use, the authors used the bed during a respiratory 
challenge and found the same results with spike amplitude correlating with breathing 
frequency and variation in oesophageal pressure (Kirjavainen et al., 1996). To detect 
abnormalities in breathing at night, Tenhunen et al., 2013, showed that the 
electromechanical film transducer (Emfit) signal in their SCSB was able to evaluate 
nocturnal breathing including obstructive and central breathing without the use of 
oximetry (Tenhunen et al., 2013). Furthermore, the Emfit can be used in all patients 
and there are no contraindications (Tenhunen et al., 2013).  
 
In a previous study by Dancey et al., PSGs in CF subjects with severe lung disease 
demonstrated reduced sleep efficiency (71 ± 25 % versus 93 ± 4 %, p = 0.004) and 
higher frequency of awakenings (4.2 ± 2.7/h versus 2.4 ± 1.4/h, p = 0.06) compared 
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with normal subjects (Dancey et al., 2002). As expected, mean nocturnal arterial SaO2 
was lower in CF subjects with severe lung disease  (84.4 ± 6.8 % versus 94.3 ± 1.5 %, 
p < 0.0001) which correlated with reduced sleep efficiency (regression coefficient = 
0.57, p = 0.014) (Dancey et al., 2002).  
 
Perin et al. demonstrated that SpO2 and end tidal CO2 during sleep were significantly 
correlated (p < 0.001) with pulmonary function (r = 0.62 for FEV1 and r = 0.66 for 
FVC), awake SpO2 (r = 0.90), at the end of a 6MWT (r = 0.78), and end tidal carbon 
dioxide (EtCO2) values (r = -0.86) (Perin et al., 2012). Furthermore, awake SpO2 at rest 
was the single best variable associated with sleep desaturation (relative risk: 0.48, 95 
% CI = 0.33 - 0.70, p < 0.001) (Perin et al., 2012). All CF patients with resting SpO2 < 
94 % demonstrated significant nocturnal desaturation (Perin et al., 2012). These 
previous studies were examining people with CF who had established daytime 
respiratory failure rather than looking at the spectrum of lung disease in people with 
CF who have differing levels of lung function including those people with normal lung 
function. 
 
The correlation of disease severity in patients with CF and increased risk of sleep 
apnoea was investigated by Veronezi et al. (Veronezi et al., 2015). This study of 34 
young CF patients (mean age 15.9 years) with a mean post-bronchodilator FEV1 of 
71% predicted did not find a correlation between FEV1 and AHI, similar to those 
findings of Ramos et al. (Veronezi et al., 2015, Ramos et al., 2011). There are few 
studies investigating subjects with only mild to moderate lung function. Hence, the 
subjects in the current novel study had a wide range of severity of lung function 
including normal lung function.  
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The Sonomat, the non-invasive device used in this current study, has been validated for 
the diagnosis of sleep apnoea similar to the gold standard PSG (Norman et al., 2014). 
As part of these validation studies, subjects from the Westmead Sleep Investigation and 
Research Centre participated in paired studies involving overnight PSG and Sonomat 
studies, similar to those performed in the current study. The data from the validation 
research indicated that the Sonomat was reliable and accurate for the diagnosis of OSA 
(Norman et al., 2014). Using Bland-Altman analysis of the AHI, there was positive 
agreement between the devices, particularly at levels around common diagnostic 
thresholds (Norman et al., 2014). Further studies are under way to examine the accuracy 
of the Sonomat in a variety of patient groups, including in asthma patients and our own 
patient group studied for this thesis.  
 
Details of the Sonomat have been documented in Chapter 2 – Methods. As described, 
using sensors to detect sounds and body movements, the Sonomat was able to record 
and analyse respiratory events such as apnoea, hypopnoeas and important respiratory 
sounds including, coughs, crackles and snores. Hence, the Sonomat can detect 
abnormal breathing during sleep to allow the determination of breathing disordered 
sleep (due to coughs or crackles) as well as the presence of sleep disordered breathing 
(apnoeas or hypopnoeas). 
 
To detect breathing abnormalities and lower airway dysfunction during sleep, a more 
sensitive testing system than the PSG is required. Furthermore, PSG is an in-laboratory 
test, which is not appropriate for long term repeated use. A home-based non-invasive 
simple recording device, such as the Sonomat, is an ideal system which can be used 
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long term. This device also has the advantage of being able to detect abnormalities of 
sleep disordered breathing. 
 
 
As people with CF are now living longer due to advances in medical care, the median 
survival is now greater than 40 years in Australia (Ruseckaite et al., 2018). This 
demographic shift has resulted in the need for adult-specific CF care programs to 
examine sleep disturbance caused by cough or breathing disorders during sleep. Thus, 
this study examined the spectrum of sleep abnormalities in adults with CF (including 
those with normal lung function) with the use of PSG and the addition of the novel 
measurement device, the Sonomat.  
 
 
4.2 AIM 
 
The aim of this study was to compare and contrast abnormalities in sleep and breathing 
using the PSG and Sonomat across a range of lung function in adults with CF. 
 
 
4.3 HYPOTHESES 
 
1. Abnormalities in sleep and breathing occur in adults with CF subjects with a 
wide range of lung disease. 
2. The Sonomat can describe abnormalities in sleep and breathing using additional 
respiratory parameters not detected by PSG.	
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4.4 METHODS 
 
4.4.1 Subjects 
 
Adults with CF were recruited from the Adult CF Service Westmead to undergo sleep 
testing (using the Sonomat simultaneously with the PSG) at the Westmead Sleep 
Investigation and Research Centre. CF diagnosis had been confirmed previously based 
on standard clinical criteria as noted in Chapter 2. The study was performed at the end 
of a hospital admission for treatment of a pulmonary exacerbation with the intention 
that the subjects achieved the best level of lung function possible. The protocols were 
approved by the Westmead Hospital Human Research Ethics Committee 
(HREC2012/12/4.9(3627) AU RED HREC/12/WMEAD/427). Written informed 
consent was obtained for all participants.  
 
All CF participants underwent a comprehensive clinical evaluation. Basic demographic 
information was recorded at the time of enrolment. Standard anthropometric 
measurements were obtained including: weight, height, body mass index (BMI). 
 
4.4.2 Lung Function 
 
Spirometry was performed according to ATS/ERS criteria (Miller et al., 2005) as 
described in Chapter 2 - Methods. Forced expiratory volume in 1 second (FEV1) and 
forced vital capacity (FVC) were recorded or tested. Predicted spirometric parameters 
were derived using reference values from Hankinson et al. (Hankinson et al., 1999).  
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4.4.3 Polysomnography 
 
As described in Chapter 2 – Methods, Section 2.6, standard overnight in-laboratory 
polysomnographic recordings were performed using a computerised acquisition system 
(Compumedics). The PSG recorded the following signals: electro-encephalogram 
(EEG), electro-oculogram (EOG), submental electro-myogram (EMG), electro-
cardiogram (ECG), thoraco-abdominal excursion (respiratory induction 
plethysmography), nasal flow (pressure transducer), oro-nasal flow (thermistor), 
snoring sounds (using a calibrated room sound meter, pulse oximetry (SpO2), leg 
movements, and body position.  
 
Polysomnography Scoring 
All PSG studies were scored according to the American Academy of Sleep Medicine 
(AASM) guidelines for scoring sleep stages, arousals, and respiratory events with the 
alternate (Type B) hypopnoea criteria used (Iber et al., 2007). The studies were all 
scored using the 2007 AASM guidelines prior to the sleep service adopting the revised 
AASM guidelines published in 2012 (Berry et al., 2012). Full details of scoring are 
discussed in Chapter 2 – Methods, Section 2.6. Sleep efficiency, Arousal index (AI), 
Apnoea-Hypopnoea index (AHI), and Respiratory disturbance index (RDI), were all 
calculated.  
 
4.4.4 Sonomat 
 
The Sonomat device was used for this study as described in Chapter 2 - Methods. Four 
identical sensors were embedded into the foam mattress and these contained a 
	 	
	 96	
polyvinylidine fluoride foam that generated a voltage when deformed. Sounds were 
recorded using these 4 sensors as well two additional room microphones embedded in 
the foam mattress. The mattress was placed directly on top of the bed in the PSG 
laboratory covered with a sheet and the subject laid on the Sonomat but was not attached 
to the Sonomat without any physical attachments to the mat.  
 
Acoustic signals were recorded at a sampling frequency of 4000 Hz and movement 
signals are recorded at a sampling frequency of 250 Hz. The software, Replay, was used 
to analyse the data from the Sonomat.  
 
Sonomat Scoring Criteria 
The analysis of the study began after the last of a series of frequent body movements 
that followed the subject lying down with the intention to sleep.  Analysis stopped when 
frequent body movements persisted or sounds indicated that the subject was awake. 
The duration of significant body movements indicating wakefulness during the night 
was removed from the total recording time (TRT) to calculate the “quiescent duration” 
(Qd or sleep time). This Qd or sleep time duration, contained all periods of postural 
immobility, was used as the estimate of total sleep time (TST). Sonomat respiratory 
events were visually scored and were also replayed through audio speakers for further 
clarification of events. The apnoea-hypopnoea index (AHI) from the Sonomat studies 
(AHI MAT) was generated by dividing the number of valid respiratory events by the 
Qd.  
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Breath sounds were scored throughout the night as detailed in Chapter 2 – Methods. 
These breath sounds included: normal breath sounds, snores, coughs, crackles and 
wheezes. At any time point during the study, respiratory sounds, such as cough or 
snores may co-exist with the presence of crackles and apnoeas / hypopnoeas. Duration 
of each of the above breath sounds per hour was calculated by dividing the total duration 
of each breath sound by the Qd (in hours). For cough, the total number of coughs was 
also summed together in three categories: 1. Single cough; 2. Two to five coughs; and 
3. Greater than 5 coughs. In addition, duration of cough during sleep and cough during 
awake time within the sleep period were calculated. The Sonomat produces a 
calculation for AHI based on apnoeas or hypopnoeas with cessation or reduction of 
body and chest movements on movement channels. As there are no oximetry data for 
the Sonomat, the Sonomat “AHI” most closely resembles RDI on the PSG. The RDI 
on the PSG is calculated based on the inclusion of apnoeas, hypopnoeas and respiratory 
effort related arousals (RERAs).  
 
4.4.5 Statistical Analyses 
 
Statistical and graphical analyses were performed using SPPS v.22 (SPSS Inc., IL, 
USA) and GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA, USA). Normally 
distributed data are presented as mean ± standard deviation (SD), and non-normally 
distributed data are presented as median and interquartile range (IQR).  
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4.5 RESULTS 
 
The paired sleep studies were performed in 40 subjects (16 male, aged 33.8 ± 10.8 
years), with demographic data reported in Table 4.1.  
 
Table 4.1 Baseline Characteristics 
Characteristic   
Male (n, %) 16, 40 
Age, years (mean ± SD) (range) 33.8 ± 10.8 (20 to 67) 
BMI, kg/m2 (mean ± SD) 21.6 ± 3.2 
Genotype, F508del Homozygous (n, %) 23, 58 
FEV1, % predicted (mean ± SD) (range) 47.9 ± 17.8 (21.0 to 100.0) 
MucPSA (n, %) 27, 68 
Pancreatic Sufficient (n, %) 3, 8 
Diabetes (n, %) 7, 18 
N = 40 subjects. Data expressed as mean ± SD. BMI: body mass index; FEV1: forced 
expiratory volume in 1 second. MucPSA: mucoid Pseudomonas aeruginosa.  
This group of subjects had moderately severe lung disease with mean FEV1 % predicted 
of 47.9 % (range between 21 to 100 FEV1 % predicted). All subjects were using 
preventer bronchodilator therapy (inhaled corticosteroids combined with long acting 
beta agonist). Nebulised dornase-alpha was used in 85 % of subjects, of these subjects, 
21 also used hypertonic saline as a mucolytic medication. Six subjects did not use 
regular oral aminoglycosides and thirteen subjects were on oral corticosteroid therapy 
(dose ranging from 5 to 15 mg per day). 
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Table 4.2 PSG Sleep Characteristics 
PSG Sleep Characteristic  
Sleep Efficiency, % 78.7 ± 13.7  
Arousal Index, events per hour 17.9 ± 8.3  
RDI, events per hour 5.6 (8.3) 
AHI, events per hour 1.1 (2.6) 
Total sleep time, minutes 341.6 ± 66.6  
REM sleep, % 15.9 ± 6.9  
NREM sleep, % 83.1 ± 6.9  
WASO, minutes 53.0 (93.5) 
Baseline SpO2, % 95.0 (1.8) 
REM min saturation, % 88.5 (6.5) 
NREM min saturation % 89.0 (4.3) 
Mean SpO2 desaturation during sleep, % 3.0 (4.0) 
Mean SpO2 during sleep, % 92.4 ± 3.0 
ODI, events per hour 0.3 (1.7) 
Nadir SpO2, % 87.6 ± 4.6 
Pulse rate, bpm 85.5 ± 13.7 
N = 40 subjects. Data expressed as mean ± SD (for normally distributed data) or median 
(IQR) (for non-normally distributed data). PSG: Polysomnogram; RDI: Respiratory 
Disturbance Index; AHI: Apnoea Hypopnoea Index; REM: rapid eye movement sleep; 
NREM: non-rapid eye movement sleep; WASO: wake after sleep onset; SpO2: oxygen 
saturation; min: minimum; ODI: oxygen desaturation index; bpm: beats per minute 
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Table 4.3 PSG Sleep Arousal Results 
Arousals Median (IQR) 
Respiratory Arousals / hr 4.5 (8.5) 
Leg Arousals / hr 0.0 (0.2) 
Spontaneous Arousals / hr 8.2 (9.1) 
 
In this group of adults with CF with moderately severe lung disease, most parameters 
measured by PSG were close to the normal reference ranges (AASM, 2014, Bonnet and 
Arand, 2007). Overall, the RDI was mildly increased with a median of 5.6 events per 
hour (normal < 5 events per hour) (AASM, 2014). The AHI was within the normal 
reference range at less than 5 events per hour (median 1.1 events per hour). There was 
one outlier, subject 9, who had previously been diagnosed with severe obstructive sleep 
apnoea (AHI 53 events per hour of sleep) and uses CPAP therapy nightly. See Figures 
4.1 and 4.2 below. 
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Figure 4.1 Range of Apnoea-Hypopnoea Index (AHI) 
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Figure 4.2 Range of Respiratory Disturbance Index (RDI) 
 
Mean SpO2 during sleep was mildly reduced with mean of 92.4 % (SD ± 3.0) and nadir 
SpO2 was also mildly reduced with mean of 87.6 % (SD ± 4.6). As shown above, 
arousals were all within reference ranges even when considering altered reference 
values in the younger age groups, where mean arousal index for 31 to 40 years has been 
reported as 16.8 ± 6.2 events per hour (Bonnet and Arand, 2007). The arousal index 
was found to be weakly negatively correlated with nadir SpO2 (p = 0.006; r2 = 0.190) 
but was not found to be correlated with other oximetry parameters including: baseline 
SpO2 and mean SpO2 during sleep time (p = 0.556 and 0.132; r2 = 0.002 and 0.049; 
respectively). 
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Sonomat 
Table 4.4 Sonomat Sleep Characteristics 
Sonomat Sleep Characteristic  
Sleep Efficiency, % (based on Qd) 93.7 ± 4.2 
Total sleep time, minutes 397.5 ± 55.2 
WASO, minutes 26.5 ± 17.9 
Total AHI, events per hour 3.4 (10.0) 
Crackles, % of sleep time 19.9 (52.0) 
Cough, % of sleep time 0.2 (0.5) 
Nocturnal awake time with cough, seconds 8.9 (18.2) 
Total sleep time with cough, seconds 53.5 (131.0) 
Cough, total number of episodes of:  
1 cough 
2 - 5 coughs 
> 5 coughs 
 
1.0 (5.8) 
12.0 (38.8) 
1.0 (4.0) 
Snores, % of sleep time 5.1 (16.8) 
N = 40 subjects. Data expressed as: mean ± SD or median (IQR). Qd: quiescent 
duration; WASO: Wake after sleep onset; AHI: apnoea-hypopnoea index. 
 
The sleep efficiency based on the Sonomat was adequate in this group of CF subjects 
with a mean sleep efficiency of 93.7 %. The % of total sleep time (Quiescent duration 
- Qd) with crackles was 19.9 % (IQR 52.0). Cough was minimally recorded at only 0.2 
% (IQR 0.5) during sleep. The % of sleep time spent snoring was 5.1 % (IQR 16.8). It 
should be noted coughs were visualised both whilst the subject was awake as well as 
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during quiescent time to look at consistency of coughs within subjects. However, data 
presented below showed specific examination of cough during quiescence (sleep) as 
well as awake time during the total recording time (TRT). 
 
Specific examination of cough in these subjects required analysis of cough sounds 
during awake time at night, not just coughs occurring during sleep to look at 
consistency of coughs within subjects. Assessment of cough during sleep and awake 
time during night demonstrated a cumulative median cough time during sleep of 53.5 
seconds. Cough during total recording time demonstrated a median of 8.9 seconds 
(range 0 to 734 seconds through the night). Dividing the number of cough episodes into 
three categories, demonstrated a wide variation between subjects with some subjects 
only ever performing single coughs, others performing cough paroxysms (greater or 
equal to 2 coughs) interspersed with single coughs during the night of study. As shown 
in Table 4.4, cough episodes of between 2 and 5 coughs per episode were more 
commonly demonstrated than either single coughs or cough paroxysms of more than 5 
coughs per coughing episode.  
 
An example of a hypnogram of a subject with coughs occurring both during sleep as 
well as during awake time is shown below in Figure 4.3. For this subject, prior to 
analysis start time, coughs occurred up until quiescent time (indicating sleep). 
Throughout the total recording time there were burst of coughs but not as numerous as 
the number occurring during awake time. 
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Figure 4.3 Hypnogram of One Subject with Coughs.  
 
Multiple events were seen in the above hypnogram including: occasional respiratory 
events (red, top row), snores (orange), crackles (bright green), movements (blue), 
talking (purple), environmental – such as external door close (bright blue), coughs 
(pink, bottom row). Analysis started (1st black line) after the last of a series of frequent 
body movements that followed the subject lying down with the intention to sleep.  
Analysis stopped (2nd dark black line) when frequent body movements persisted or 
sounds indicated that the subject was awake. Qd is the duration of time where no body 
movements were detected during the recording time. 
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Comparison of Sonomat and PSG Data 
 
The sleep characteristics from the Sonomat and PSG are shown in Table 4.5 below.  
 
Table 4.5 Sonomat and PSG Data 
Sleep Characteristic Sonomat PSG Correlation 
Sonomat and PSG 
p-value r2 
Sleep efficiency, % 94.7 (3.6) 79.0 (16.5) 0.001 0.443 
AHI, events per hour 3.4 (10.0) 1.1 (2.3) 0.001 0.788 
Respiratory events 
(apnoeas/hypopnoeas),  
events per hour 
3.4 (10.0)  
(Sonomat AHI) 
5.5 (7.6) 
(PSG RDI) 
0.001 0.561 
N = 40 subjects. Data expressed as Median (IQR). PSG: Polysomnogram; AHI: 
Apnoea-hypopnoea index; RDI: Respiratory disturbance index.  Correlation is 
significant at the 0.05 level (2-tailed). 
 
Although the Sonomat showed a high sleep efficiency overall, there was a statistically 
significant positive correlation between sleep efficiency in the Sonomat and the PSG 
(r2 = 0.443, p = 0.001), Figure 4.4. Overall, the Sonomat tended to overestimate the 
sleep efficiency as well as the PSG AHI but underestimate the PSG RDI. The Sonomat 
overestimated the period of quiescence as the Qd was based on absence of body 
movements as a surrogate for sleep duration.  The AHI was positively correlated 
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between Sonomat and PSG (r2 = 0.788, p = 0.001), as shown in Figure 4.5. In addition, 
there was a moderately strong correlation between Sonomat AHI and PSG RDI (r2 = 
0.561, p = 0.001), as demonstrated in Figure 4.6 below. 
 
 
Figure 4.4 Sleep Efficiency – Sonomat and PSG 
PSG: Polysomnography. Solid line: linear regression line. Dashed line: line of identity. 
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Figure 4.5 AHI – Sonomat and PSG 
AHI: apnoea-hypopnoea index; PSG: polysomnography. Solid line: linear regression 
line. Dashed line: line of identity. 
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Figure 4.6 Sonomat AHI and PSG RDI 
AHI: Apnoea-hypopnoea index; RDI: Respiratory disturbance index; PSG: 
polysomnography. Solid line: linear regression line. Dashed line: line of identity. 
 
 
Lung Function and PSG Sleep Parameters 
Using linear regression to assess influence of lung function (FEV1 % predicted) on sleep 
parameters, only awake SpO2 and nadir SpO2 were positively correlated even weakly 
with FEV1 % predicted (p = 0.001 and p = 0.003; r2 = 0.253 and 0.186; respectively), 
see Figure 4.7 and Figure 4.8 below. Table 4.6 demonstrates the correlations of lung 
function with PSG parameters. For total RDI, total AHI, ODI and mean SpO2 during 
	 	
	 110	
sleep time, there were no statistically significant correlations with FEV1 % predicted (p 
= 0.293, 0.475, 0.564, 0.025; and r2 = 0.032, 0.001, 0.001, 0.079; respectively).  
 
Table 4.6 Correlation of Lung Function with PSG Parameters 
Objective Sleep Variables Correlation with lung function (FEV1) 
p-value r r2 
Arousal Index 0.743 -0.054 0.001 
Sleep Efficiency 0.256 0.184 0.020 
RDI 0.293 0.170 0.032 
AHI 0.475 -0.116 0.001 
ODI 0.564 -0.094 0.001 
Awake SpO2 0.001* 0.492  0.253 
Mean SpO2 during sleep 0.025 0.354 0.079 
Nadir SpO2 0.003* 0.455  0.186 
Time spent with SpO2 < 90 % 0.001* -0.550  0.139 
N = 40 subjects. FEV1: Forced expiratory volume in 1 second; AHI: apnoea-hypopnoea 
index; RDI: respiratory disturbance index; ODI: oxygen disturbance index; SpO2: 
oxygen saturation; *: significant correlation, using Spearman’s calculation, correlation 
significant at the 0.05 level (2-tailed).  
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Figure 4.7 Lung Function and Awake SpO2 
SpO2: oxygen saturation; FEV1: forced expiratory volume in 1 second 
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 Figure 4.8 Lung Function and Nadir SpO2 
SpO2: oxygen saturation; FEV1: forced expiratory volume in 1 second 
 
 
Lung Function and Sonomat Sleep Parameters 
Using linear regression to assess the influence of lung function (FEV1 % predicted) on 
Sonomat sleep parameters, it was found that there was no influence of FEV1 on AHI, 
sleep efficiency nor % cough time (r2 = 0.040, 0.002, 0.069, respectively). There was a 
weak significant correlation between % of sleep time spent with crackles and lung 
function (r2 = 0.136), demonstrated in Figure 4.9. There was no correlation found 
between % time spent with cough and lung function, as shown in Table 4.7 below. 
These findings were similar to those we described above for the PSG parameters with 
total RDI and total AHI not significantly correlated with lung function (r2 = 0.032 and 
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0.001; respectively). Awake SpO2 and nadir SpO2 were weakly positively correlated 
with FEV1 % predicted (r2 = 0.253 and 0.186; respectively), shown above in Table 4.6.  
 
Table 4.7 Correlation of Lung Function and Sonomat Sleep Parameters 
Sonomat Sleep Parameters Correlation with lung function 
(FEV1) 
p-value r r2 
Crackles, % of total sleep time 0.032* -0.339 0.136 
Cough, % of total sleep time 0.058 -0.302 0.061 
N = 40 subjects. FEV1: forced expiratory volume in 1 second.  *p-value significant < 
0.05. 
 
	 	
	 114	
 
Figure 4.9 Lung Function and Percentage of Sleep Time with Crackles 
FEV1: Forced expiratory volume in 1 second. 
 
Oxygen and PSG Parameters 
SpO2 during sleep time was statistically significantly correlated with awake SpO2 (p = 
0.001, r2 = 0.623; shown in Figure 4.10) and nadir SpO2 (p = 0.001, r2 = 0.565; shown 
in Figure 4.11). There was no correlation between average SpO2 during sleep and total 
RDI or total AI (p = 0.137, 0.112; and r2 = 0.027, 0.051; respectively). However, there 
was a weak negative but statistically significant correlation between average SpO2 
during sleep time and total AHI (p = 0.002, r2 = -0.064). 
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Figure 4.10 Oxygen Saturation during Sleep and Oxygen Saturation during 
Awake Time. 
SpO2: oxygen saturation. 
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Figure 4.11 Oxygen Saturation during Sleep and Nadir Oxygen Saturation.  
SpO2: oxygen saturation. 
 
 
Oxygen and Sonomat Parameters 
Spearman’s correlation to investigate the relationship between Sonomat results and 
oximetry from the PSG demonstrated a negative correlation between total AHI on the 
Sonomat with awake SpO2 and nadir SpO2 (r2 = 0.180 and 0.257, respectively; p = 
0.006 and 0.001, respectively). Time spent coughing was also inversely correlated with 
both awake SpO2 and nadir SpO2, see Table 4.8 and Figures 4.12 and 4.13 below. 
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Table 4.8 Correlations between PSG and Sonomat Oxygen Parameters 
PSG 
parameter 
Sonomat parameter Spearman’s Correlation 
r2 value                               p value 
Awake SpO2 AHI 0.180 0.006* 
Sleep efficiency 0.051 NS 
% sleep time with cough 0.110 0.001* 
% sleep time with crackles 0.117 NS 
% sleep time with snores 0.016 NS 
Nadir SpO2 AHI 0.257 0.001* 
Sleep efficiency 0.042 NS 
% sleep time with cough 0.160  0.001* 
% sleep time with crackles 0.108 NS 
% sleep time with snores 0.011 NS 
PSG: Polysomnogram; SpO2: oxygen saturation; AHI: apnoea-hypopnoea index. 
*Correlation is significant at 0.05 level (2-tailed). 
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Figure 4.12 Cough Duration and Awake SpO2 
SpO2: Oxygen saturation. 
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Figure 4.13 Cough Duration and Nadir SpO2 
SpO2: oxygen saturation. 
 
 
4.6 DISCUSSION 
 
Polysomnography 
In our cohort with mild through to severe CF lung disease, we found a low prevalence 
of sleep disordered breathing with RDI and AHI close to normal reference ranges (< 5 
events per hour). Perin et al. found that there was an extremely low prevalence of 
obstructive sleep apnoea (3.9 %) observed in 51 clinically stable adult CF patients with 
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a mean FEV1 % predicted of 57.7 ± 24.7 % (range 115 % to 19.5 % predicted) (Perin 
et al., 2012). Compared with the population studied by Perin et al., our subjects were 
older (mean age 33.8 vs 25.1 years in Perin et al.) and their lung function deficit was 
more severe (mean FEV1 % predicted 47.9 vs 57.7 %) (Perin et al., 2012). In our study 
we found a higher prevalence of OSA of 12.5 % (where obstructive sleep apnoea was 
defined as AHI > 5 events per hour based on AASM 2007 Guidelines (Iber et al., 
2007)), which may be due to an older and more compromised subject group in our 
study, compared with the Perin et al. study (Perin et al., 2012). Furthermore, if we use 
the definition of RDI > 5 events per hour for the diagnosis of at least mild obstructive 
sleep apnoea, the prevalence in our population was severely elevated at 57.5 %. 
However, other findings of our study are in keeping with those from Perin et al., 2012, 
who similarly found that awake SpO2 correlated well with SpO2 during sleep (Perin et 
al., 2012).  In addition, we found that nadir SpO2 correlated with SpO2 during sleep. 
 
In our study, we found a mean arousal index of 17.9 ± 8.3 events per hour which was 
higher than that reported by Perin et al. and de Castro-Silva et al. but similar to those 
reported by Bonnet and Arand (Bonnet and Arand, 2007, de Castro-Silva et al., 2009, 
Perin et al., 2012). Furthermore, Naqvi reported an increased arousal index of 28.3 ± 
2.9 events per hour due to an increase in spontaneous arousals (Naqvi et al., 2008). This 
was not seen in our patient group. The mildly increased arousal index in our participants 
may be due to our subjects being older (mean age 33.8 years in our study vs 26.1 years 
in the Perin study) (Perin et al., 2012). There was no statistically significant correlation 
between age and AI in our subject group (r2 = 0.064).   
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Reviewing sleep efficiency reported from previous papers, a reduced sleep efficiency 
of 71 % in 19 CF subjects with very severe lung disease (FEV1 of 28 ± 7 % predicted), 
reduced SaO2 during awake (mean 87 ± 6 %) and asleep (mean 84.4 ± 6.8 %) has been 
demonstrated (Dancey et al., 2002). In contrast, our population showed well preserved 
sleep efficiency at 78.7 ± 13.7 % and % of time spent in REM sleep. These differences 
between our findings and those above may be related to those subjects with poorer lung 
function experiencing chronic sleep restriction with sleep disruption and worse 
nocturnal hypoxaemia (Dancey et al., 2002).  
 
In a small study from 30 years ago, with a total of 8 CF patients, Spier et al. reported a 
very low sleep efficiency of 58 % and reduced % of REM sleep (9.4%) in this group of 
adolescents and adults with severe lung disease secondary to CF (Spier et al., 1984). 
This contrasts with the findings of our study, where sleep efficiency and time spent in 
REM sleep were both within the lower limits of reference ranges. These differences 
may be due to the different study populations. Our subject group had more females, 
increased BMI and higher lung function than the 8 patients in Spier et al. (Spier et al., 
1984). Spier further described that bouts of coughing often coincided with arousal and 
arousals sometimes occurred simultaneously with transient reductions in oxygen 
saturation measured by ear oximetry and reported as SaO2 (Spier et al., 1984). 
However, they found that arousals more often occurred without drops in SaO2 and drops 
in SaO2 often did not result in arousals (Spier et al., 1984). Further, larger sample size 
populations may better address these issues.  
 
Changes in sleep architecture as described by lower % REM sleep and reduced sleep 
efficiency / disruption have been shown to be correlated with the severity of lung 
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disease in the study by Naqvi et al. (Naqvi et al., 2008).  This US study examined 24 
children and adolescents with CF and found their sleep efficiency was within reference 
limits (at > 75 %) but lower than those of the 14 subjects in the control group at 85.6 % 
(Naqvi et al., 2008). The reported sleep efficiency in the CF group was similar to that 
in our group at 75.2 ± 2.5 % but they reported reduced % of REM sleep of 12.7 ± 1.5 
% (Naqvi et al., 2008). In the Naqvi study, the degree of sleep disruption, as indicated 
by sleep efficiency, was correlated with severity of lung disease (Naqvi et al., 2008).   
 
As discussed previously, EEG arousals have been shown to increase with increasing 
age (Bonnet and Arand, 2007). These authors found that the arousal index for the age 
group of 31 - 40 years, was 16.8 ± 6.2 events per hour (Bonnet and Arand, 2007). In 
our study of younger adult patients, with a mean age of 33.6 years, the arousal index 
was similar at 17.9 ± 8.3 events per hour (mean ± SD). The Naqvi study of children and 
adolescents looked at the arousal index and found a significantly higher arousal index, 
due to an increase in spontaneous arousals that was noted in CF patients (28.3 ± 2.9 
events per hour vs 14.5 ± 1.4 events per hour; p < 0.05) (Naqvi et al., 2008). Cough 
related arousals are unable to be delineated from a spontaneous arousal by the PSG and 
hence, the Sonomat, a non-invasive recording device, may be useful to detect the causes 
of further abnormalities during sleep. 
 
Night-time cough is thought to contribute to sleep fragmentation in patients with 
respiratory disease but few studies have looked at this specifically. Stokes performed 
an observational study of 9 patients with CF lung disease and found that cough in 3 of 
the patients resulted disruption of normal sleep stages and sleep cycles (Stokes et al., 
1980). The contribution of cough resulting in sleep fragmentation contributing to 
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increased arousals and possible hypoxaemia was discussed by Perin but not accurately 
quantified in their study (Perin et al., 2012).  
 
 The presence of nocturnal hypoxaemia could potentially lead to arousal and sleep 
fragmentation / disruption. However, in our study we found that only nadir SpO2 was 
weakly negatively correlated with arousal index and neither baseline SpO2 nor mean 
SpO2 during sleep time were correlated. Previous studies have looked at sleep 
disruption using actigraphy rather than PSGs (Amin et al., 2005, Jankelowitz et al., 
2005). Jankelowitz et al. studied 20 stable CF patients and found that although these 
patients had disrupted sleep with a higher fragmentation index (calculated by summing 
the percentage of minutes spent moving with the % time spent in the immobility phase 
per minute) than controls (31.72 vs 18.04), CF patients and control subjects had similar 
sleep duration (7.52 hours vs 7.1 hours), sleep latency (12.75 min vs 13.85m min) and 
sleep efficiency (mean 85.2 % vs 85.4 %) (Jankelowitz et al., 2005).   
 
Sonomat 
The present study is the first study using the non-invasive device, the Sonomat, to 
investigate abnormalities breathing during sleep in adult subjects with CF. Norman et 
al. found a significant difference between sleep time based on the PSG and that from 
the Sonomat with PSG sleep time reported as 342.9 ± 10.6 minutes compared with 
Sonomat sleep time reported as 379.4 ± 10.0 minutes (p < 0.001) (Norman et al., 2014). 
This study showed that the total sleep time (TST) generated from Sonomat recordings 
overestimated the precise EEG derived TST by 37 minutes on average, but this 
difference was not sufficient to impact significantly on the AHI (Norman et al., 2014). 
These results differ from our own data with the TST derived from the Sonomat 
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overestimating the TST from the PSG by 62 minutes, on average. This may be due to 
the younger subjects in our study who may be awake but do not move sufficiently 
enough to activate the movement sensors on the Sonomat. Hence, we scored these 
periods as sleep but the precise EEG might score these periods as wakefulness based 
on the presence of alpha rhythms. Although, we found a moderately positive correlation 
of sleep efficiency between Sonomat and PSG (r2 = 0.443), it is likely not to be accurate 
due to the above limitations of scoring TST using the Sonomat.   
 
An advantage of the Sonomat, in this patient population, is its’ ability to assess cough 
and lung sounds during sleep which are not recorded by the standard PSG. The 
interesting finding in this study was that the Sonomat can detect cough effectively but 
at the end of an admission, the range of cough duration during sleep was 0 to 734 
seconds. Despite relatively little coughing, crackles were noted during 19.9 % of sleep 
time. The presence of crackles can suggest sputum retention and in keeping with those 
respiratory parameters that can be detected by the PSG (namely the awake SpO2 and 
nadir SpO2), respiratory function is compromised in these subjects with CF. With 
reduced lung function (FEV1), the duration of crackles during sleep increases in 
keeping with poorer respiratory status. These additional parameters detected by the 
Sonomat can provide further supporting evidence that the respiratory status of subjects 
with CF can be affected both during the day time (as per lung function) and night time 
(based on crackles, cough and oxygen parameters).  
 
It would be expected that the Sonomat AHI was correlated better with the PSG RDI 
rather than the PSG AHI due to the difference in scoring of events between the two 
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modalities. Arousals scored by the Sonomat by assessing changes in body movement 
sensors may be seen to be similar to arousals scored as respiratory effort related arousals 
(RERAs) in the PSG. We found weak correlation for sleep efficiency between the 
Sonomat and PSG (median 94.7 % vs 79.0 %; r2 = 0.443) as well as a strong correlation 
between the Sonomat AHI and PSG AHI (median 3.4 events per hour vs 1.1 events per 
hour; r2 = 0.788). Interestingly, in our study we found that PSG RDI was not as well 
correlated as the PSG AHI with Sonomat AHI, suggesting that the Sonomat may 
underestimate RERAs.  
 
These results may be underpowered with our small sample size in this study. We found 
there was no influence of lung function on the AHI in both the Sonomat and PSG 
studies. It was described above, that only awake SpO2 and nadir SpO2 were positively 
correlated with lung function confirming that oximetry is a useful clinical tool in the 
assessment of subjects with lung disease. Further studies using the Sonomat along with 
oximetry will be valuable in the assessment of such patients in the long term. 
Limitations of this study included lack of control group, which may have allowed for a 
more direct comparison of our data to healthy or disease specific controls. In our small 
sample size, there was a wide range of AHI (0.0 to 53.4 events per hour). This low AHI 
may not be ideal for scoring of respiratory events from the Sonomat. 
This study was a novel study using the non-invasive Sonomat device to characterise 
respiratory sounds in subjects with CF that are not detected by the conventional PSG. 
Extension of the single overnight study described in this chapter has been undertaken 
in Chapter 5 –Longitudinal data which details additional parameters useful in 
investigating the respiratory status of individuals with CF during sleep.  
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4.7 CONCLUSION 
 
This study demonstrated that in these 40 CF adults (mean age of 33.8 years) with a 
range of lung disease severity, sleep parameters (sleep efficiency, sleep stages and 
arousal index) measured on polysomnography are similar to reported reference values 
in both CF and non-CF populations. We also demonstrated a high prevalence of mild 
(RDI > 5 events per hour) sleep disordered breathing (median RDI 5.6 events per hour), 
although the median AHI was within reference range (median AHI 1.1 events per hour). 
The main finding from the current study was that measurement of oximetry overnight 
can be correlated with lung function. Poorer lung function correlated with lower SpO2 
both awake as well as at the nadir SpO2 but not the mean SpO2 during sleep time. We 
found there was no correlation between poorer lung function and reduced sleep 
efficiency, AHI, RDI or AI in our study. A larger study to substantiate these findings 
and to further address the effects of sleep disruption and nocturnal hypoxaemia on 
quality of life and clinical outcomes is needed.  
 
Based on the findings of the Sonomat alone, these adults with CF have good sleep 
efficiency (median of 94.7 %). AHI was reported to be within reference limits (median 
of 3.4 events per hour). Although, the percentage of sleep time with cough and snore is 
minimal, the presence of crackles at 19.9 % of sleep time is consistent with respiratory 
compromise in these subjects. The sleep efficiency of both the Sonomat and PSG is 
within reference values and correlates weakly (r2 = 0.443). The overall AHI is similar 
between the Sonomat and PSG with a strong correlation demonstrated.  
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The Sonomat can be used to detect abnormalities in sleep and breathing using additional 
parameters, such as recording of coughs and crackles, not attainable with the PSG. In 
addition, lung function is not found to be correlated with AHI, sleep efficiency nor 
cough. Both the Sonomat and PSG showed there is no evidence of correlation between 
lung function and AHI in this current project. Hence, other parameters, such as crackles 
identified by the Sonomat, can be used to assess subject’s respiratory status for adults 
with a wide range of lung function varying from normal to very severe airflow 
obstruction. 
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CHAPTER 5: OBJECTIVE SLEEP MEASUREMENTS IN ADULTS 
WITH CYSTIC FIBROSIS AND DETERIORATING LUNG DISEASE 
 
5.1 INTRODUCTION 
 
A number of measures can be used to assess nocturnal respiratory failure including 
overnight oximetry and polysomnography to assess sleep fragmentation, apnoeas and 
other respiratory events. Furthermore, with the use of the Sonomat, other aspects of 
sleep disordered breathing can be assessed. In particular, presence or absence of 
adventitial sounds which suggest pulmonary congestion and exacerbation of asthma or 
bronchiectasis can be assessed using the Sonomat over a period of time or at different 
time points.  
 
Objective measurements of cough during pulmonary exacerbations have been studied 
previously by Smith et al. (Smith et al., 2006). These authors reported a reduction in 
cough rate with treatment but did not publish any longitudinal data to assess if cough 
rate increased again with future exacerbations and the effect of lung function 
deterioration on cough rate (Smith et al., 2006). In particular, these studies did not 
measure crackles or wheeze, only cough was recorded.  In contrast to the study by 
Smith et al., fourteen CF children were studied by Hamutcu et al., and they found that 
the treatment of respiratory exacerbation improved neither the subjective (cough scores 
or visual analogue score) nor objective (ambulatory cough recording device – LR 100) 
measures of cough in CF children (Hamutcu et al., 2002, Smith et al., 2006). There 
have been no previous studies investigating the effect of deteriorating lung function on 
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overnight cough and other adventitial sounds, such as crackles, recorded by 
longitudinal studies.  
 
In addition, if a patient is found to demonstrate nocturnal respiratory failure they can 
be offered treatment with non-invasive ventilation in an attempt to stabilise gas 
exchange function, especially as a bridge to lung transplantation (Hodson et al., 1991, 
Flight et al., 2012, Gozal, 1997, Milross et al., 2001a, Piper et al., 1992). 
 
To perform repeated measures in the same individuals over time would then help to 
control for the individual variation in upper air physiology, and may allow delineation 
of a subtle relationship between lung function and SDB. Therefore, we undertook repeat 
studies in patients who had clinically deteriorated over a 1 to 3-year period to determine 
the severity of any changes in the night-time PSG and Sonomat recordings, and to 
compare the major clinical changes in functioning with the changes in PSG and 
Sonomat.  
 
5.2 AIMS 
 
The aims of this study included:  
1. Assessment of nocturnal sleep disordered breathing in a subset of adults with 
CF after they have clinically deteriorated (shown by reduction in lung function, 
increased oxygen requirements or increased exacerbations) from their baseline 
study approximately 2 years earlier, to assess if SDB has deteriorated using PSG 
and Sonomat data. 
	 	
	 130	
2. Assessment of changes in measures of breathing disordered sleep using the 
additional respiratory parameters from the Sonomat.  
 
5.3 HYPOTHESES 
 
1. Nocturnal sleep disordered breathing is more severe in adults with CF after 
disease progression. 
2. Deterioration of respiratory parameters during sleep detected by the PSG and 
the Sonomat (such as cough and crackles) correlates with deterioration in lung 
function in a subset of CF subjects. 
 
 
5.4 METHODS 
 
5.4.1 Subjects 
 
Eight patients were enrolled who had clinical deterioration with: reductions in lung 
function (between 2 and 24 % drop in FEV1 % predicted); frequent exacerbations (> 4 
in the preceding 12 months); or worsening daytime hypoxaemia.   
 
5.4.2 Measurements 
 
Simultaneous overnight polysomnography and Sonomat use was repeated 1 to 3 years 
following the subject’s first study, again at the end of an admission for an exacerbation. 
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The measurements used have been described in detail in Chapter 2 – Methods and 
further details discussed in Chapter 4.  
 
5.4.3 Statistical Analyses 
 
Using SPSS version 22 (SPSS Inc., IL, USA), the differences between the two groups 
at time baseline and the subsequent period were analysed using paired t-tests. Normally 
distributed data are presented as mean ± standard deviation (SD), and non-normally 
distributed data are presented as median and interquartile range (IQR).  
 
5.5 RESULTS 
 
Eight subjects were studied on 2 separate occasions. Demographic data is shown below 
in Table 5.1. There were 2 male subjects and 6 female subjects with a mean age of 26.5 
years (SD ± 4.9 years).  Overall, they were in the healthy weight range at baseline with 
a mean BMI of 21.0 kg/m2 (SD ± 2.3 kg.m2). Five subjects (63%) were homozygous 
for the F508del genotype. The mean FEV1 (% predicted) had reduced from 45 % 
predicted initially to a mean of 33 % at the subsequent time period (SD ± 11.9), 
indicating overall a very severe obstructive ventilatory defect as per the American 
Thoracic Society and European Respiratory Society reference ranges (Pelligrino et al., 
2005). FEV1 % predicted and FVC % predicted both decreased from baseline to the 
subsequent study (p = 0.002 and p = 0.003, respectively). No other characteristics 
changed significantly from baseline to the subsequent study, except for awake SpO2. 
On average, the subsequent sleep study was performed 1.8 years (range 325 to 1127 
days) following the initial sleep study.  
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Table 5.1 Patient Characteristics in Longitudinal Study 
Characteristics  Baseline Subsequent p - value 
Male (n, %) 2, 25 -  
Age, years (mean ± SD) 
(range) 
26.5 ± 4.9 
(20 to 34) 
28.5 ± 5.2 - 
BMI, kg/m2  21.0 ± 2.3 20.0 ± 2.0 0.184 
Genotype, Homozygous 
F508del (n, %) 
5, 63 -  
MucPSA (n, %) 4, 50 -  
FEV1, % predicted  45.0 ± 11.9 33.0 ± 8.6 0.002* 
FVC, % predicted  68.6 ± 13.9 53.1 ± 13.5 0.003* 
Awake SpO2, %  94.9 ± 2.0 92.9 ± 3.5 0.017* 
N = 8 subjects. Data expressed as mean ± SD. BMI: body mass index; MucPSA: 
mucoid Pseudomonas aeruginosa; FEV1: forced expiratory volume in 1 second; FVC: 
forced vital capacity; SpO2: oxygen saturation. *p-value significant < 0.05. 
 
Polysomnography 
 
Data presented in Table 5.2 below, showed that sleep efficiency did not significantly 
change from baseline to the subsequent study (p = 0.827) and remained in the normal 
range (> 75 %). Although the arousal index did not significantly increase over time, it 
was above reference limits as per the reference ranges documented by Bonnet and 
Arand: for the age group between 21- 30 years, AI should be 10.8 ± 4.6 (Bonnet and 
Arand, 2007).  
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In this small group of CF subjects with deteriorating lung disease, mild sleep disordered 
breathing for the group was demonstrated with a mean respiratory disturbance index 
(RDI) rising from 6.9 events per hour at baseline (range: 0.3 to 18.5 events per hour) to 
11.0 events per hour at the subsequent study (range: 1.2 to 21.7 events per hour; normal 
RDI is < 5 events per hour). Five out of the 8 subjects had a RDI greater than 5 events 
per hour.  
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Table 5.2 Baseline and Subsequent PSG Parameters in Longitudinal Study 
N = 8 subjects. Data expressed as mean ± SD. Mins: minutes; NREM: non-rapid eye 
movement sleep; REM: rapid eye movement sleep; AI: arousal index (normal < 11 
events per hour) (Bonnet and Arand, 2007); RDI: Respiratory disturbance index 
(normal < 5 events per hour); AHI: Apnoea-hypopnoea index (normal < 5 events per 
hour); SpO2: oxygen saturation. * p-value significant at < 0.05. 
Characteristic Baseline Subsequent p-value 
Sleep efficiency, % 78.3 ± 13.1 79.6 ± 11.7 0.827 
NREM sleep, mins 280.7 ± 50.6 280.2 ± 34.7 0.984 
REM sleep, mins 47.6 ± 27.5 65.7 ± 23.9 0.178 
AI, events per hour 15.8 ± 6.5 20.0 ± 7.0 0.086 
RDI, events per hour 6.9 ± 6.4 11.0 ± 7.4 0.085 
AHI, events per hour 2.5 ± 4.1 5.1 ± 4.7 0.090 
NREM AHI, events per hour 0.7 ± 1.2 1.2 ± 0.9 0.277 
REM AHI, events per hour 11.7 ± 20.8 21.9 ± 17.3 0.133 
Mean SpO2 during sleep, % 93.4 ± 2.3 90.3 ± 4.0 0.016* 
Nadir SpO2, % 89.0 ± 4.6 82.8 ± 8.9 0.065 
Oxygen desaturation during sleep, % 1.4 ± 1.9 4.0 ± 2.1 0.01* 
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Mean SpO2 during sleep was mildly reduced initially at 93.4 % dropping significantly 
to 90.3 % at the repeat study (p = 0.016). It was also shown that oxygen desaturation 
during sleep significantly increased between the two studies from 1.4 to 4.0 % (p = 
0.01). Although, nadir SpO2 was low and reduced further on the subsequent study, it 
was not statistically significant (p = 0.065).  
 
The longitudinal data for individual subjects (n = 8) are shown for the sleep parameters 
of: arousal index, RDI and oxygen desaturation in Figures 5.1 to 5.3. Shown in Figure 
5.1, one subject (subject no. 3) had a mild reduction in AI over time but for all other 
subjects AI increased, although it was not statistically significant.   
 
 
Figure 5.1 Arousal Index shown at Baseline and at Subsequent Study. 
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Figure 5.2 Respiratory Disturbance Index (RDI) at Baseline and Subsequent 
Study 
 
The above figure, Figure 5.2, demonstrated the change in RDI between the two-time 
periods with 2 subjects (subject no. 6 and no. 8) showing a reduction in RDI over time. 
The numbers remain small and were not statistically significant. 
	 	
	 137	
Figure 5.3 Oxygen Desaturation during Sleep at Baseline and Subsequent Study 
 
As shown above in Figure 5.3, in CF subjects with deteriorating lung function, oxygen 
desaturation worsened over time for all except 2 subjects (subject no. 3 and no. 8) which 
remained stable from baseline.  
 
Sonomat 
 
Further baseline data for Sonomat results are shown in Table 5.3. 
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Table 5.3 Demographic Data for Individual Subjects at Baseline Study 
Subject 
 
Age (yrs), 
Gender 
FEV1 
(% pred.) 
Genotype Cough,  
% sleep 
time 
Crackles, 
% sleep 
time 
Snores, 
% sleep 
time 
Sonomat 
AHI, 
events 
per hour 
1 34, F 45 F508del/UNK 0.79 24.7 15.6 0.0 
2 29, F 39 F508del/F508del 0.03 16.4 0.1 0.7 
3 20, F 46 1898+IG>A/UNK 0.12 34.2 61.1 0.1 
4 25, M 68 F508del/F508del 0.09 0 1.3 1.6 
5 32, F 52 F508del/Other 0.09 35.2 2.0 0.0 
6 21, M 27 F508del/F508del 0.27 40.4 4.0 0.7 
7 26, F 38 F508del/F508del 0.22 18.8 0.2 1.0 
8 25, F 45 F508del/F508del 2.48 0.2 24.3 0.0 
N = 8 subjects. F: female; M: male; FEV1: forced expiratory volume in 1 second; UNK: 
unknown genotype; AHI: apnoea-hypopnoea index.  
 
Sleep efficiency based on quiescent time was shown to be normal (mean of > 92 %) 
both at baseline and at the subsequent study. Of note, in this small group of CF subjects 
with severe lung disease, there was no evidence of sleep disordered breathing with a 
mean apnoea-hypopnoea index (AHI) of 2.1 events per hour at the subsequent study 
(normal AHI is defined as < 5 events per hour), shown in Table 5.4. 
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Table 5.4 Sonomat Sleep Characteristics – Baseline to Subsequent Study 
Characteristic Baseline Subsequent p-value 
Sleep efficiency, % 92.7 ± 6.2 93.2 ± 5.3 NS 
AHI, events per hour 0.5 ± 0.6 2.1 ± 1.7 0.022 
Cough, % of sleep 
time 
0.2 (0.6) 0.2 (0.4) NS 
Total sleep time with 
cough, seconds 
36.0 (136.3) 42.0 (100.5) NS 
Coughs, per hour 3.6 (8.5) 2.6 (7.8) NS 
Cough, total number 
of episodes of:  
1 cough 
2 - 5 coughs 
> 5 coughs 
 
 
0.0 (7.0) 
9.5 (51.3) 
0.5 (2.5) 
 
 
0.0 (0.0) 
15.0 (47.8) 
2.0 (9.3) 
 
 
NS 
NS 
NS 
Crackles, % of sleep 
time 
21.8 (30.7) 81.7 (24.9) 0.001 
Snores, % of sleep 
time 
3.0 (21.6) 5.3 (11.6) NS 
N = 8 subjects. Data expressed as: mean ± SD for normally distributed data or median 
(IQR) for non-normally distributed data. AHI: apnoea-hypopnoea index; NS: not 
statistically significant. Correlation significant at the 0.05 level (2-tailed). 
 
In patients with deteriorating lung function, there was a marked increase in sleep time 
spent with crackles. There was an overall minor increase in AHI between the two 
studies, however, it remained within the normal reference range (normal < 5 events per 
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hour). There was a trend to an increase which was not significant in coughs but not 
snores, Table 5.4.  
 
 
Figure 5.4 Longitudinal AHI Data for Sonomat 
Subjects: n = 8. AHI: apnoea-hypopnoea index.  
 
Figure 5.4 demonstrated the individual variability between the two-time points with 
some subjects (subject numbers 1, 3 and 5) showing little difference in AHI between 
the two Sonomat studies. Whereas, subjects 6 and 8 showed larger differences in AHI 
between the two sleep studies, but none of clinical significance (all < 5.0 events/hour).  
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Figure 5.5 Longitudinal Data for Crackles from Sonomat 
Subjects: n = 8.  
 
In the figure above, all subjects increased in the percentage of time spent with crackles 
(p = 0.001).  
 
 
5.6 DISCUSSION 
 
Polysomnography 
We found that SpO2 was reduced over time with more desaturation events, but 
interestingly this was not reflected in deterioration of some of the indicators of 
nocturnal sleep disordered breathing (arousal index, RDI and AHI). 
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Our study demonstrated the arousal index was above the reference limits proposed by 
Bonnet and Arand but did not change significantly over time which was an unexpected 
result (Bonnet and Arand, 2007). Although the arousal index was above reference 
limits, the sleep efficiency was normal (mean 79.6 %) even at the subsequent study in 
our small group. This suggests that although the subjects are roused during the night it 
does not impact on the overall sleep duration / efficiency, which may be due to their 
younger age compared with the older age population of OSA subjects from where the 
reference values are derived or may be due to the fact that the subjects were studied 
immediately post treatment of an exacerbation. Previous studies by Boselli et al. and 
Mathur and Douglas have shown significant correlation between age and AI in normal 
subjects (Boselli et al., 1998, Mathur and Douglas, 1995). 
 
An earlier study performed by de Castro et al. of 40 CF subjects and 20 control subjects 
found that PSG can reveal the occasional subject with OSA (n = 3, AHI reported at 8 
to 11 events per hour) but no major sleep alterations other than oxygen desaturation in 
clinically stable CF patients with and without significant CF lung disease (mean FEV1  
65.3 % and 99.8 % predicted, respectively) (de Castro-Silva et al., 2009). In our study 
of 8 subjects, we found 3 of the subjects fulfilled the criteria of mild to moderate OSA 
(where AHI > 5 events per hour; range 7.3 to 13.8 at the subsequent sleep study). If we 
look at RDI instead, there was an increase in sleep disordered breathing with mean RDI 
of 11.0 events per hour at the subsequent study. The inclusion of RERAs as part of the 
definition of RDI suggests these subjects have arousals due to respiratory efforts but as 
this does not reach the criteria for hypopnoea is not included as part of the AHI 
definition. It could be possible that the subtle RERAs are due to the effects of lung 
disease / poorer ventilation that affect the overall subject’s breathing during sleep. 
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Small alterations in gas exchange and ventilation that normally occur during sleep can 
be exaggerated in patients with CF lung disease resulting in significant oxygen 
desaturation which may be due to hypoventilation or ventilation/perfusion mismatching 
(Milross et al., 2004). 
 
As expected, in our study, mean daytime SpO2 (94.9 ± 2.0 % reduced to 92.9 ± 3.5%) 
and mean night-time SpO2 (93.4 ± 2.3 % reduced to 90.3 ± 4.0 %) deteriorated 
significantly over the 2-year period. Milross et al. studied 32 CF subjects with moderate 
to severe lung disease and found similarly mean awake SaO2 was 93 % and nocturnal 
SaO2 was 90 % (Milross et al., 2001b). Bradley et al. reported a mean nadir SpO2 of 82 
± 8 % in 14 younger subjects with CF which is similar to our findings in the repeat PSG 
study of a nadir SpO2 of 82.8 ± 8.9 % (Bradley et al., 1999). These changes in oximetry 
measurements may be due to deteriorating lung function leading to an overall lower 
baseline SaO2 with these awake saturations being near or on the start of the steep portion 
of the oxyhaemoglobin-dissociation curve, as previously described by Francis in 1980 
(Francis et al., 1980). Hence, a small fall in SaO2 would result in greater falls in PaO2 
over the time period. This may also impact on the measurement of AHI, as AHI is 
scored based on reductions in SaO2. The issue of posture may also contribute to these 
changes. In subjects with CF, the supine position is associated with increased perfusion 
of the apical, likely more scarred, and poorly ventilated zones, thereby worsening 
ventilation and perfusion matching  (Wood et al., 1976). 
 
Interestingly, in our study we found that sleep architecture and sleep efficiency did not 
change over time as expected. In the study by Milross et al., they too found that sleep 
efficiency (mean 87 ± 6 %) and sleep architecture were not abnormal in their CF 
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subjects with moderate to severe lung disease (Milross et al., 2001b). Likewise, 
Jankelowitz et al. (2005) demonstrated that using actigraphy sleep duration and sleep 
efficiency (mean 85.2 ± 6.15 %) were within normal limits in CF patients with moderate 
CF lung disease but showed increased fragmentation (Jankelowitz et al., 2005).  
 
These results may be due to the small subject numbers which may reduce the size of 
effect but it also raises the question that different parameters may be more useful to 
assess respiratory status during sleep in these subjects. Using the Sonomat to analyse 
adventitial sounds during the night may provide further information which can assist 
clinicians in making decisions regarding treatment of abnormal sleep parameters.  
 
To our knowledge, this is the first study to investigate the longitudinal effects on sleep 
using PSG in CF patients with deteriorating lung function of up to a 3-year period of 
review.  However, these results should be interpreted with caution due to the small 
subject number making it difficult to draw firm conclusions. The analyses of paired 
data were utilised in an attempt to minimise this limitation. However, larger sample 
sizes are warranted to further evaluate the abnormalities of sleep over a longitudinal 
period to detect a significant effect.  
 
Sonomat 
This was the first study to use a non-invasive sleep monitoring device, the Sonomat, in 
CF subjects to assess abnormalities during sleep longitudinally. The Sonomat is useful 
in detecting adventitial sounds which provide additional data to analyse the sleep 
abnormalities in adults with CF. It was hypothesised that nocturnal cough and crackles 
would worsen over time in these CF subjects with deteriorating lung function. 
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Interestingly, coughs did not increase but the presence of crackles increased 
substantially in this study. This may be due to suppression of cough during sleep as 
reported previously by a number of authors including Krajnik et al., Power et al., and 
Smith et al., 2008 (Krajnik et al., 2010, Power et al., 1984, Smith and Woodcock, 2008). 
Hence, a potential limitation in our study may be insufficient awake data to analyse the 
cough duration prior to sleep time.  
 
One of the seminal papers investigating the suppression of cough during sleep presented 
findings indicating that cough and smooth airway muscle constriction in response to 
bronchopulmonary irritants do not occur in sleeping tracheotomised dogs in the absence 
of arousal, and that arousal responses to such stimuli are depressed in REM sleep 
(Sullivan et al., 1979). In patients with chronic cough, Krajnik et al. found that at night 
the median time spent coughing was 3 seconds per hour compared with daytime cough 
of 20 seconds per hour in a small study of 13 patients (Krajnik et al., 2010). Power et 
al. reported that of 10 patients with nocturnal cough, only one patient coughed during 
REM sleep and none coughed during Stage 3 or 4 sleep (Power et al., 1984). They also 
found no correlation between cough and sleep disordered breathing (Power et al., 
1984), but were not able to measure other adventitial sounds such as crackles or 
wheezes.   
 
Our results may also be influenced by the fact that both studies were performed when 
the subjects were stable, that is, they did not have a pulmonary exacerbation at the time 
of the study. Although the adults with CF had exhibited a deterioration in FEV1 over 
the 2-year follow-up, there may have been less difference between the recordings when 
relatively well, with differences only exhibited when the adults were unwell. Hence, 
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nocturnal cough might not be evident unless increased mucus clearance is needed to 
expel increased sputum volume from the airways. In a study of 133 patients with a 
respiratory illness and use of nocturnal long-term recording of respiratory sounds, 
Gross et al. found that following therapeutic treatment of bronchial obstruction, there 
was a clear reduction in cough and wheezing events (Gross et al., 2007).  
 
Smith et al. used ambulatory sound recordings on patients with CF at the beginning and 
end of a hospital admission for the management of a pulmonary exacerbation. Median 
cough rate during the day on admission was 21.2 cough seconds per hour and by 
discharge, it was 9.0 cough seconds per hour. During the night, the cough rate was 
much lower with median cough rate at night on admission of 4.8 cough seconds per 
hour and on discharge, median cough rate of 1.5 cough seconds per hour (Smith et al., 
2006). There was a significant decrease in cough rate with the treatment of a pulmonary 
exacerbation both during the day (median fall of 51.3% (IQR 32.2 – 77.5)) and night 
(median fall of 72.2% (IQR 28.6 – 90.1))  (Smith et al., 2006). It was postulated that 
the coughing that occurs overnight with exacerbations may be a better reflection of 
airway inflammation than daytime coughing as overnight the subjects are less likely to 
be exposed to environmental irritants or changes in temperature than during the day 
(Smith et al., 2006). Similar to the Smith et al. study, in our study, there was minimal 
coughs per hour of sleep with a median of 3.6 per hour at initial study and 2.6 coughs 
per hour at subsequent study (Smith et al., 2006). Noting again, our study was 
performed during a period of non-exacerbation where cough may be minimal.  
In our small group of CF subjects re-studied after the development of more severe lung 
disease, there was no evidence of sleep disordered breathing with mean apnoea-
hypopnoea index (AHI) of 2.1 events per hour (normal AHI < 5 events per hour). 
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However, the AHI did significantly increase over the time period from the initial study 
to the subsequent study. This may be in part due to the technical limitation of the 
Sonomat with simultaneous scoring of crackles, hypopnoea/apnoeas and other sounds 
in the same time period (epoch) making it difficult to score each respiratory event 
individually. The presence of cough or crackles in both the audio and movement sensors 
can occasionally override the body movement sensor tracings alone which is used to 
classify the apnoeas or hypopnoeas.  
 
Adding further information onto the standard PSG may be useful in CF patients. If it is 
noted over time that nocturnal crackles (indicative of mucus retention) are increasing 
on home-based monitoring, treatment might be directed to increase mucus clearance 
with increased physiotherapy regimens to prevent a pulmonary exacerbation. 
Furthermore, using the Sonomat or another non-invasive device, such as a recording 
electronic stethoscope, during the daytime may also be useful to detect and quantify 
crackles indicating reduced mucus clearance. These methods may in fact be more cost 
effective than overnight monitoring using a PSG. However, the duration and timing of 
daytime recordings has not been previously validated and this would need to be 
performed prior to establishing a threshold for the presence of crackles or other 
adventitial sounds.  
 
Limitations to this study included the small sample size which restricts the 
generalisability of these measurements. With larger sample sizes, the effect of the 
presence of cough, crackles and snores during sleep may change. Interestingly, wheeze 
was seldom recorded overnight in these subjects. As discussed above, the simultaneous 
presence of multiple sounds and respiratory events have made it difficult to score each 
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individual event using the Sonomat. Hence, the Sonomat may sometimes underestimate 
the presence of sleep disordered breathing including apnoeas or hypopnoeas due to the 
presence of cough or crackles overriding the audio sound above the changes in body 
movement data tracings. However, future studies developing automated algorithms 
using the Sonomat may assist in overcoming these issues and are currently underway.  
 
 
5.7 CONCLUSION 
 
Our longitudinal study of CF subjects with severe CF lung disease demonstrated that 
sleep efficiency and sleep architecture were within reference values and did not change 
significantly over time. However, there was a trend to an increase in RDI and AI over 
this period with a higher prevalence than was expected in sleep disordered breathing. 
As expected with deterioration in lung function, overall oxygenation during sleep was 
reduced at both the baseline and further reduced at the subsequent study. However, only 
the oxygen desaturation showed a statistically significant increase between the two 
study periods. The above results warrant further validation with larger paired studies to 
analyse sleep abnormalities that occur in CF subjects with a range of lung function 
severity. 
 
In this subset of patients with severe CF lung disease, sleep efficiency did not between 
two periods of review. The time spent with crackles during the night increased 
significantly over the course of 1-3 years (from median of 21.8 to 81.7 % of total sleep 
time). Interestingly, the time spent coughing or snoring did not change significantly 
over the course of this time period. Larger longitudinal studies with increased subject 
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sample size and more frequent testing would aid in determining if the presence of or an 
increase in crackles suggests worsening respiratory function or an exacerbation of 
disease and the need to act earlier to treat subclinical pulmonary exacerbations to 
minimise deterioration.  
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CHAPTER 6: SLEEP QUALITY AND QUALITY OF LIFE IN 
ADULTS WITH CYSTIC FIBROSIS  
 
6.1 INTRODUCTION 
 
As outlined in Chapter 1, Quality of life (QoL) reflects an individual’s subjective 
evaluation of his or her daily functioning and well-being. QoL measures incorporate 
several core domains, such as physical functioning and symptoms, psychological and 
emotional state, and perception of ability to perform activities of daily living. The QoL 
questionnaires can provide a formal, reproducible and structured method of establishing 
the patient’s perspective as to the effectiveness of their current or previous therapies.  
 
In the CF group, it is known that objective clinical measures, such as forced expiratory 
volume in 1 second (FEV1) and six-minute walk test (6MWT), are useful in assessing 
objective effectiveness of therapy, but do not relate closely to measures of QoL 
including sleep QoL (Fauroux et al., 2012). Hence, health related quality of life is an 
important outcome measure in CF (Abbott et al., 2011). Previous studies have looked 
at both generic QoL measures as well as disease-specific QoL measures (CF QoL and 
CFQ-R) and have reported that the disease-specific measures can be used in different 
applications including detecting transient changes in health status as well as looking at 
longitudinal changes that occur in adults with CF due to progression of disease (Gee et 
al., 2000, Modi and Quittner, 2003, Quittner et al., 2012).  
 
In particular, reduced disease specific health QoL (CFQ-R) has also previously been 
shown to be related to impaired sleep quality even in clinically stable CF patients 
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(Bouka et al., 2012).  Sleep disturbances in individuals with CF may be due to 
fragmented sleep and arousals, or other respiratory events such as cough, and can 
impact the subjects’ perception of sleep quality and in turn poor sleep quality may 
impact the overall QoL (Katz, 2014, Milross et al., 2002). 
 
Sleep disturbance can be measured subjectively by sleep specific QoL questionnaires 
but it can also be objectively measured using polysomnography or non-invasive 
methods, such as the Sonomat. The results of these objective measurements can be 
found in this thesis in Chapters 4 and 5. This present chapter investigates the sleep 
quality and overall QoL of adults with CF using both subjective measures (PSQI and 
ESS) as well as objective measures of sleep (using parameters of the PSG and 
Sonomat). The way in which the sleep quality impacts on overall QoL and impact of 
the CF lung disease state will be examined.  
 
 
6.2 AIMS 
 
1. To investigate sleep quality together with quality of life in adults with CF using 
subjective measures (PSQI, CF QoL and CFQ-R). 
2. To assess the impact of lung function and subjective and objective (PSG / 
Sonomat) measures of sleep on overall QoL. 
3. To assess the impact of worsening CF lung function on both subjective (PSQI, 
CF QoL and CFQ-R) and objective (PSG / Sonomat) measures of sleep quality 
and overall quality of life. 
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6.3 HYPOTHESES 
 
1. Quality of life is related to subjective sleep quality in CF subjects.  
2. Lung function and sleep parameters are correlated with quality of life in adults 
with CF. 
3. Overall quality of life and sleep quality deteriorate as lung function deteriorates 
in CF subjects.  
 
6.4 METHODS 
 
6.4.1 Quality of Life and Sleep Quality in Adults with CF Attending a Single CF 
Centre. 
 
Subjects 
 
In a prospective, cross-sectional study, adults with CF attending the CF Clinic at 
Westmead Hospital were recruited. All patients were approached and offered the 
opportunity to complete questionnaires. Subjects were not recruited if: they did not 
attend an outpatient clinic appointment between 1st January 2013 and 30th November 
2016; or chose not to complete the questionnaires. All subjects had a diagnosis of CF 
confirmed on standard clinical criteria. The protocols were all approved by the 
Westmead Hospital Human Research Ethics Committee (HREC2012/12/4.9(3627) AU 
RED HREC/12/WMEAD/427. Written informed consent was obtained for all subjects.  
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Baseline Characteristics 
 
Standard anthropometric data were recorded including: weight, height, body mass 
index (BMI); Spirometry (forced expiratory volume in 1 second, (FEV1) and forced 
vital capacity (FVC)); as well as CFTR genotype. All responses to the questionnaires 
were de-identified but linked to clinical data.  
 
Questionnaires 
 
The subjects completed three questionnaires related to sleep and overall quality of life: 
i) Cystic Fibrosis Questionnaire – revised (CFQ-R) (Quittner et al., 2005); ii) CF 
Quality of Life (CF QoL) questionnaire (Gee et al., 2000); iii) Pittsburgh Sleep Quality 
Index (PSQI) (Buysse et al., 1989). Details of these questionnaires can be found in 
Chapter 2 - Methods. The respondents also had an opportunity to speak to their 
specialist CF physician if questions arose following completion of the questionnaires.  
 
The CFQ-R questionnaire is a disease-specific questionnaire that measures health 
related quality of life for people with CF older than 14 years over the preceding 2 weeks 
(Quittner et al., 2005). This questionnaire consists of 44 items on 12 generic and 
disease-specific scales. It encompasses general domains of quality of life: physical 
functioning, role functioning, vitality, health perceptions, emotional functioning and 
social functioning; as well as domains specific to CF: body image, eating disturbances, 
treatment burden, and respiratory and digestive symptoms (Quittner et al., 2005). Each 
item included ratings of frequency or difficulty on a 4-point scale (where 1 = always, 2 
= often, 3 = sometimes, 4 = never; or 1 = very true, 2 = somewhat true, 3 = somewhat 
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false, 4 = very false; see Table 2.2). Scores are then standardised on a 0 to 100-point 
scale, with higher scores representing better quality of life for each particular domain. 
 
The CF Quality of Life questionnaire (CF QoL) measures the self-described quality of 
life over the previous 2 weeks in several domains (Gee et al., 2000). This questionnaire 
contains 52 items in total which covers the 8 domains of: physical functioning; social 
functioning; treatment issues and chest symptoms; emotional functioning; concerns for 
the future; interpersonal relationships; body image; and career concerns. All items are 
scored from 1 to 6 and then scaled to produce a transformed score of between 0 and 
100 for each section. A transformed score indicates the value that has been achieved 
out of a maximum of 100 with 100 indicating the most positive QoL levels possible.  
The total QoL score is scored out of 312 (52 questions, each with a score up to 6).  
 
The PSQI consists of 19 questions with seven domains of sleep covered including: 
duration of sleep; sleep disturbance; sleep latency; daytime dysfunction due to 
sleepiness; sleep efficiency; overall subjective sleep quality; requirement of 
medications to sleep. The range of values for each scored domain is 0 to 3 points. In all 
cases, a score of “0” indicates no difficulty, while a score of “3” indicates severe 
difficulty. The seven domain scores are then added to yield one “global” score, with a 
range of 0 to 21 points, “0” indicating no difficulty and “21” indicating severe 
difficulties in all areas. A global PSQI score of greater than 5 indicates that a subject is 
a “poor sleeper” (Buysse et al., 1989). 
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6.4.2 Subjective and Objective Sleep Quality and QoL Data for the Adults with 
CF undergoing PSG and Sonomat Studies. 
 
Subjects 
 
Subjects (n = 40) who underwent an overnight diagnostic sleep study (in Chapter 4) 
also completed the sleep specific questionnaires: Epworth Sleepiness Scale (ESS) 
(Johns, 1991) and PQSI; as well as the disease-specific questionnaires:  CFQ-R and CF 
QoL, on the night of the study and the results of these studies are presented below. 
These subjects also performed spirometry as part of the baseline demographic data 
collection. 
 
Epworth Sleepiness Scale 
 
As described in Chapter 2 – Methods, the Epworth Sleepiness Scale is a measurement 
of daytime sleepiness (Johns, 1991). It is a self-administered questionnaire and the 
subjects were asked to rate on a scale of 0 to 3 the likelihood of dozing off in eight 
different situations (Johns, 1991). The raw numbers were then added to give a score 
between 0 and 24. A raw score of 10 or greater in the general population suggests 
increased daytime somnolence (Johns, 1991).  
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Polysomnography 
 
In addition to the above questionnaire data collected for all participants, data from the 
polysomnogram (reported in Chapter 4) were recorded to assess objective measures of 
sleep disturbance and compare these results with results of QoL questionnaires. 
 
Data from the polysomnogram performed in 40 subjects reported in Chapter 4 – Table 
4.2 included: Sleep efficiency (SE); Arousal index (AI); Respiratory disturbance index 
(RDI); Apnoea-hypopnoea index (AHI); total sleep time; REM sleep %; NREM sleep 
%; Wakefulness after sleep onset (WASO). Oximetry data included: Baseline SpO2; 
mean SpO2 during sleep; oxygen desaturation index (ODI); nadir SpO2. In addition, 
respiratory, leg and spontaneous arousals were also documented in Table 4.3 – Sleep 
Arousal Results.  
 
Furthermore, to look at comparisons with previous studies (Young et al., 2011), 
desaturators with a 10 % threshold were defined as subjects spending ≥ 10 % of 
recording time with SpO2 < 90 %. Desaturators with a 30 % threshold were defined as 
subjects spending ≥ 30 % of recording time with SpO2 < 90 %. 
 
Sonomat 
 
The Sonomat was used to calculate the % of total sleep time in which coughs and 
crackles present were present during the night. Description of the classification of 
adventitial sounds was described in Chapter 4 – Cross Sectional Objective Sleep 
Measurements in Adults with CF.  
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Lung Function  
 
Spirometry was performed in accordance with American Thoracic Society/European 
Respiratory Society criteria (Miller et al., 2005). Forced expiratory volume in 1 second 
(FEV1) and forced vital capacity (FVC) were recorded. Predicted spirometric 
parameters were derived using reference values from Hankinson et al, 1999 (Hankinson 
et al., 1999). 
 
6.4.3 Sleep Quality and QoL in a Subset of Adults with CF with Deteriorating 
Lung Function. 
 
Subjects 
 
Eight patients were enrolled who had clinical deterioration over a 1 to 3 year period 
with: reductions in lung function (between 2 and 24 % drop in FEV1 % predicted); 
frequent exacerbations (> 4 in the preceding 12 months); or worsening daytime 
hypoxaemia.  
 
Measurements 
 
Overnight polysomnography along with the Sonomat, questionnaires (CFQ-R, CFQoL, 
PSQI and ESS) and lung function were repeated 1 to 3 years following their first study, 
again at the end of an admission for an exacerbation. These above measures have been 
described in detail in Chapter 2 – Methods.  
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6.4.4 Statistical Analyses 
 
Statistical and graphical analyses were performed using SPPS version 22 (SPSS Inc., 
IL, USA) and GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA, USA). 
Normally distributed data were presented as mean ± standard deviation (SD), and non-
normally distributed data were presented as median and interquartile range (IQR). 
Correlation was performed using Spearman’s correlation analyses. Results were 
deemed statistically significant if p < 0.05. For correlation data, regression lines were 
shown on the graphs with r2, r and p-values reported.  
 
 
6.5 RESULTS 
 
6.5.1 Quality of Life and Sleep Quality in Adults with CF Attending a Single CF 
Centre. 
 
One hundred and twenty participants completed the 3 questionnaires at the time of their 
routine CF clinic visit. This represented an overall response rate of 74 % (120 / 162) of 
the total patient clinic population at that time. Detailed baseline characteristics of the 
group are shown in Table 6.1 below. The mean FEV1 was 64 % predicted which 
demonstrated an overall moderate disease category with a large range from 17 % (very 
severe) to 117 % (normal) FEV1 % predicted. The mean BMI was in the normal weight 
category at 22.1 kg/m2. As expected, approximately half of the participants were 
homozygous for F508 del (47 %).  
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Table 6.1 Baseline Characteristics for QoL Data 
Characteristic  Results 
Male (n, %) 58, 48 
Age, years (mean ± SD) 29.0 ± 9.6 
F508del homozygous (n, %) 56, 47 
BMI, kg/m2 (mean ± SD) 22.4 ± 3.3 
FEV1, % predicted (mean ± SD) 65.6 ± 23.3 (range 17-117 %) 
N = 120 subjects. Data presented as mean ± SD. BMI: body mass index. FEV1: forced 
expiratory volume in 1 second.  
 
Results for each of the domains of the 3 questionnaires are detailed in the following 
Tables (Tables 6.2 to 6.5). The transformed scores for CFQ-R, CF QoL and PSQI 
demonstrated the variation in different domains of QoL for these CF subjects.  
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CFQ-R Results 
 
Table 6.2 CFQ-R Results  
CFQ-R Domain  
Physical functioning 75.0 (45.8) 
Vitality 54.0 ± 20.7 
Emotion 80.0 (33.3) 
Eating 100.0 (22.2) 
Treatment Burden 50.8 ± 22.5 
Health Perceptions 58.9 ± 24.5 
Social 66.2 ± 19.2 
Body Image 77.8 (55.6) 
Role 83.3 (25.0) 
Weight 66.7 (66.7) 
Respiratory 66.7, 33.3 
Digestive System 88.9 (22.2) 
N = 120 subjects. CFQ-R: CF Questionnaire - Revised. Transformed scores: 0 = worst, 
100 = best QoL possible. Normally distributed data expressed as mean ± SD. Non-
normally distributed data expressed as median (IQR).  
 
Of the scores which demonstrated the highest level of quality of life, the “eating” 
domain scored the highest with a median score of 100 (IQR of 22.2). There was a 
discrepancy, however, with “weight” and “body image” domains which scored lower 
with medians at 66.7 and 77.8, respectively, compared with those scored for “eating”. 
In keeping with their disease severity as a group, the participants reported “respiratory 
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symptoms” as lower with a median of 66.7 (IQR 33). Our group also perceived their 
health as between “fair” and “good” with a median of 66.7 (IQR 33). Despite their 
reporting of reduced health, the CF participants reported higher quality of life in terms 
of the “role” domain which focuses on their ability to keep up with daily activities.  
 
As detailed in Table 6.2, body image had a median transformed score of 77.8 out of a 
possible score of 100 indicating that in our patients, body image was perceived as 
positive rather than negative. In addition, looking at gender and body image, we found 
that the median transformed score for males was 66.7 (IQR 44.4) and for females it was 
77.8 (IQR 44.4) suggesting that females have better body image perception than males, 
and this was found to be statistically significant (p = 0.039). 
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CF QoL Results 
 
Table 6.3 CF QoL Questionnaire Results 
QoL Domain Results  
Physical functioning 91.0 (26.0) 
Social functioning 90.0 (23.8) 
Treatment issues 66.7 (40.0) 
Chest symptoms 80.0 (30.0) 
Emotional functioning 87.5 (25.0) 
Future concerns 45.6 ± 24.3 
Relationships 62.0 (41.5) 
Body image 73.3 (40.0) 
Career concerns 70.0 (45.0) 
Total CF QoL 236.5 (66.8) 
N = 120 subjects. Units: arbitrary units. Data expressed as mean ± SD for normally 
distributed data and median (inter-quartile range) for non-normally distributed data. 
Transformed scores: 0 = worst, 100 = most positive QoL levels possible. Total CF QoL 
scored out of possible 312 points.  
 
Looking at each domain separately, the areas where patients indicated poorest quality 
of life included: treatment issues, future concerns, relationships and career concerns.  
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PSQI Results 
 
The results of the sleep specific questionnaire, the PSQI, are shown below in Table 6.4.  
For each domain, there was a total score out of 3, with the combined score out of a total 
of 21. A global PSQI score of greater than 5 indicated poorer subjective sleep quality 
(Figure 6.1), with 52 subjects (43 %) scoring above 5. 
 
 
Figure 6.1 Global PSQI score 
PSQI: Pittsburgh Sleep Quality Index. Units are arbitrary units. Global score out of 21. 
A global score greater than 5 indicated poorer sleep quality.  
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Table 6.4 PSQI results 
PSQI Domain Results 
Sleep Duration 0.4 ± 0.8 
Sleep Disturbance 1.4 ± 0.6 
Sleep Latency 1.2 ± 1.1 
Daytime Dysfunction 1.0 ± 0.9 
Sleep Efficiency 0.7 ± 1.0 
Sleep Quality 1.1 ± 0.8 
Sleep Medications 0.1 ± 0.5 
Global PSQI score 5.9 ± 3.6 
N = 120 subjects. Data expressed as mean ± SD. Units are arbitrary units. PSQI: 
Pittsburgh Sleep Quality Index. Each domain is scored out of 3, (0 = best, 3 = worst), 
with total global score out of 21.  
 
The above results for PSQI indicated that in our adult CF population, there was 
increased reporting of poor subjective sleep quality with a mean PSQI score of 5.9 (SD 
± 3.6). Range of total scores from 1 to 17 (total out of 21). Out of a total of 3 for each 
separate question, the domain of sleep disturbance represented the highest score with a 
mean at 1.4 units.  
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Lung Function 
 
CFQ-R and Lung Function 
Using Spearman’s test of correlation, significant correlation was found between FEV1 
for the domains of: physical functioning, eating, treatment burden, health perceptions, 
social role, body image, role, weight and respiratory issues (Table 6.5).  
 
Table 6.5 CFQ-R Domains and Correlation with FEV1  
CFQ-R domain Correlation with FEV1 
p-value r r2 
Physical functioning 0.001 0.551 0.305 
Vitality 0.022  0.210 0.039 
Emotion 0.176 NS 0.124 0.010 
Eating 0.005 0.255 0.068 
Treatment Burden 0.001 0.295 0.089 
Health Perceptions 0.001 0.475 0.247 
Social 0.004 0.260 0.065 
Body Image 0.001 0.310 0.117 
Role 0.001 0.350 0.133 
Weight Issues 0.002 0.282 0.100 
Respiratory Issues 0.001 0.299 0.070 
Digestion Issues 0.788 NS 0.025 0.042 
N = 120 subjects. CFQ-R: CF questionnaire – revised; FEV1: forced expiratory volume 
in 1 second; NS: not significant. Using Spearman’s rho, where correlation is significant 
at the 0.05 level (2-tailed). 
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Two domains were not correlated with FEV1: emotion and digestion with p-value not 
significant, as shown in Table 6.5. Below are graphs representing select CFQ-R 
domains – physical and heath perception domains, presenting the correlations with lung 
function (FEV1 % predicted), Figures 6.2 and 6.3.  
 
 
Figure 6.2 Lung Function and Physical Domain 
 
FEV1: Forced expiratory volume in 1 second. 
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Figure 6.3 Lung Function and Health Perceptions Domain 
FEV1: Forced expiratory volume in 1 second. 
 
 
CF QoL and Lung Function 
 
Using Spearman’s calculation for correlation, total CF QoL score was statistically 
significantly correlated (p = 0.001) with FEV1 (r = 0.345; r2 = 0.130), see Figure 6.4, 
although there was a wide variation in QoL for different adults with similar FEV1. 
There was no correlation between total CF QoL score and either BMI or gender (p = 
0.704 and 0.483, respectively).   
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Figure 6.4 Lung Function and Total CF QoL Score.  
CF QoL: Cystic Fibrosis Quality of Life Questionnaire. FEV1: Forced expiratory 
volume in 1 second. Line on graph is regression line.  
 
All domains of the CF QoL except emotional functioning and concerns for the future 
correlated significantly with FEV1 (Table 6.6), using Spearman’s correlation test.   
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Table 6.6 CF QoL Domains and Correlation with FEV1 
CF QoL Domain Correlation with Lung Function 
p-value r r2 
Physical functioning 0.001 0.490 0.231 
Social functioning 0.005 0.257 0.084 
Treatment issues 0.001 0.310 0.095 
Chest symptoms 0.001 0.315 0.101 
Emotional functioning 0.057 NS 0.174 0.010 
Future concerns 0.157 NS 0.130 0.013 
Relationships 0.001 0.293 0.086 
Body image 0.002 0.276 0.085 
Career concerns 0.002 0.284 0.074 
Total CF QoL  0.001 0.345 0.130 
N = 120 subjects. FEV1: forced expiratory volume in 1 second; QoL: Quality of Life; 
NS: not significant. Correlation was significant at the 0.05 level (2-tailed) using 
Spearman’s correlation test. 
 
 
PSQI and Lung Function 
 
Importantly, total global PSQI was only weakly correlated with FEV1 (r = -0.292; p = 
0.001; r2 = 0.085), shown in Figure 6.5 below. Of the adults with a FEV1 % predicted 
< 35 % (n = 9) only 1 reported a normal PSQI score of < 5 arbitrary units.  
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Figure 6.5 Lung Function and Global PSQI score 
PSQI: Pittsburgh Sleep Quality Index; FEV1: Forced expiratory volume in 1 second. 
 
We also looked at the correlation between overall QoL using the CF QoL questionnaire 
and the sleep specific questionnaire, the PSQI, and found they were strongly negatively 
correlated (r = -0.508; p = 0.001; r2 = 0.286) (Figure 6.6). Those subjects with higher 
overall CF QoL scores also scored lower on the PSQI.  
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Figure 6.6 PSQI and CF QoL scores 
PSQI: Pittsburgh Sleep Quality Index; QoL: Quality of Life. 
 
 
6.5.2 Subjective and Objective Sleep Quality and QoL Data for the Adults with 
CF undergoing PSG and Sonomat Studies. 
 
The baseline characteristics of subjects who participated in this study has been shown 
in Table 4.1 in Chapter 4. Of the 40 subjects, 16 were male and the mean age of all 
participants was 33.8 years (SD ± 10.8). In this smaller study, the average FEV1 % 
predicted was in the severe range at 47.9 %.   
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Subjective Measures 
 
Table 6.7 Subjective Sleep Quality 
Subjective Measures Results 
Total CF QoL, arbitrary units 206.9 ± 50.6 
PSQI, arbitrary units 7.3 ± 3.3 
ESS, arbitrary units 5.4 ± 3.0 
N = 40 subjects. Data expressed as mean ± SD. CF QoL: Cystic Fibrosis Quality of 
Life Questionnaire; PSQI: Pittsburgh Sleep Quality Index; ESS: Epworth Sleepiness 
Scale.  
 
Table 6.8 Subjective Sleep Quality and Lung Function 
Subjective Sleep Quality Variables Correlation with lung function (FEV1) 
p-value r r2 
Total CF QoL 0.073 0.286 0.100 
PSQI 0.394 -0.139 0.028 
ESS 0.817 -0.038 0.001 
N = 40 subjects. FEV1: forced expiratory volume in 1 second; CF QoL: Cystic Fibrosis 
Quality of Life Questionnaire; PSQI: Pittsburgh Sleep Quality Index; ESS: Epworth 
Sleepiness Scale. 
 
As shown in Table 6.8, there were no statistically significant correlations between 
subjective sleep quality and lung function.  
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Table 6.9 Subjective QoL Results in Desaturators vs Non-desaturators 
 
N = 40 subjects. Data expressed as mean ± SD. NS: not significant; BMI: body mass 
index; FEV1: forced expiratory volume in 1 second; SpO2: oxygen saturation; CF QoL: 
Cystic Fibrosis Quality of Life Questionnaire; PSQI: Pittsburgh Sleep Quality Index; 
ESS: Epworth Sleepiness Scale; Desaturators: Desaturators are classified as those 
subjects who spent ≥ 10 % of recording time with SpO2 < 90 % (n = 12 subjects); Non-
desaturators (n = 28 subjects).  
 
When dividing the group into desaturators (oxygen saturation of < 90 % for more than 
10 % of total recording time) and non-desaturators, as expected, the FEV1 was 
significantly different with a mean of 33.8 % predicted for the desaturators, and 53.9 
FEV1 % predicted for the non-desaturators (p = 0.001). In addition, awake SpO2 
differed for the two groups, where desaturators had an awake SpO2 of 93.2 % compared 
with 95.9 % for the non-desaturators group (p = 0.001). When looking at each of the 
Characteristic Non-desaturators 
(n = 28) 
Desaturators 
(n = 12) 
p-value 
Age, years 32.3 ± 9.5 36.5 ± 13.2 NS 
Gender F 20, M 8 F 4, M 8 NS 
BMI, kg/m2 21.6 ± 3.3 21.4 ± 3.1 NS 
FEV1, % predicted 53.9 ± 16.6 33.8 ± 11.7 0.001 
Baseline SpO2, % 95.9 ± 1.5 93.2 ± 2.8 0.001 
Total CF QoL  
(total out of 312) 
212.4 ± 44.7 194.0 ± 62.8 NS 
PSQI  
(0 = best, 21 = worst) 
7.1 ± 3.0 7.6 ± 4.3 NS 
ESS  
(0 = best, 24 = worst) 
4.9 ± 2.3 6.5 ± 4.3 NS 
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domains of the CFQ-R, quality of life appeared unrelated to more severe nocturnal 
hypoxaemia (all p-values were not significant).   
 
Objective Measures 
 
Polysomnography 
Polysomnography data have been previously described in detail in Table 4.2, Chapter 
4. In addition, types of arousals and details of desaturators and non-desaturators can be 
found below in Table 6.10. 
 
 
Table 6.10 Polysomnogram Results  
PSG Sleep Characteristic Results 
Respiratory arousals, events per hour 4.5 (8.5) 
Leg arousals, events per hour 0.0 (0.2) 
Spontaneous arousals, events per hour 8.2 (9.1) 
Desaturators 10% threshold, n (%) 12 (30 %) 
Desaturators 30% threshold, n (%) 7 (17.5 %) 
N = 40 subjects. Data expressed as median (IQR). PSG: polysomnogram; Desaturators 
10 % threshold = Subjects spending ≥ 10 % of recording time with SpO2 < 90 %; 
Desaturators 30 % threshold = Subjects spending ≥ 30 % of recording time with SpO2 
< 90 %. 
 
Lung function and objective sleep quality based on the PSG did not appear to be related, 
except for those oximetry parameters including awake SpO2, nadir SpO2 and time spent 
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with SpO2 < 90 % shown previously in Table 4.6 in Chapter 4. Using linear regression 
to assess influence of lung function (FEV1 % predicted) on sleep parameters, only 
awake SpO2 and nadir SpO2 were positively correlated weakly with FEV1 % predicted 
(p = 0.001 and p = 0.003; r2 = 0.253 and 0.186; respectively). 
 
Sonomat 
 
The Sonomat showed no significant correlations between Sonomat parameters (cough 
and crackles during sleep) and any of the sleep quality and QoL questionnaires, as 
shown in Tables 6.11 – 6.13 below. 
 
Table 6.11 Sonomat Variables and ESS 
Sonomat Sleep Quality Variables Correlation with ESS 
p-value r r2 
Crackles, % of total sleep time 0.604 -0.084 0.004 
Cough, % of total sleep time 0.204 0.205 0.001 
N = 40 subjects. ESS: Epworth Sleepiness Scale 
 
 
Table 6.12 Sonomat Variables and PSQI 
Sonomat Sleep Quality Variables Correlation with PSQI 
p-value r r2 
Crackles, % of total sleep time 0.449 0.125 0.0009 
Cough, % of total sleep time 0.936 0.013 0.002 
N = 40 subjects. PSQI: Pittsburgh Sleep Quality Index. 
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Table 6.13 Sonomat Variables and Total CF QoL Score 
Sonomat Sleep Quality Variables Correlation with Total CF QoL score 
p-value r r2 
Crackles, % of total sleep time 0.698 -0.063 0.0002 
Cough, % of total sleep time 0.056 -0.305 0.150 
N = 40 subjects. CF QoL: Cystic Fibrosis Quality of Life questionnaire. 
 
 
6.5.3 Sleep Quality and QoL in a Subset of Adults with CF with Deteriorating 
Lung Function. 
 
In this study, 8 subjects who had clinical deterioration over 1 - 3 years underwent 
objective and subjective measures of sleep quality and QoL. The demographic data of 
these subjects has been described previously in Table 5.1 – Patient Characteristics in 
Longitudinal Study in Chapter 5.  
 
 
 
Table 6.14 Baseline and Subsequent QoL, Sleep Quality and Objective Sleep 
Quality Measures in Longitudinal Study. 
 
Characteristic Baseline Subsequent p-value 
Total CF QoL 221.3 ± 51.5 198.0 ± 58.2 0.106 
PSQI 6.8 ± 2.3 7.9 ± 3.1 0.425 
ESS 3.9 ± 2.2 5.0 ± 1.8 0.122 
N = 8 subjects. Data expressed as mean ± SD. CF QoL: Cystic Fibrosis Quality of Life 
questionnaire; PSQI; Pittsburgh Sleep Quality Index; ESS: Epworth Sleepiness Scale; 
* p-value significant at < 0.05. 
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 As shown in the above table, the Total CF QoL score tended to decrease over time and 
the results of the ESS and PSQI tended to increase, but, none of the measures exhibited 
a statistically significant change over time. There was a negative correlation between 
total CF QoL score and PSQI with lung function at baseline but they were not 
statistically significant, Table 6.15.  
 
Table 6.15 Correlation of Lung Function with QoL and Subjective Sleep Quality 
Parameters at Baseline 
Measure Correlation with Lung Function  
(FEV1 % predicted) 
p-value r r2 
Total CF QoL 0.866 -0.072 0.011 
PSQI 0.753 -0.133 0.231 
ESS 0.699 0.164 0.012 
N = 8 subjects. FEV1: forced expiratory volume in 1 second; CF QoL: CF quality of 
life questionnaire; PSQI: Pittsburgh Sleep Quality Index; ESS: Epworth Sleepiness 
Scale. * Correlation significant at 0.05 level (2-tailed). 
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Figure 6.7 Total CF QoL at Baseline and at Subsequent Study. 
CF QoL: Cystic Fibrosis Quality of Life questionnaire. 
 
Half of the subjects reported reduction in CF QoL between baseline and subsequent 
studies. There were 2 subjects (subjects 2 and 6) who reported a minor increase in CF 
QoL scores.  
 
	 	
	 179	
 
Figure 6.8 PSQI at Baseline and at Subsequent Study. 
 
As shown in Figure 6.8, there was a wide variation in responses to PSQI between 
baseline and subsequent studies with half reporting worsening sleep quality, 3 reporting 
a mild improvement and one that did not change between the studies. The PSQI results 
seem unrelated to progression of disease. 
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Figure 6.9 ESS at Baseline and at Subsequent Study. 
ESS: Epworth Sleepiness Scale. 
For ESS over time, 6 out of 8 subjects reports an increase in daytime somnolence as 
indicated by the increase in ESS scores, as shown in Figure 6.9. 
 
The correlations between the change in objective sleep variables and their correlation 
with change in subjective QoL measures were evaluated. Using Spearman’s test for 
correlation, none of the objective parameters of sleep from the PSG between baseline 
and subsequent studies were shown to be correlated with change in total CF QoL score 
nor change in PSQI, Table 6.16. For the change in ESS, only the change in arousal 
index was found to be significantly positively correlated (p = 0.026, r = 0.768, r2 = 
0.437), Figure 6.10. 
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Table 6.16 Change in Objective Sleep Measures from PSG and Correlation with 
Change in Subjective QoL Measures. 
  ∆ Total CF QoL ∆ PSQI ∆ ESS 
∆ AI p-value 
r 
r2 
0.136 
-0.575 
0.365 
0.700 
0.163 
0.013 
0.026* 
0.768 
0.437 
∆ AHI p-value 
r 
r2 
0.531 
-0.262 
0.035 
0.866 
0.072 
0.005 
0.932 
0.036 
0.0001 
∆ RDI p-value 
r 
r2 
0.320 
-0.405 
0.075 
0.756 
-0.132 
0.023 
0.775 
0.121 
0.005 
∆ Awake SpO2 p-value 
r 
r2 
0.865 
-0.072 
0.0008 
0.853 
-0.079 
0.007 
0.943 
-0.031 
0.061 
∆ Nadir SpO2 p-value 
r 
r2 
0.799 
0.108 
0.0008 
0.606 
-0.217 
0.0006 
0.643 
0.195 
0.025 
Subjects: n = 8. QoL: Quality of Life; AI: arousal index; AHI: apnoea-hypopnoea 
index; RDI: respiratory disturbance index; SpO2: oxygen saturation; CF QoL: Cystic 
Fibrosis Quality of Life questionnaire; PSQI: Pittsburgh Sleep Quality Index; ESS: 
Epworth Sleepiness Scale. * significance at p < 0.05. 
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Figure 6.10 Correlation of Change in AI and Change in ESS. 
AI: Arousal Index; ESS: Epworth Sleepiness Scale. 
 
Although, there were no statistically significant correlations between change in lung 
function (FEV1 % predicted) and change in subjective sleep quality and QoL measures 
(CF QoL, PSQI and ESS), there was a trend towards a correlation between change in 
lung function and change in CF QoL (p = 0.071, r = 0.667, r2 = 0.320), shown in Figure 
6.11. 
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Figure 6.11 Correlation of Change in Lung Function and Change in CF QoL 
FEV1: Forced expiratory volume in 1 second; CF QoL: Cystic Fibrosis Quality of Life 
questionnaire. 
 
There were no correlations identified between change on CF QoL or change in PSQI 
nor change in ESS, Table 6.17. 
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Table 6.17 Correlations between Changes in QoL Measures over Time. 
Measure Correlation with ∆ Total CF QoL 
p-value r r2 
∆ PSQI 0.204 -0.503 0.483 
∆ ESS 0.120 -0.594 0.413 
 
CF QoL: Cystic Fibrosis Quality of Life questionnaire; PSQI: Pittsburgh Sleep Quality 
Index; ESS: Epworth Sleepiness Scale. 
 
 
6.6 DISCUSSION  
 
6.6.1 Quality of Life and Sleep Quality in Adults with CF Attending a Single CF 
Centre. 
 
Comparing the results of the CFQ-R in our study with those reported in the large 
landmark study by Quittner et al. (2012), many of the findings (except treatment burden 
and health perceptions) were similar (Quittner et al., 2012). In their study, the FEV1 % 
predicted and BMI were similar to ours (FEV1 % predicted: 66.5 ± 25.1 % and BMI: 
21.1 ±  3.3 kg/m2) (mean ± SD) in their teen/adult subset. Hence, their patient 
population as based on lung disease severity and BMI in the US, was similar to our 
population in Australia.  However, the population in the Quittner study was from a 
younger mean age (23.5 ± 9.6 years) compared with this current study (33.0 ± 10.8 
years) (Quittner et al., 2012). This may explain some of the variation in the results of 
treatment burden in our slightly older population. As patients age, increased treatment 
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requirements may be required to maintain lung function stability. This was discussed 
by Abbott et al. as greater longevity was at a cost of increased and more complex and 
onerous daily routines (Abbott et al., 2015). 
 
Although, Quittner et al. had a large cohort of 4,679 adults/teens, all of the domains 
except treatment burden and health perceptions were comparable with our results 
(Quittner et al., 2012). In our cohort, participants reported a higher level of treatment 
burden and lower perception of health compared with the Quittner study. In the Quittner 
study, a mean of 61.5 ± 21.0 for treatment burden and mean 67.2 ± 24.1 for health 
perceptions was reported (Quittner et al., 2012). This may be in part due to increased 
financial provisions in the care of CF patients in Australia where the patients are not 
reliant on private health insurance for medications. Hence, more treatment including 
medications and physiotherapy is recommended regardless of patient’s insurance 
status. 
 
Gee et al. (2005) assessed the variables that might be correlated with different domains 
in the CF QoL questionnaire (Gee et al., 2005). Simple linear and multiple regression 
analysis using forward selection was used to construct models relating each variable to 
each HR QoL domain. These authors found a modest positive correlation between 
FEV1 % predicted and BMI (r = 0.39) and a small positive correlation between age and 
BMI (r = 0.27) (Gee et al., 2005). Regression analyses between potential variables (such 
as FEV1 %, age and transplant status) and CF QoL domains showed FEV1 was 
positively correlated with all HR QoL domains, but this only explained a small 
proportion of variability. In our study, we found FEV1 % predicted was positively 
correlated with all domains other than emotional functioning and concerns for the 
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future. Patients with a chronic lung disease, such as CF, are highly cognisant of their 
mortality and for some this can weigh heavily in all of their interactions but for others 
it does not appear to significantly impact on them.  
 
However, the results of the questionnaires should be interpreted with caution as these 
particular domains (emotional functioning and concerns for the future) focus on the 
past 2 weeks and our participants completed this questionnaire during a routine 
outpatient clinic visit rather than at the beginning or end of an exacerbation. It should 
be noted as CF is a genetic disease and most of these adults have grown up with the 
disease, they are likely to be accustomed to its limitations.  
 
Despite our population having a mean FEV1 % predicted of 64 % indicating a moderate 
disease severity, the CF participants reported that CF affected their social life minimally 
(transformed mean score of 82.4) suggesting that it is not solely lung function that 
contributes to the subject’s ability to function as they would like to in the community. 
There are many other factors including treatment and nutritional regimens that subjects 
need to adhere to in order to maintain their own level of function.  
 
Patients with greater levels of nutritional intervention or lower BMIs reported a poorer 
body image in the Gee et al. study (Gee et al., 2005). As previously shown, body image 
is extremely important to adolescents and adults with CF (Abbott et al., 2000, Walters 
et al., 1994). However, it is important to note that in a study by Abbott et al., females 
with CF were happy with their lean body shape, whereas males preferred to be much 
heavier and bulkier (Abbott et al., 2000). These findings have also been shown in 
longitudinal studies of CF patients (Abbott et al., 2015). In a society where a slim body 
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frame is thought to be more desirable for females, our female patients with lower BMI 
perceive good body image. On the other hand, as discussed above in the study by Abbott 
et al., and demonstrated in our study, males prefer to be heavier and bulkier and hence 
if their BMI is at the lower limit of reference range, the males perceive poorer body 
image compared with their female counterparts (Abbott et al., 2000). 
 
Advancing age, lung function and transplantation are important predictors of outcome 
across many domains of life quality (Abbott et al., 2015). A longitudinal observational 
study undertaken by Abbott et al. demonstrated that the treatment burden of CF on 
patients profoundly impacts all aspects of a person’s quality of life and the patient 
reported QoL declines slowly over time at approximately 1 % per year (Abbott et al., 
2015). Further longitudinal research based on our own patient cohort would lead to 
additional information in this area.  
 
Our response rate was 74 %, better than many previous studies, likely related to the 
questionnaires being distributed at the time of clinical review by the primary researcher 
(OE). Response rate from other studies was typically 50-60 % (Gee et al., 2005, 
Goldbeck and Schmitz, 2001, Walters et al., 1994). The respondents to the UK study 
differed from our study as only 65% of respondents saw a chest physician specialising 
in CF. In our study, the respiratory physician attending the CF clinic is a CF specialist 
and reviews all patients in a dedicated multidisciplinary CF clinic.  
 
A study of 23 adults with CF (61% female), showed that greater than half of the subjects 
(56.5%) were poor sleepers based on PSQI results and 13% reported poor sleep quality. 
19 of these 23 subjects underwent PSG and sleep efficiency was less than 90% in 61% 
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of these subjects (Iscar-Urrutia et al., 2018). These authors also found a significant 
correlation between PSQI and all domains of the CFQR 14 (Iscar-Urrutia et al., 2018). 
Similarly, Bouka et al., found that impaired sleep quality (measured by PSQI > 5) was 
related to the specific domains of vitality, emotional functioning, social, role, eating 
disturbances and digestive symptoms in the CFQ-R (German version) (Bouka et al., 
2012). These results are in keeping with our results discussed above. 
 
In terms of sleep quality, we found that a lower PSQI score correlated with a higher 
overall CF QoL score (as shown in Figure 6.6) but we did not find a significant 
correlation between subjective sleep quality and lung function. In a study of 19 CF 
subjects with severe lung disease (mean FEV1 28 ± 7 % predicted) and 10 control 
subjects, Dancey et al. found that the ESS was within normal limits in both groups (7.3 
± 4.4 in the CF group vs 5.6 ± 4.1 in the control group) (Dancey et al., 2002). These 
authors did not use the sleep specific QoL measure, PSQI but did use the Mood Profile 
and Stanford Sleepiness Scale to evaluate mood and daytime sleepiness and found that 
CF subjects reported significantly lower values for activation domain and happiness as 
well as reporting a greater level of fatigue when compared with normal subjects 
(Dancey et al., 2002). The results of the Stanford Sleepiness Scale were not statistically 
significant between the groups, but the CF subjects showed a trend to greater sleepiness 
than the control group (Dancey et al., 2002). In our study, which used the well-validated 
ESS, both in “desaturator” and “non-desaturator” subjects, the ESS was within normal 
limits in keeping with the data that in CF subjects, sleepiness is reported but not in the 
abnormal range and subjects may not be aware of excessive sleepiness or have become 
accustomed to it.  
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Another study evaluating sleep quality in patients with CF was undertaken by Milross 
et al., who found that 38% of their subjects (14/37) had a high PSQI (ie. PSQI score > 
5) (Milross et al., 2002). The mean PSQI in their subjects was 5.7 ± 4.0 arbitrary units 
and they found that the areas that contributed most to higher PSQI scores were the 
questions relating to subjective quality, sleep latency and sleep disturbance (Milross et 
al., 2002). These results were similar to ours with our mean PSQI reported as 5.9 ± 3.6 
and we also found that sleep disturbance, sleep quality and sleep latency all contributed 
to the higher PSQI scores (where mean was > 1.0 for these domains).  
 
6.6.2 Subjective and Objective Sleep Quality and QoL Data for the Adults with 
CF undergoing PSG and Sonomat Studies. 
 
Sleep disturbances may be in many forms, external disturbances from bed partners, 
children, traffic noises or from restless sleep due to leg movements, respiratory events 
including coughing and arousals post hypopnoeas or apnoeas. 
 
In our study of a subset of CF subjects undertaking an overnight sleep study, we found 
that nocturnal oxygen desaturation was not associated closely with QoL as measured 
by CFQ-R. In addition, we did not find that measures of oxygen desaturation correlated 
with subjective reporting of sleep quality as measured by PSQI findings. It is possible 
that patients are unaware of their symptoms during sleep so do not report on these on 
the PSQI. It is only when lung function becomes very severe that patients report issues 
with their sleep. In a study by Young et al., CF subjects were found to have poor 
nocturnal oxygenation and this correlated with QoL but was independent of the effect 
of lung function and awake gas exchange in stable CF patients with moderate to severe 
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lung disease (Young et al., 2011). Our percentage of “desaturators” (subjects who spent 
≥ 10 % of recording time with SpO2 < 90 %), was comparable with the study by Young 
et al. who reported that 27% of CF patients in their study had a desaturation of < 90 % 
for 10 % of recording time (Young et al., 2011). 
 
Comparing those patients who were “desaturators” and those who were not, there was 
no statistically significant difference on any domain of CF QoL when adjusted for the 
effects of FEV1 and awake gas exchange (Young et al., 2011). However,  for the most 
severe group (those  spending ≥ 30 % of recording time with SpO2 < 90 %), the “30 % 
desaturators” had reduced physical functioning, increased treatment issues and more 
chest symptoms on the CF QoL questionnaire (Young et al., 2011). These authors also 
found the “30 % desaturators” had more subjective daytime sleepiness on the ESS and 
greater exertional dyspnoea on the MRC than non-desaturators (Young et al., 2011) 
There was no difference in these parameters in the “10% desaturator” group when 
compared with the non-desaturators (Young et al., 2011). Our patient population had 
slightly better lung function than the Young et al. population (where FEV1 was 45 ± 11 
FEV1 % predicted for the “non-desaturators” and 33 ± 13 FEV1 % predicted for the 
“10% desaturators” (Young et al., 2011)  We did not find any difference between those 
subjects who desaturated overnight and those who did not in all domains of the CFQ-
R, except for the domain of Role Functioning, which may be due to the slightly higher 
lung function in our subject group.  This is in keeping with the fact that the patients 
with lower lung function are more often away from school / work due to their illness 
which can often interfere the ability to participate fully in an active life. 
 
	 	
	 191	
6.6.3 Sleep Quality and QoL in a Subset of Adults with CF with Deteriorating 
Lung Function. 
 
This is the first study to our knowledge evaluating longitudinal subjective sleep quality 
in CF subjects. In our small subject group with deteriorating disease status, at the 
subsequent study, total CF QoL was lower but the difference was not statistically 
significant. We also found that ESS deteriorated slightly but PSQI did not change over 
time. These results suggest worsening lung function over time was associated with 
worsening overall QoL. None of the objective parameters of sleep from the PSG 
between baseline and subsequent studies were shown to be correlated with change in 
total CF QoL score nor change in PSQI, only the change in ESS was found to be mildly 
correlated with arousal index. The ESS is a score based on the adult’s perception of 
daytime somnolence which reflects what is happening with increased fragmentation / 
arousal during the night.  
 
6.6.4 Strengths of the Study 
 
The strengths of this study included assessment of a wide variety of disease severity in 
patients with CF. Also, the questionnaires were performed during a period of clinical 
stability or at the end of an exacerbation. We have used CF specific validated 
questionnaires to assist in assessing disease specific issues that relate to our patients. 
Analysis of the oximetry data was based on national and international guidelines for 
nocturnal oxygen therapy and hence these cut-offs of oximetry may be used in future 
studies of oxygen treatment for CF patients (Beasley et al., 2015, McDonald et al., 
2005, Yankaskas et al., 2004). 
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6.6.5 Limitations of the Study 
 
These studies were performed in a single CF adult centre in metropolitan Sydney. 
Although, these results cannot be generalised to the entire CF population, in Australia 
almost all adults with CF attend a specialised CF clinic in a major city. These results 
are limited to the general CF Australian adult population and the response rate at 74 % 
may be a bias towards patients who felt they could complete the questionnaire in a 
positive way or a way in which the physicians wanted at the clinic. Several important 
variables were not evaluated including the frequency of pulmonary exacerbations, 
microbiological status, CFRD status, nutritional supplementation status and vascular 
access status. These confounding factors may play an important role in confirming 
assessing the true effects of disease variables and QoL.  
 
 
6.7 CONCLUSION 
 
In conclusion, these studies of adults with CF have demonstrated that overall QoL was 
strongly correlated with subjective sleep quality as shown by the PSQI. There was no 
significant correlation between subjective sleep quality or QoL (Total QoL, PSQI or 
ESS) and lung function. As noted in Chapter 4, objective sleep quality measures (based 
on the PSG) were not found to correlate with lung function. In addition, the objective 
parameters of sleep from the PSG were not shown to be correlated with change in total 
CF QoL score nor change in PSQI between baseline and subsequent studies. However, 
there was a positive correlation between change in ESS and change in arousal index 
over time in the longitudinal study. Although, not statistically significant in our subject 
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group with deteriorating clinical status, subjective QoL measures worsened with 
worsening clinical status. Further trials are required to assess if other factors play an 
important role in quality of life for CF patients, or whether any interventions can 
improve QoL or quality of sleep. 
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CHAPTER 7: CONCLUSION AND SUMMARY OF RESULTS 
 
This thesis has examined the effect of lung disease in adult cystic fibrosis on sleep and 
quality of life by using standard PSG measurements of sleep, quality of life and sleep 
questionnaires, in addition to novel non-invasive sleep and breathing measurement 
techniques.  In adults with CF with clinical deterioration, changes in sleep were 
systematically assessed to identify abnormalities that may occur over time. 
 
In Chapter 3, it was shown the use of the non-invasive sleep and breathing measurement 
device, Sonomat, enabled characterisation of respiratory sounds (normal lung sounds, 
coughs, crackles and wheezes) based on spectrographic and audio analysis. Crackles 
were identified by short bursts of sound with high amplitude and frequency. Wheezes 
had a loud musical sound at approximately 400 Hz. In addition to using the Sonomat at 
a single time point, the Sonomat can also be used longitudinally over a number of days 
or weeks to identify changes in the above sounds in adults with cystic fibrosis. 
 
In Chapter 4, polysomnography and the Sonomat were used to assess objective 
measures of sleep in adults with CF. It was found that sleep efficiency, sleep stages and 
arousal index were similar in our CF population to the non-CF population. However, a 
high prevalence of mild sleep disordered breathing (RDI > 5 events per hour) was 
demonstrated. It remains to be seen whether this prevalence is clinically relevant and 
future larger studies would help in addressing this question. In this study, poorer lung 
function correlated with lower oxygen saturation both during awake time as well as the 
nadir oxygen saturation. No correlation was found between poorer lung function and 
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reduced sleep efficiency, apnoea-hypopnoea index, respiratory disturbance index or 
arousal index. 
 
The use of the non-invasive device, the Sonomat, in adults with CF was reported in 
Chapters 4 and 5. The results of the Sonomat demonstrated that the sleep efficiency and 
AHI were within normal limits for these adults with CF. Subsequent to the 
identification of respiratory sounds in Chapter 3, it was shown that the Sonomat can be 
used to detect abnormalities in sleep and breathing that are not measureable using PSG 
alone. The high percentage of crackles (19.9 % of total sleep time) reported in these 
adults is consistent with respiratory compromise. In addition, lung function was not 
found to be correlated with AHI, sleep efficiency or cough. Further, correlations 
between PSG data and Sonomat data showed that sleep efficiency and AHI were similar 
for the two recording devices, although RDI tended to be higher for the PSG recording. 
In addition, there was no relationship between lung function and AHI using either PSG 
or Sonomat.  
 
In the longitudinal PSG studies reported in Chapter 5, it was demonstrated in adults 
with severe cystic fibrosis lung disease that sleep efficiency and sleep architecture were 
within normal limits and that these parameters did not change over time. Although not 
significant, there was a trend to an increase in RDI and AI over time. In this small subset 
of adults with CF, overall oxygenation during sleep was reduced at both baseline and 
subsequent studies. However, only the amount of oxygen desaturation showed a 
statistically significant increase between the baseline and subsequent studies. 
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Furthermore, in Chapter 5, the longitudinal effect of deteriorating clinical function on 
Sonomat sleep parameters was examined. In this small subset of adults with CF, sleep 
time spent with crackles increased significantly over time (from median 21.8 to 81.7 % 
of total sleep time). In contrast, coughing or snoring did not change significantly over 
the time period examined. The need for larger studies examining the effects of 
deteriorating clinical status is supported by the above results. The finding of increased 
adventitial sounds in adults with CF might suggest worsening respiratory function over 
time or signs of an impending exacerbation requiring early intervention to prevent or 
minimise deterioration.  
 
The quality of life and sleep quality were examined in adults with CF in Chapter 6. The 
overall QoL strongly correlated with subjective sleep quality (using the PSQI). There 
was no significant relationship between either subjective sleep quality or QoL with lung 
function. Furthermore, objective sleep quality measures (arousal index and sleep 
efficiency) were not related to change in total CF QoL nor change in PSQI. There was 
a positive relationship between change in ESS and change in arousal index over time 
in the longitudinal study. Over time, subjective QoL measures tended to worsen with 
deteriorating clinical status, although this finding was not statistically significant. 
 
In summary, this thesis has used a novel non-invasive measurement device, the 
Sonomat, to identify respiratory sounds and breathing events in adults with CF. The 
presence of these sounds during sleep can assist the physician in identifying 
abnormalities of sleep and breathing. In turn, the physician can use these abnormalities 
and their clinical acumen to recognise a pulmonary exacerbation earlier and hence 
intervene earlier to limit or minimise respiratory deterioration in adults with CF.  
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This thesis also examined quality of life and sleep quality measures and found that 
overall QoL demonstrated a strong relationship with subjective sleep quality (PSQI) 
but not with objective measures of sleep quality (such as arousal index, AHI or sleep 
efficiency based on the PSG or Sonomat) suggesting that qualitative perception of sleep 
is more important in the overall perception of QoL in adults with CF.  
 
With the advent of novel targeted therapies, it is an exciting time for physicians working 
in the field of cystic fibrosis. By being able to identify clinical deterioration using non-
invasive methods, such as the Sonomat, there is optimism that respiratory deterioration 
can be further minimised.  
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Understanding	the	impact	of	your	illness	and	treatments	on	your	everyday	life	can	help	your	healthcare	team	keep	track	
of	your	health	and	adjust	your	treatments.	For	this	reason,	this	questionnaire	was	specifically	developed	for	people	who	
have	cystic	fibrosis.	Thank	you	for	your	willingness	to	complete	this	form.	
	
Instructions:			
The	following	questions	are	about	the	current	state	of	your	health,	as	you	perceive	it.	This	information	will	allow	
us	to	better	understand	how	you	feel	in	your	everyday	life.		
	
Please	answer	all	the	questions.	There	are	no	right	or	wrong	answers!	If	you	are	not	sure	how	to	answer,	choose	
the	response	that	seems	closest	to	your	situation.	
	
	
A. What	is	your	date	of	birth?	 	 	 	 F.	What	is	the	highest	level	of	education	you	
Date		 ☐☐	/	☐☐	/	☐☐☐☐     have	completed?	
	 	 	 	 	 	 	 	 Some	secondary	school	or	less		
B. What	is	your	gender?	 	 	 	 	 	 GCSEs/	O-levels	
	 Male	☐		 Female	☐     A/AS-levels	
	 	 	 	 	 	 	 	 Other	higher	education	
C. During	the	past	two	weeks,	have	you	been	on	holiday	or		 	 University	degree	
out	of	school	or	work	for	reasons	NOT	related	to	your	 	 Professional	qualification	or	post	
health?	 	 	 	 	 	 	 	 	 graduate	study	
Yes	 No
	
D. What	is	your	current	marital	status?	 	 	 G.	Which	of	the	following	best	describes	your	
Single/never	married	 	 	 	 	 	 current	work	or	school	status?	
Married	 	 	 	 	 	 	 Attending	school	outside	the	home	
Widowed	 	 	 	 	 	 	 Taking	educational	courses	at	home	
Divorced	 	 	 	 	 	 	 Seeking	work	
Separated	 	 	 	 	 	 	 Working	full	or	part-time	
Remarried	 	 	 	 	 	 	 Full	time	homemaker	
With	a	partner	 	 	 	 	 	 Not	attending	school	or	work	due	to	
         my	health	
E. Which	of	the	following	best	describes	your	racial		 	 	 Not	working	for	other	reasons	
background?	
White	–	UK	
White	–	other
Indian/Pakistani
Chinese/	Asian
Caribbean
Other	(not	represented	above	or	people	whose	predominant	origin	cannot	be	determined/mixed	race)
Prefer	not	to	answer	this	question
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Understanding the i pact of your illness and treatments on your everyday life can help your healthcare team 
keep track of your health and adjust your treatments.  For this reason, this questionnaire was specifically 
developed for people who have cystic fibrosis.  Thank you for your willingness to complete this form. 
 
Instructions: The following questions are about the current state of your health, as you perceive it.  This 
information will allow us to better understand how you feel in your everyday life.    
 Please answer all the questions. There are no right or wrong answers! If you are not sure how to 
answer, choose the response that seems closest to your situation. 
 
A. What is your date of birth? 
Date         
 Day Month Year 
B. What is your gender? 
  Male  Female 
C.  During the past two weeks, have you been on holiday or 
out of sc ool or work for reasons NOT related to your 
health? 
  
  Yes  No 
D. What is your current marital status? 
  Single/never married 
  Married 
  Widowed 
  Divorced 
  Separ ted 
  Remarried  
  With a partner 
E. Which of the following best describes your racial 
background? 
       White - UK 
       White - other 
          Indian/ Pakistani 
         Chinese/ Asian 
          African 
        Caribbean 
          Other [not represented above or people whose predominant 
origin cannot be determined/ mixed race] 
          Prefer not to answer this question 
F. What is the highest level of education you have        
completed? 
        Some secondary school or ss 
  GCSEs/ O-levels 
  A/AS-levels 
  Other higher education 
  University degree 
         Professional qualification or post-graduate study  
 
 
G.  Which of the following best describes your current work 
or school status? 
        Attending school outside the home 
  Taking educational courses at home 
  Seeking work  
        Working full or part time (either outside the home or 
at a home-based business) 
  Full time homemaker 
  Not attending school or working due to my health  
  Not working for other reasons 
Please fill-in the information or tick the box indicating your answer. Section I. Demographics 
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Understanding the impact of your illness and treatments on your everyday life can help your healthcare team 
keep track of y ur health nd adjust your treatme ts.  For this reason, this questi nnaire wa specifically 
developed for people who have cystic fibrosis.  Thank you for your willingness to complete this form. 
 
Instructions: The following qu sti ns ar  abo t he current stat  of your health, as you perceive it.  This 
information will allow us to bette  understand how you feel in your everyday life.    
 Please answer all the questions. There are no right or wrong answers! If you are not sure how to 
answer, choose the response that seems closest to your situation. 
 
A. What is your date of birth? 
Date         
 Day Month Year 
B. What is your gender? 
  Male  Female 
C.  During the past two weeks, have you been on holiday or 
out of school or work for reasons NOT related to your 
health? 
  
  Yes  No 
D. What is your current marital status? 
  Single/never married 
  Married 
  Widowed 
  Divorced 
  Separated 
  Remarried  
  With a partner 
E. Which of the following best describes your racial 
background? 
       White - UK 
       Whit  - other 
       Indian/ Pakistani 
      Chin se/ Asian 
       African 
        Caribbean 
          Other [not represented above or people whose predominant 
origin cannot be determined/ mixed race] 
          Prefer not to answer this question 
F. What is the highest level of education you have        
completed? 
        Som  secondary school or less 
  GCSEs/ O-levels 
  A/AS-levels 
  Other higher education 
  University degree 
         Professional qualification or post-graduate study  
 
 
G.  Which of the following best describes your current work 
or school status? 
        Attending school outside the home 
  Taking educational courses at home 
  Seeking work  
        Working full or part time (either outside the home or 
at a home-based business) 
  Full time homemaker 
  Not attending school or working due to my health  
  Not working for other reasons 
Please fill-in the information or tick the box indicating your answer. Section I. Demographics 
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During	the	past	two	weeks,	to	what	extent	have	you	had	difficulty:	 	
	 A	lot	of	
difficulty	
Some	
difficulty	
A	little	
difficulty	
No	
difficulty	
1.	Performing	vigorous	activities	such	as	running	or	playing	
sports	
	 	 	 	
2.	Walking	as	fast	as	others	 	 	 	 	
3.	Carrying	or	lifting	heavy	things	such	as	books	or	shopping	 	 	 	 	
4.	Climbing	one	flight	of	stairs	 	 	 	 	
5.	Climbing	stairs	as	fast	as	others	 	 	 	 	
	
During	the	past	two	weeks,	indicate	how	often:	
	 Always	 Often	 Sometimes	 Never	
6.	You	felt	well	 	 	 	 	
7.	You	felt	worried	 	 	 	 	
8.	You	felt	useless	 	 	 	 	
9.	You	felt	tired	 	 	 	 	
10.	You	felt	full	of	energy	 	 	 	 	
11.	You	felt	exhausted	 	 	 	 	
12.	You	felt	sad	 	 	 	 	
	
Please	circle	the	number	indicating	your	answer.	Please	choose	only	one	answer	for	each	question.	
	
Thinking	about	the	state	of	your	health	over	the	last	two	weeks:	
	
13.	To	what	extent	do	you	have	difficulty	walking:	
	 1.	You	can	walk	a	long	time	without	getting	tired	
	 2.	You	can	walk	a	long	time	but	you	get	tired	
	 3.	You	cannot	walk	a	long	time	because	you	get	tired	quickly	
	 4.	You	avoid	walking	whenever	possible	because	it’s	too	tiring	for	you	
	
14.	How	do	you	feel	about	eating?	
	 1.	Just	thinking	about	food	makes	you	feel	sick	
	 2.	You	never	enjoy	eating	
	 3.	You	are	sometimes	able	to	enjoy	eating	
	 4.	You	are	always	able	to	enjoy	eating	
	
15.	To	what	extent	do	your	treatments	make	your	daily	life	more	difficult?	
	 1.	Not	at	all	
	 2.	A	little	
	 3.	Moderately	
	 4.	A	lot	
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Understanding the impact of your illness and treatments on your everyday life can help your healthcare team 
keep track of your health and adjust your treatments.  For this reason, this questionnaire was specifically 
developed for people who have cystic fibrosis.  Thank you for your willingness to complete this form. 
 
Instructions: The following questions are about the current state of your health, as you perceive it.  This 
information will allow us to better understand how you feel in your everyday life.    
 Please answer all the questions. There are no right or wrong answers! If you are not sure how to 
answer, choose the response that seems closest to your situation. 
 
A. What is your date of birth? 
Date         
 Day Month Year 
B. What is your gender? 
  Male  Female 
C.  During the past two weeks, have you been on holiday or 
ut of schoo  or work for reasons NOT related to your 
health? 
  
  Yes  No 
D. What is yo r curre t marital status? 
  Single/never married 
  Married 
  Widowed 
  Divorced 
  Separated 
  Remarried  
  With a partner 
E. Which of the following best describes your racial 
background? 
       White - UK 
       White - other 
          Indian/ Pakistani 
         Chinese/ Asian 
          African 
        Caribbean 
          Other [not represented above or people whose predominant 
origin cannot be determined/ mixed race] 
          Prefer not to answer this question 
F. What is the highest level of education you have        
completed? 
        Some secondary school or less 
  GCSEs/ O-levels 
  A/AS-levels 
  Other higher education 
  University degree 
         Professional qualification or post-graduate study  
 
 
G.  Which of the following best describes your current work 
or school status? 
        Attending school outside the home 
  Taking educational courses at home 
  Seeking work  
        Working full or part time (either outside the home or 
at a home-based business) 
  Full time homemaker 
  Not attending school or working due to my health  
  Not working for other reasons 
Please fill-in the i formation or tick the box indicating your answer. Section I. Demographics 
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uring the past t o weeks, to what extent have you had difficulty: 
A lot of 
difficulty 
Some 
difficulty 
A little 
difficulty 
No 
 difficulty 
  1.  Performing vigorous activities such as running or playing sports .....................      
  2.  Walking as fast a  others ............................ ......................................................      
  3.  Carrying or lifting heavy things such as books, shopping, or school bags ........      
  4.  Climbing one flight of stair ..............................................................................      
  5.  Climbing stairs as fast as others .........................................................................      
 
During the past two weeks, indicate how often: Always Often Sometimes Never 
  6.  You felt well .......................................................................................................     
  7.  You felt worried ..................................................................................................     
  8.  You felt useless ...................................................................................................     
  9.  You felt tired .......................................................................................................     
10. You felt full of energy .........................................................................................     
. You felt exhausted ..............................................................................................     
12. You felt sad .........................................................................................................     
Please circle the number indicating your answer.  Please choose only one answ r for ac  question. 
Thinking about the state of your health over the last two weeks:   
13.  To what extent do you have difficulty walking? 
1. You can walk a long time without getting tired 
2. You can walk a long time but you get tired 
3. You cannot walk a long time because you get tired quickly 
4. You avoid walking whenever possible because it’s too tiring for you 
14.  How do you feel about eating? 
1. Just thinking about food makes you feel sick 
2. You never enjoy eating 
3. You are sometimes able to enjoy eating 
4. You are always able t  enjoy eating 
15.  To what extent do your treatments make your daily life more difficult?  
1. Not at all 
2. A little 
3. Moderately 
4. A lot 
 
 
 
Section II. Quality of Life 
Please tick the box indicating your answer. 
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16.		How		much		time		do		you		currently		spend		each		day		on		your		treatments?	
1.	 A		lot	
2.	 Some	
3.	 A		little	
4.	 Not		very		much	
17.		How		difficult		is		it		for		you		to		do		your		treatments		(including		medications)		each		day?	
1.	 Not		at		all	
2.	 A		little	
3.	 Moderately	
4.	 Very	
18.		How		do		you		think		your		health		is		now?	
1.	 Excellent	
2.	 Good	
3.	 Fair	
4.	 Poor	
 
Please	select	a	box	indicating	your	answer.	
	
Thinking	about	your	health	during	the	past	two	weeks,	indicate	the	extent	to	which	each	sentence	is	true	or	false	for	you.	
	
	 Very	true	 Somewhat	
true	
Somewhat	
false	
Very		
false	
19.	I	have	trouble	recovering	after	physical	effort	 	 	 	 	
20.	I	have	to	limit	vigorous	activities	such	as	running	or	playing	
sports	
	 	 	 	
21.	I	have	to	force	myself	to	eat	 	 	 	 	
22.	I	have	to	stay	at	home	more	than	I	want	to	 	 	 	 	
23.	I	feel	comfortable	discussing	my	illness	with	others	 	 	 	 	
24.	I	think	I	am	too	thin	 	 	 	 	
25.	I	think	I	look	different	from	others	my	age	 	 	 	 	
26.	I	feel	bad	about	my	physical	appearance	 	 	 	 	
27.	People	are	afraid	that	I	may	be	contagious	 	 	 	 	
28.	I	get	together	with	my	friends	a	lot	 	 	 	 	
29.	I	think	my	coughing	bothers	others	 	 	 	 	
30.	I	feel	comfortable	going	out	at	night	 	 	 	 	
31.	I	often	feel	lonely	 	 	 	 	
32.	I	feel	healthy	 	 	 	 	
33.	It	is	difficult	to	make	plans	for	the	future	(eg.	Going	to	
college,	getting	married,	getting	promoted	at	work	etc)	
	 	 	 	
34.	I	lead	a	normal	life	 	 	 	 	
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Understanding the impact of your illness and treatments on your everyday life can help your healthcare team 
keep track of your health and adjust your treatments.  For this reason, this questionnaire was specifically 
developed for people who have cystic fibrosis.  Thank you for your willingness to complete this form. 
 
Instructions: The following questions are about the current state of your health, as you perceive it.  This 
information will allow us to better understand how you feel in your everyday life.    
 Please answer all the questions. There are no right or wrong answers! If you are not sure how to 
answer, choose the response that seems closest to your situation. 
 
A. What is your date of birth? 
Date         
 Day Month Year 
B. What is your gender? 
  Male  Female 
C.  During the past two weeks, have you been on holiday or 
out of school or work for reasons NOT related to your 
health? 
  
  Yes  No 
D. What is y ur current marital status? 
  Single/never married 
  Married 
  Widowed 
  Divorced 
  S parated 
  Remarried  
  With a partner 
E. Which of the following best describes your racial 
background? 
       White - UK 
       White - other 
          Indian/ Pakistani 
         Chinese/ Asian 
          African 
        Caribbean 
          Other [not represented above or people whose predominant 
origin cannot be determined/ mixed race] 
          Prefer not to answer this question 
F. What is the highest level of education you have        
completed? 
        Some secondary school or less 
  GCSEs/ O-levels 
  A/AS-levels 
  Other higher education 
  University degree 
         Professional qualification or post-graduate study  
 
 
G.  Which of the following best describes your current work 
or school status? 
        Attending school outside the home 
  Taking educational courses at home 
  Seeking work  
        Working full or part time (either outside the home or 
at a home-based business) 
  Full time homemaker 
  Not attending school or working due to my health  
  Not working for other reasons 
Please fill-in the information or tick the box indicating your answer. Section I. Demographics 
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Questions		35		to		38		are		about		school,		work,		or		other		daily		tasks.	
35.		To	what	extent	did	you	have	trouble	keeping	up	with	your	schoolwork,	professional	work,	or	other	daily	activities	
during	the	past	two		weeks?	
1.	 You	have	had	no	trouble	keeping	up	
2.	 You	have	managed	to	keep	up	but	it’s	been	difficult	
3.	 You	have	been	behind	
4.	 You	have	not	been	able	to	do	these	activities	at	all	
	
36.		How	often	were	you	absent	from	school,	work,	or	unable	to	complete	daily	activities	during	the	last	two	weeks	
because	of	your	illness	or	treatments?	
 Always	 Often	 Sometimes	 Never	
37.		How	often	does	CF	get	in	the	way	of	meeting	your	school,	work,	or	personal	goals?	
	 Always	 Often	 Sometimes	 Never	
38.		How	often	does	CF	interfere	with	getting	out	of	the	house	to	run	errands	such	as	shopping	or	going	to	the	bank?	
	 Always	 Often	 Sometimes	 Never	
	
Indicate	how	you	have	been	feeling	during	the	past	two	weeks.	
	 A	great	
deal	
Somewhat		 A	little	 Not	at	all	
39.	Have	you	had	trouble	gaining	weight?	 	 	 	 	
40.	Have	you	been	congested?	 	 	 	 	
41.	Have	you	been	coughing	during	the	day?	 	 	 	 	
42.	Have	you	had	to	cough	up	mucus?	 	 	 	 Go	to	44	
	
43.	Has	your	mucus	been	mostly:	
	 Clear	 Clear	to	yellowYellow-greenGreen	with	traces	of	bloodDon’t	know	
	
How	often	during	the	past	two	weeks:		
	 Always	 Often		 Sometimes	 Never	
44.	Have	you	been	wheezing?	 	 	 	 	
45.	Have	you	had	trouble	breathing?	 	 	 	 	
46.	Have	you	woken	up	during	the	night	because	you	were	
coughing?	
	 	 	 	
47.	Have	you	had	problems	with	wind?	 	 	 	 	
48.	Have	you	had	diarrhea?	 	 	 	 	
49.	Have	you	had	abdominal	pain?	 	 	 	 	
50.	Have	you	had	eating	problems?	 	 	 	 	
Please	make	sure	you	have	answered	all	the	questions.	
THANK	YOU	FOR	YOUR	COOPERATION!	
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Understanding the impact of your illness and treatments on your everyday life can help your healthcare team 
keep track of your health and adjust your treatments.  For this reason, this questionnaire was specifically 
developed for people who have cystic fibrosis.  Thank you for your willingness to complete this form. 
 
Instructions: The following questions are about the current state of your health, as you perceive it.  This 
information will allow us to better understand how you feel in your everyday life.    
 Please answer all the questions. There are no right or wrong answers! If you are not sure how to 
answer, choose the response that seems closest to your situation. 
 
A. What is your date of birth? 
Date         
 Day Month Year 
B. What is your gender? 
  Male  Female 
C.  During the past two weeks, have you been on holiday or 
out of school or work for reasons NOT related to your 
health? 
  
  Yes  No 
D. What is your current marital status? 
  Single/never married 
  Married 
  Widowed 
  Divorced 
  Separated 
  Remarried  
  With a partner 
E. Which of the following best describes your racial 
background? 
       White - UK 
       White - other 
          Indian/ Pakistani 
         Chinese/ Asian 
          African 
        Caribbean 
          Other [not represented above or people whose predominant 
origin cannot be determined/ mixed race] 
          Prefer not to answer this question 
F. What is the highest level of education you have        
completed? 
        Some secondary school  less 
  GCSEs/ O-levels 
  A/AS-levels 
  Other higher education 
  University degree 
         Professional qualification or post-graduate study  
 
 
G.  Which of the following best describes your current work 
or school status? 
        Attending school outside the home 
  Taking educational courses at home 
  Seeking work  
        Working full or part time (either outside the home or 
at a home-based business) 
  Full time homemaker 
  Not attending school or working due to my health  
  Not working for other reasons 
Please fill-in the information or tick the box indicating your answer. Section I. Demographics 
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Questions 35 to 38 are about school, work, or other daily tasks. 
35.  To what extent did you have trouble keeping up with your schoolwork, professional work, or other daily activities during the past 
two weeks?  
1. You have had no troubl  keeping up 
2. You hav  managed to keep up but it’s been difficult 
3. You have been behind 
4. You have not been able to do these activities at all 
36.  How often were you absent from school, work, or unable to complete daily activities during the last two weeks because of your 
illness or treatments? 
            Always       Often                     Sometimes                   Never         
37. How often does CF get in the way of meeting your school, work, or personal goals? 
                  Always              Often                Sometimes          Never       
38. How often does CF interfere with getting out of the house to run errands such as shopping or going to the bank? 
                         Always              Often                Sometimes          Never       
   
 
 
Indicate how you have been feeling during the past two weeks.  A great deal Somewhat A little Not at all 
39. Have you had trouble gaining weight? ......................................................     
40. Have you been congested? ........................................................................     
41. Have you been coughing during the day? .................................................     
42. Have you had to cough up mucus? ............................................................     
    Go to 
Question 44 
43.  Has your mucus been mostly:    Clear   Clear to yellow   Yellowish-green   G een with traces of blood    Don't know 
 
How often during the past two weeks: Always Often Sometimes Never 
44.  Have you been wheezing? .........................................................................     
5.  Have you had trouble breathing? ...............................................................     
46.  Have you woken up during the night because you were coughing? ..........     
47.  Have you had problems with w nd? ..........................................................     
48.  Have you had diarrhoea? ...........................................................................     
49.  Have you had abdominal pain? ..................................................................     
50.  Have you had eating problems? .................................................................     
Please make sure you have answered all the questions.  
 
Section III. School, Work, or Daily Ac ivities 
Section IV. Symptom Difficulties 
Please select a box indicating your answer. 
THANK YOU FOR YOUR COOPERATION!
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Questions 35 to 38 are about sch ol, work, or othe  daily tasks. 
35.  To what extent did you have trouble keeping up with your schoolwork, professional work, or other daily activities during the past 
two weeks?  
1. You have had no trouble keeping up 
2. You have managed to keep up b t i ’s been difficult 
3. You have been behind 
4. You have not been able to do these activities at all 
36.  How often were you absent fr m sc ool, work, or un ble to complete daily activities during the last two weeks because of your 
illness or treatments? 
            Always       Often                     Sometimes                   Never         
37. How often does CF get in the way of mee i g your school, work, or per onal goals? 
                Always              Often                Sometimes         Never       
38. How often does CF interfere with getting out of the house to run errand such as shopping o going to the bank? 
                         Always              Often                Som times          Never       
   
 
 
Indicate how you have been feeling during the past two weeks.  A great deal Somewha  A little Not at all 
39. Have you had trouble gaining w ight? ......................................................     
40. Have you been congested? ........................................................ ...............     
41. Have you been coughing during the day? .................................................     
42. Have you had to cough up mucus? ............................................................     
    Go to 
Question 44 
43.  Has your mucus been mostly:    Clear   Clear to yellow   Yellowish-green   Green with traces of blood    Don't know 
 
How often during the past two we ks: Always Often Sometimes Never 
44.  Have you been wheezing? .........................................................................     
45.  Have you had trouble breathing? ...............................................................     
46.  Have you woken up during the night because you were coughing? ..........     
47.  Have you had problems with wind? ..........................................................     
48.  Have you had diarrhoea? ...........................................................................     
49.  Have you had abdominal pain? ..................................................................     
50.  Have you had eating problems? .................................................................     
Please make sure you have answered all the questions.  
 
Section III. School, Work, or Daily Activities 
Section IV. Symptom Difficulties 
Please select a box indicating your answer. 
THANK YOU FOR YOUR COOPERATION!
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Subject ID________________ Date:_________   
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The Cystic Fibrosis Quality of Life Questionnaire. 
The following questionnaire is designed to find out how CF affects your life. Read each statement, 
and then indicate which response is closest to how you feel, by ticking (Ö) one of the boxes after 
each statement. Please try to answer ALL the questions, as honestly as you can. 
 
SECTION ONE: 
How often, over the last two weeks, do you feel that your CF has affected the following aspects of 
your physical functioning/mobility? 
 
1. Because of my CF, During the last two weeks, I have had difficulty doing heavy physical jobs. 
For example, digging, moving furniture, washing the car, vacuuming etc. 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
 
2. During the last two weeks, my CF has prevented me from getting out of the house to run errands. 
For example, paying bills, posting a letter, doing light shopping etc. 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
 
3. Because of my CF, over the last two weeks, it has been difficult for me to do light tasks around 
the house. For example, preparing a light snack, washing up, picking up the mail etc. 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
 
4. Over the last two weeks, getting around the house has been difficult because of my CF. 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
 
5. For the last two weeks, CF has made it difficult to move from my bed or my chair. 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
 
6. Despite CF, over the last two weeks I have got around and done what I like. 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
 
7. During the last two weeks, there are places that I would like to have gone but didn’t because of 
my CF. 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
 
8. My CF has limited the type of sports and exercise I have been able to do over the last two weeks. 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
 
 
9. During the last two weeks, my CF has made me feel lacking in energy. 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
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10. Over the last two weeks, I have found that my physical functioning and mobility have affected 
my quality of life by making life less enjoyable. 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
 
 
SECTION TWO: 
Over the past two weeks, has CF affected your social life in any of the following ways? 
11. When I have been out socialising, over the last two weeks, I have behaved more cautiously than 
I would like to because of my CF. 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
 
12. Because of my CF, during the last two weeks, I have tended to avoid visiting friends. 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
 
13. For the last two weeks, I have avoided going out and socialising because of my CF. 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
 
14. I find that the way in which CF affects my socialising interferes with my overall enjoyment of 
life. 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
 
 
SECTION THREE: 
The following questions ask you about symptom and treatment aspects of your CF. How have the 
following factors affected you over the last two weeks? 
15. Over the last two weeks, I have found my treatments (ie physio, enzymes etc) very time 
consuming. 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
 
16. During the last two weeks, my treatments have interfered with other things that I have wanted 
to do. 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
 
 
17. Over the last two weeks, I have found that my treatments have interfered with my enjoyment of 
life. 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
 
18. I have found my breathlessness troublesome, during the last two weeks. 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
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19. Over the last two weeks, I have found my coughing troublesome. 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
 
20. I have found my coughing embarrassing over the last two weeks. 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
 
21. For me, over the past two weeks, breathlessness / coughing have made life less enjoyable. 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
 
 
SECTION FOUR: 
Over the past two weeks, I have found that my CF has made me feel: 
22. Resentful: 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
 
23. Angry: 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
 
24. Embarrassed: 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
 
25. Irritable: 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
 
26. So fed up that nothing can cheer me up: 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
 
 
27. Anxious: 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
28. Frustrated: 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
 
29. The way that my CF makes me feel emotionally interferes with my quality of life. 
 
£All of the time  £most of the time  £good bit of the time  £sometimes  £occasionally  £ never 
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PLEASE NOTE, the remaining sections have a slightly different response scale, which asks you to 
indicate to what extent you either agree or disagree with each statement. Again, indicate which 
response is the closest to how you feel by ticking (u) one of the boxes after each statement. Please 
try to answer ALL questions as honestly as possible. 
SECTION FIVE: 
The next section asks you about any concerns that you may have for the future because of your CF: 
30. It concerns me that I may not be able to have any/have more children. 
 
£Strongly agree  £Agree £Slightly agree £Slightly disagree £Disagree  £Strongly disagree 
 
31. I have concerns about being assessed for a heart-lung transplant. 
 
£Strongly agree  £Agree £Slightly agree £Slightly disagree £Disagree  £Strongly disagree 
 
32. The possibility of needing a heart-lung transplant worries me. 
 
£Strongly agree  £Agree £Slightly agree £Slightly disagree £Disagree  £Strongly disagree 
 
33. I worry about CF shortening my life. 
 
£Strongly agree  £Agree £Slightly agree £Slightly disagree £Disagree  £Strongly disagree 
 
34. In general thinking about the future makes me feel concerned / worried. 
 
£Strongly agree  £Agree £Slightly agree £Slightly disagree £Disagree  £Strongly disagree 
 
35. The worries that I have about the future make life less enjoyable. 
 
£Strongly agree  £Agree £Slightly agree £Slightly disagree £Disagree  £Strongly disagree 
 
 
SECTION SIX: 
In general , do you agree or disagree that your CF has affected your relationships with other people 
in any of the following ways? 
 
36. Establishing new relationships / friendships is difficult because of my CF. 
 
£Strongly agree  £Agree £Slightly agree £Slightly disagree £Disagree  £Strongly disagree 
 
37. I find that my friends don’t always understand the limits that my CF places on me. 
 
£Strongly agree  £Agree £Slightly agree £Slightly disagree £Disagree  £Strongly disagree 
 
38. My CF makes it difficult for me to establish intimate relationships. 
 
£Strongly agree  £Agree £Slightly agree £Slightly disagree £Disagree  £Strongly disagree 
 
39. My CF makes it difficult for me to maintain intimate relationships. 
 
£Strongly agree  £Agree £Slightly agree £Slightly disagree £Disagree  £Strongly disagree 
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40. I find that my CF interferes with me having a satisfactory sex life. 
 
£Strongly agree  £Agree £Slightly agree £Slightly disagree £Disagree  £Strongly disagree 
 
41. I find that CF makes me feel different from other people my own age. 
 
£Strongly agree  £Agree £Slightly agree £Slightly disagree £Disagree  £Strongly disagree 
 
42. My CF makes me feel isolated from other people. 
 
£Strongly agree  £Agree £Slightly agree £Slightly disagree £Disagree  £Strongly disagree 
 
43. I am concerned that my CF is stressful for those who are close to me. 
 
£Strongly agree  £Agree £Slightly agree £Slightly disagree £Disagree  £Strongly disagree 
 
44. I worry that, because of my CF, I will never be able to lead an independent life. 
 
£Strongly agree  £Agree £Slightly agree £Slightly disagree £Disagree  £Strongly disagree 
 
45. The way in which CF affects my relationships with other people interferes with my quality of life 
by making life less enjoyable. 
 
£Strongly agree  £Agree £Slightly agree £Slightly disagree £Disagree  £Strongly disagree 
 
 
SECTION SEVEN: 
CF can affect your height/weight, in general how has this made you feel? 
46. I believe that my CF has made me too small. 
 
£Strongly agree  £Agree £Slightly agree £Slightly disagree £Disagree  £Strongly disagree 
 
47. I feel that because of my CF I am too thin. 
 
£Strongly agree  £Agree £Slightly agree £Slightly disagree £Disagree  £Strongly disagree 
 
48. The way that my CF has made me look because of my height / weight makes life less enjoyable. 
 
£Strongly agree  £Agree £Slightly agree £Slightly disagree £Disagree  £Strongly disagree 
 
SECTION EIGHT: 
The next section asks you about problems you may experience at college, work OR school as a 
result of your CF. If you are no longer working or at college, please answer the questions in relation 
to your past experiences. 
 
49. CF makes/has made, finding a suitable college course/job difficult. 
 
£Strongly agree  £Agree £Slightly agree £Slightly disagree £Disagree  £Strongly disagree 
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50. Holding down a job / college course is / has been difficult because of my CF. 
 
£Strongly agree  £Agree £Slightly agree £Slightly disagree £Disagree  £Strongly disagree 
 
51. I am now unable to work / go to college because of my CF. 
 
£Strongly agree  £Agree £Slightly agree £Slightly disagree £Disagree  £Strongly disagree 
 
52. I find that CF interferes with my career / college OR school life to such an extent that it makes 
life less enjoyable. 
 
£Strongly agree  £Agree £Slightly agree £Slightly disagree £Disagree  £Strongly disagree 
 
Thank you for completing the questionnaire 
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A SERIES PROVIDED BY
The Hartford Institute for Geriatric Nursing
EMAIL: hartford.ign@nyu.edu
HARTFORD INSTITUTE WEBSITE: www.hartfordign.org
CONSULTGERIRN WEBSITE: www.ConsultGeriRN.org
5. During the past month, how often have you had 
trouble sleeping because you…
a. Cannot get to sleep within 30 minutes
b. Wake up in the middle of the night or early morning
c. Have to get up to use the bathroom
d. Cannot breathe comfortably
e. Cough or snore loudly
f. Feel too cold
g. Feel too hot
h. Have bad dreams
i. Have pain
j. Other reason(s), please describe, including how often you 
have had trouble sleeping because of this reason(s):
6. During the past month, how often have you taken medicine 
(prescribed or “over the counter”) to help you sleep?
7. During the past month, how often have you had trouble staying 
awake while driving, eating meals, or engaging in social activity?
8. During the past month, how much of a problem has it been for 
you to keep up enthusiasm to get things done?
9. During the past month, how would you rate your sleep
quality overall?
The Pittsburgh Sleep Quality Index (PSQI)
Instructions: The following questions relate to your usual sleep habits during the past month only. Your answers should
indicate the most accurate reply for the majority of days and nights in the past month. Please answer all questions.
During the past month,
1. When have you usually gone to bed? ___________________
2. How long (in minutes) has it taken you to fall asleep each night? ___________________
3. When have you usually gotten up in the morning? ___________________
4. How many hours of actual sleep do you get at night? (This may be different than the number of hours 
you spend in bed) ___________________
Not during
the past
month (0)
Less than
once a
week (1)
Once or
twice a
week (2)
Three or
more times
a week (3)
Component 1 #9 Score  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .C1_______
Component 2 #2 Score (≤15min=0; 16-30 min=1; 31-60 min=2, >60 min=3) + #5a Score 
(if sum is equal 0=0; 1-2=1; 3-4=2; 5-6=3) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .C2_______
Component 3 #4 Score (>7=0; 6-7=1; 5-6=2; <5=3)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .C3_______
Component 4 (total # of hours asleep)/(total # of hours in bed) x 100
>85%=0, 75%-84%=1, 65%-74%=2, <65%=3  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .C4_______
Component 5 Sum of Scores #5b to #5j (0=0; 1-9=1; 10-18=2; 19-27=3)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .C5_______
Component 6 #6 Score  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .C6_______
Component 7 #7 Score + #8 Score (0=0; 1-2=1; 3-4=2; 5-6=3)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .C7_______
Add the seven component scores together ________ Global PSQI Score ________
Reprinted from Journal of Psychiatric Research, 28(2), Buysse, D.J., Reynolds III, C.F., Monk, T.H., Berman, S.R., & Kupfer, D.J. The Pittsburgh
Sleep Quality Index: A New Instrument for Psychiatric Practice and Research, 193-213, Copyright 1989, with permission from Elsevier Science.
Very
good (0)
Fairly
good (1)
Fairly
bad (2)
Very
bad (3)
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EPWORTH SLEEPINESS SCALE 
 
 
 
 
 
 
 
 
	
Epworth Sleepiness Scale 
 
 
Name: ______________________________________________ Today’s date: _________________ 
 
Your age (Yrs): _______________ Your  sex (Male = M, Female = F): ________ 
 
 
How likely are you to doze off or fall asleep in the following situations, in contrast to feeling just 
tired? 
 
This refers to your usual way of life in recent times. 
 
Even if you haven’t done some of these things recently try to work out how they would have affected 
you. 
 
Use the following scale to choose the most appropriate number for each situation: 
           
0  =  would never doze 
1  =  slight chance of dozing 
2  =  moderate chance of dozing 
3  =  high chance of dozing 
 
It is important that you answer each question as best you can. 
 
Situation        Chance of Dozing (0-3) 
 
  
Sitting and reading        ________________________________________   
 
Watching TV                ________________________________________  
 
Sitting, inactive in a public place (e.g. a theatre or a meeting)    _________  
 
As a passenger in a car for an hour without a break    _________________  
 
Lying down to rest in the afternoon when circumstances permit   ________  
 
Sitting and talking to someone   __________________________________  
 
Sitting quietly after a lunch without alcohol   ________________________  
 
In a car, while stopped for a few minutes in the traffic  ________________  
 
 
 
THANK YOU FOR YOUR COOPERATION 
 
 
 M.W. Johns  1990-97 
 
 
___ 
 
___ 
 
___ 
 
___ 
 
___ 
 
___ 
 
___ 
